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Abstract 
Aromatic L-amino acid decarboxylase (AADC) catalyses the conversion of 5-
hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (L-dopa) to the 
neurotransmitters serotonin and dopamine respectively.  The inherited disorder AADC 
deficiency leads to a severe deficit of serotonin and dopamine as well as an 
accumulation of 5-HTP and L-dopa.  This thesis investigated the potential role of 5-
HTP/L-dopa accumulation in the pathogenesis of AADC deficiency.  Treatment of 
human neuroblastoma cells with L-dopa or dopamine was found to increase intracellular 
levels of the antioxidant reduced glutathione (GSH).  However inhibiting AADC 
prevented the GSH increase induced by L-dopa.  Furthermore dopamine but not L-dopa, 
increased GSH release from human astrocytoma cells, which do not express AADC 
activity. GSH release is the first stage of GSH trafficking from astrocytes to neurons.  
This data indicates dopamine may play a role in controlling brain GSH levels and 
consequently antioxidant status.  The inability of L-dopa to influence GSH 
concentrations in the absence of AADC or with AADC inhibited indicates GSH 
trafficking/metabolism may be compromised in AADC deficiency. 5-HTP was 
demonstrated to potentially be mildly toxic to human neuroblastoma cells but not 
astrocytoma cells; however the concentrations required for this response are likely to be 
higher than pathophysiological levels in AADC deficiency.  These results indicate the 
need for investigations addressing the effects of chronic 5-HTP exposure as only acute 
effects were investigated in the current study.  This thesis also investigated the effect of 
altered availability of the AADC coenzyme pyridoxal 5‟-phosphate (PLP) on AADC 
activity, protein and expression. In two patients with inherited disorders of PLP 
metabolism reductions in plasma AADC activity were observed.  Furthermore PLP-
deficient human neuroblastoma cells were found to exhibit reduced levels of AADC 
activity and protein but not altered expression.  These findings suggest maintaining 
adequate PLP availability may be important for optimal treatment of AADC deficiency.   
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Chapter 1 
1 Introduction 
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1.1 Monoamine Neurotransmitters 
Serotonin and dopamine are aromatic amines derived from the decarboxylation of the 
amino acids L-5-hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (L-
dopa) respectively, by the enzyme aromatic L-amino acid decarboxylase (AADC; EC 
No. 4.1.1.28).  These two amines act as extracellular molecular signals within the 
nervous system and in peripheral tissues.  Both serotonin and dopamine have been 
demonstrated to participate in a range of physiological and behavioural processes.  
Serotonin was first identified and purified as a substance in platelets and serum with 
constrictor activity of smooth muscle, including blood vessels and duodenum (Zucker et 
al, 1944; Rapport et al, 1948).  Subsequently serotonin was found to be present in 
rodent and dog brain and was consequently suggested to act as a neurotransmitter 
(Twarog et al, 1953; Amin et al, 1954).  Dopamine was first isolated from sheep heart 
and adrenal medulla, but was considered to act primarily as the immediate precursor of 
noradrenaline (Goodall, 1951).  However it was subsequently demonstrated that 
administered dopamine could reduce arterial blood pressure in guinea pig 
(Hornykiewicz, 1958).  Furthermore enhanced concentrations of dopamine, but not 
noradrenaline, in the brain were found to reverse the tranquilizing effect of reserpine in 
rodents (Carlsson et al, 1957; Carlsson et al, 1958; Everett and Weigand, 1962).  This 
latter evidence indicated that dopamine was also a neurotransmitter and that it was 
involved in motor behaviour (reviewed by Hornykiewicz, 1966). 
1.1.1 Serotonin 
Serotonin has been demonstrated to play a complex modulatory role in a wide range of 
behavioural functions (reviewed by Jacobs and Fornal, 1997a; Lucki, 1998).  Central 
serotonin is considered to be important for the induction and maintenance of sleep such 
that pharmacological depletion of serotonin has been shown to disturb sleep or reduce 
some stages of sleep (Koella et al, 1968; Wyatt et al, 1969; Sheard, 1969).  Eating 
behaviour is also thought to be modulated by serotonin (reviewed by Simansky, 1996).  
Serotonin reuptake inhibitors and non-selective serotonin agonists have been found to 
reduce food intake and induce satiety while serotonin depletion can produce 
hyperphagia and weight gain (Breisch et al, 1976; Saller and Stricker, 1976; Blundell 
and Latham, 1980; Simansky and Vaidya, 1990).  This effect may in part relate to 
serotonergic modulation of neuroendocrine functions such as release of melanocortins 
(Heisler et al, 2002; Heisler et al, 2006).  Moreover serotonin is known to play a 
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complex role in the control of mood and emotion, for example serotonin depletion 
enhances cognitive and behavioural responses to punishment or fearful stimuli whilst 
also reducing the ability to modify behaviour to avoid punishment (Cools et al, 2005; 
van der Veen et al, 2007; Cools et al, 2008; Crockett et al, 2009).  Further roles of 
central serotonin include modulation of body temperature, movement and memory 
(Yamada et al, 1988; Fornal et al, 1996; Jacobs and Fornal, 1997b, Stewart et al, 1997; 
Riedel et al, 1999; Molodtsova, 2008). 
1.1.2 Dopamine 
Dopaminergic pathways in the brain are considered to be involved in a range of 
behavioural and cognitive functions.  The neuronal dopamine pathway originating in the 
substantia nigra pars compacta and terminating in the corpus striatum is known to play 
an essential role in the basal-ganglia motor circuits that are involved in the planning and 
execution of voluntary movement (reviewed by Mink and Thach, 1993).  This is 
perhaps best demonstrated by the primary pathology of Parkinson‟s disease which 
involves the degeneration of this dopaminergic pathway leading to the characteristic 
clinical Parkinsonian features of hypokinesia, rigidity and tremor (Hassler, 1938; 
Hornykiewicz, 1963; Dahlstrom and Fuxe, 1964; Fuxe, 1965).  Dopamine is also 
thought to be involved in learning and working memory (reviewed by Robbins and 
Everitt, 2002).  Dopamine antagonists have been found to impair spatial working 
memory and planning whilst dopamine agonists can improve some aspects of working 
memory (Luciana et al, 1992; Luciana et al, 1997; Mehta et al, 1999).  In addition 
dopamine is considered to modulate reward and motivational behaviour, which can be 
disrupted with dopamine antagonists (Wise et al, 1978; Beninger and Hahn, 1983; 
Beninger et al, 1987). Central dopamine may also be involved in the modulation of the 
sleep-wake cycle (Monti, 1968; Kafi and Gaillard, 1976) and hypothalamic dopamine is 
known to be involved in the inhibition of prolactin and melanocyte stimulating hormone 
secretion (Caron et al, 1978; Munemura et al, 1980).   
1.2 Monoamine Metabolism 
1.2.1 Indoleamine Metabolism 
Both serotonin and dopamine are formed from the essential aromatic amino acids L-
tryptophan and L-phenylalanine respectively.  Serotonin is produced from L-tryptophan 
by two sequential steps (see figure 1.1).  L-tryptophan is hydroxylated to 5-HTP by 
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tryptophan hydroxylase (EC No. 1.14.16.4) requiring tetrahydrobiopterin (BH4) and O2 
(Grahame-Smith, 1964; Green and Sawyer, 1966; Friedman et al, 1972).  The 
hydroxylation of L-tryptophan is considered to be rate limiting for serotonin synthesis, 
although the availability of L-tryptophan can also influence synthesis rate (Neckers et 
al, 1977).  Subsequently 5-HTP is decarboxylated to serotonin by AADC which 
requires pyridoxal 5‟-phosphate (PLP) as a co-enzyme (Lovenberg et al, 1962).  In 
melatonin producing cells such as in the pineal gland serotonin undergoes acetylation to 
N-acetylserotonin by arylamine N-acetyltransferase (EC No. 2.3.1.5) using acetyl 
coenzyme A as a cofactor and subsequently methylated by acetylserotonin-O-
methyltransferase (EC No. 2.1.1.4) to melatonin with S-adenosylmethionine (SAM) as a 
methyl donor (Weissbach et al, 1960; Axelrod and Weissbach, 1960).  
1.2.2 Catecholamine Metabolism 
L-phenylalanine is hydroxylated at the 4-position of the phenyl group to produce L-
tyrosine by the enzyme phenylalanine hydroxylase (EC No. 1.14.16.1) that requires BH4 
and O2 (Udenfriend and Cooper, 1952; Mitoma, 1956, Kaufman, 1959).  The 
subsequent hydroxylation of L-tyrosine at position-3 of the phenyl group to give L-dopa 
is catalysed by tyrosine hydroxylase (EC No. 1.14.16.2). This is the rate limiting step 
for dopamine synthesis and also requires BH4 and O2 (see figure 1.2; Hess et al, 1961; 
Nagatsu et al, 1964).  L-dopa is then decarboxylated by AADC to dopamine, again 
requiring PLP (Holtz et al, 1938; Holtz et al, 1939).  In noradrenergic cells dopamine is 
further hydroxylated to noradrenaline by dopamine β-hydroxylase (EC No. 1.14.17.1) in 
a reaction requiring ascorbate and O2 (Levin et al, 1960), and in adrenergic cells 
noradrenaline is methylated by phenylethanolamine N-methyltransferase (EC No. 
2.1.1.28) to adrenaline using S-adenosylmethionine as a methyl donor (Axelrod, 1962).   
1.3 Monoamine Neurotransmission 
1.3.1 Vesicular Uptake 
Following production within neurons or neuroendocrine cells the monoamine 
neurotransmitters are packaged into small synaptic vesicles or dense core secretory 
vesicles.  Uptake of monoamines into vesicles is catalysed by vesicular monoamine 
transporters of which there are two forms termed vesicular monoamine transporter 1 
(VMAT1) and vesicular monoamine transporter 2 (VMAT2; see figure 1.3; Liu et al, 
1992; Erickson et al, 1992).  VMAT2 is expressed in both central and peripheral 
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neurons while VMAT1 is expressed mainly in the adrenal medulla and endocrine cells 
of the gastrointestinal tract (Peter et al, 1995).  It has recently been demonstrated that 
VMAT2 forms a complex with AADC and TH in rat striatal neurons suggesting that 
there may be integration of dopamine metabolism and vesicular storage (Cartier et al, 
2010).  The Km apparent for the vesicular uptake of dopamine and serotonin 
respectively were measured as 21.0μM and 0.6μM (Gershten et al, 1983; Ruth et al, 
1986).  These Km values are at least 10-fold lower than those for AADC (see section 
1.6.3) indicating that, following production, vesicular uptake of monoamines has the 
potential to be highly efficient.  The uptake of monoamines into vesicles is driven by a 
proton gradient whereby one molecule of monoamine in cationic form is exchanged for 
2H
+
 (Knoth et al, 1980; Daniels and Reinhard, 1988; Darchen et al, 1988).  The proton 
gradient is established by the vacuolar-type H
+
 ATPase proton pump (Xie and Stone, 
1986; Moriyama and Nelson, 1987; Cidon and Sihra, 1989). 
1.3.2 Release 
Once filled with neurotransmitter, synaptic vesicles translocate to the active zone of the 
synapse, the presynaptic area directly adjacent to the synaptic cleft.  Vesicles make 
contact with the plasma membrane in a process referred to as docking, and subsequently 
become primed for neurotransmitter release (reviewed by Sudhof, 2004; Wojcik and 
Brose, 2007).  Priming is thought to involve the assembly of a complex of proteins 
including the SNARE proteins that collectively form the machinery for membrane 
fusion (Sollner et al, 1993; McMahon et al, 1995).  Upon membrane depolarisation, due 
to an action potential, voltage gated Ca
2+
 channels within the active zone open leading 
to Ca
2+
 influx that triggers vesicle exocytosis.  Ca
2+
 evoked exocytosis most likely 
involves synaptotagmin proteins which are considered to act as Ca
2+
 sensors and that 
also interact with the membrane fusion protein complex (Geppert et al, 1994; Reim et 
al, 2001). Following neurotransmitter release vesicles undergo endocytosis and are 
recycled either directly or via endosomes (Ceccarelli et al, 1973; Heuser and Reese, 
1973; Sudhof, 2004). 
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Figure 1.1 Indoleamine metabolic pathway. BH4: tetrahydrobiotperin, AADC: 
aromatic L-amino acid decarboxylase, PLP: pyridoxal 5‟-phosphate, MAO: monoamine 
oxidase, ALDH: aldehyde dehydrogenase, 5-HIAA: 5-hydroxyindoleacetic acid. 
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1.3.3 Receptors 
Serotonin or dopamine released into the synaptic cleft bind to specific receptors located 
at the post-synaptic membrane, but also to receptors at the presynaptic membrane, 
termed autoreceptors.  The serotonin receptors are grouped into seven families termed 
5-HT1-7 with between one and five receptors in each family (reviewed by Hartig, 1997).  
All serotonin receptors are G-protein coupled receptors (GPCRs) except for the 5-HT3 
receptors which are ligand-gated ion channels.  The 5-HT3 receptor ion channels are 
cation selective and when activated lead to membrane depolarisation (Derkach et al, 
1989).  There are two families of dopamine receptor, the D1-like receptors and the D2-
like receptors, of which D1 and D5 belong to the former and D2, D3 and D4 belong to the 
latter (reviewed by Missale et al, 1998).  All dopamine receptors are GPCRs.  In an 
unactivated state GPCRs are associated with specific G-proteins.  Upon receptor 
activation the G-protein becomes dissociated from the receptor and can then activate 
multiple intracellular proteins, termed effectors (reviewed by Gilman, 1987).  Each 
serotonin and dopamine GPCR is linked to a specific range of effector proteins.  It is 
important to note that different serotonin or dopamine receptors may have opposing 
intracellular actions.  For example D1-like receptors stimulate cyclic adenosine 
monophosphate (cAMP) production, whilst D2-like receptors inhibit cAMP production 
(Kebabian and Calne, 1979; Onali et al, 1984; Picetti et al, 1997).  In addition to the 
diversity of intracellular signalling, each dopamine and serotonin receptor has a unique 
central and peripheral distribution (Weiner et al, 1991; Tecott et al, 1993; Pompeiano et 
al, 1994).  This complexity of receptor distribution and intracellular signalling may 
underlie some of the difficulties in targeting these receptors for disease treatment (see 
section 1.5.4). 
1.3.4 Re-uptake 
Neurotransmitter released into the synaptic cleft can be sequestered back into the 
presynaptic nerve terminal.  This process is achieved in the case of serotonin and 
dopamine by specific membrane transporter proteins, respectively termed the serotonin 
transporter (SERT) and the dopamine transporter (DAT; Kilty et al, 1991; Shimada et 
al, 1991; Blakely et al, 1991; Hoffman et al, 1991).  At the axon terminal electron 
microscopy indicates that SERT and DAT are located mainly at the plasma membrane 
but not directly positioned within the synaptic cleft, suggesting that serotonin and 
dopamine diffuse out of the synaptic cleft prior to re-uptake (Nirenberg et al, 1996; 
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Figure 1.2 catecholamine metabolic pathway. BH4: tetrahydrobiotperin, AADC: 
aromatic L-amino acid decarboxylase, L-dopa: L-3,4-dihydroxyphenylalanine, PLP: 
pyridoxal 5‟-phosphate, DβH: dopamine β-hydroxylase, PNMT: phenolethanolamine N-
methyltransferase, SAM: S- adenosylmethionine, SAH: S-adenosylhomocysteine, 
MAO: monoamine oxidase, ALDH: aldehyde dehydrogenase, COMT: Catechol O-
methyltranserafe, DOPAC: 3,4-dihydroxyphenylacetic acid, HVA: Homovanillic acid. 
Zhou et al, 1998).  Transport across the plasma membrane is driven by the Na
+
 and Cl
-
 
concentration gradient.  For serotonin one Na
+
 ion and one Cl
-
 ion are co-transported, 
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whilst dopamine is co-transported with two Na
+
 ions and one Cl
-
 ion (Gu et al, 1994).  
Similar to vesicular uptake the ion concentration gradient is energetically established 
via an ATPase pump, in this case the plasma membrane Na
+
/K
+
 ATPase (Dunham and 
Glynn, 1961; Tissari et al, 1969).  Once returned to the presynaptic terminal dopamine 
and serotonin can be taken back up into vesicles.  SERT and DAT knock-out mice have 
reduced tissue concentrations of serotonin or dopamine respectively, but extracellular 
concentrations are increased (Giros et al, 1996; Bengel et al, 1998).  This suggests that 
not only is re-uptake the major mechanism for clearance of extracellular monoamine 
neurotransmitters but also that reuptake makes a substantial contribution to the levels of 
stored serotonin and dopamine.  However tyrosine hydroxylase was down-regulated in 
the DAT knock-out mouse which may suggest that the decrease in stored dopamine may 
have been related to decreased synthesis as well as to reduced recycling.   
1.3.5 Degradation 
Serotonin or dopamine that is not recycled back into vesicles is degraded either within 
neurons or glial cells (Levitt et al, 1982).  The initial step in serotonin breakdown is 
catalysed by monoamine oxidase (MAO; EC No. 1.4.3.4; see figure 1.1) that exists in 
two isoforms termed MAO-A and MAO-B derived from different genes (Bach et al, 
1988).  MAO oxidises serotonin to 5-hydroxyindoleacetaldehyde, requiring H2O and O2 
(Sjoerdsma et al, 1955).  This product is then dehydrogenated to 5-hydroxyindoleacetic 
acid (5-HIAA) by aldehyde dehydrogenase (ALDH; EC No. 1.2.1.3) with oxidised 
nicotinamide adenine dinucleotide (NAD
+
; Maring et al, 1985).  Dopamine can be 
broken down by two alternative metabolic routes both producing homovanillic acid 
(HVA; see figure 1.2).  Firstly dopamine can be converted to 
dihydroxyphenylacetaldehyde by MAO, which is rapidly converted to 
dihydroxyphenylacetic acid (DOPAC) by ALDH with NAD
+
, and is then converted to 
HVA by catechol-O-methyltransferase (COMT; EC No. 2.1.1.6) using SAM as a 
methyl donor (Rosengren, 1960; Maring et al, 1985).  Alternatively COMT can 
metabolise dopamine to 3-methoxytyramine and subsequently MAO and ALDH convert 
3-methoxytyramine to HVA (Axelrod and Tomchick, 1958). 
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Figure 1.3 Monoamine neurotransmission. MA: monoamine, AADC: aromatic L-
amino acid decarboxylase, VMAT2 vesicular monoamine transporter 2, DAT: 
dopamine transporter, SERT: serotonin transporter, GPCR: g-protein coupled receptor, 
LGIC: ligand-gated ion channel, AC: adenylyl cyclase, PLC-β: phospholipase C-β, 
PIP2: phosphatidylinositol 4,5-bisphosphate, DAG: diacylglycerol, IP3: inositol 1,4,5-
triphosphate. 
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1.4  Disorders of Aromatic Amino Acid Metabolism 
1.4.1 Hyperphenyalaninemia 
The first disorder affecting the metabolism of an aromatic amino acid to be described 
was phenylalanine hydroxylase deficiency (Folling, 1934; Penrose, 1935).  This 
condition was originally recognised by the high urinary excretion levels of 
phenylpyruvic acid, phenylketonuria, found in some patients with severe mental 
retardation.  Controlling the hyperphenylalaninemia in these patients, by restricting 
phenylalanine intake, was found to be an effective treatment, leading to some reversal 
of cognitive deficits, hence in this disorder the accumulation of precursor appears to be 
the primary pathogenic mechanism (see section 1.7.1; Bickel et al, 1953; Woolf et al, 
1955; Blainey and Gulliford, 1956).  The subsequent realisation that 
hyperphenylalaninemia was not exclusive to phenylalanine hydroxylase deficiency led 
to the discovery of the deficiencies of BH4 metabolism, the cofactor for phenylalanine 
hydroxylase (Kaufman et al, 1975; see figure 1.4).  Disorders of BH4 metabolism have 
been described for both the enzymes involved in BH4 recycling, 4a-carbinolamine 
dehydratase and dihydropteridine reductase (DHPR), as well as those involved in BH4 
synthesis, guanosine triphosphate cyclohydrolase (GTPCH), 6-pyruvoyltetrahydropterin 
synthase (PTPS) and sepiapterin reductase (Kaufman et al, 1975; Neiderwieser et al, 
1984; Niederwieser et al, 1985; Citron et al, 1993; Bonafe et al, 2001a). With the 
exception of sepiapterin reductase deficiency and the dominant form of GTPCH 
deficiency all of these conditions present with hyperphenylalaninemia.  For those BH4 
conditions with hyperphenylalaninemia correcting phenylalanine levels forms an 
essential part of treatment, however as BH4 also acts as a cofactor for tyrosine 
hydroxylase and tryptophan hydroxylase most forms of BH4 deficiency also present 
with a severe deficit of serotonin and dopamine (Hyland, 1999; Blau, 2004; Longo, 
2009). 
1.4.2 Monoamine Neurotransmitter Deficiency 
A near absence of serotonin and dopamine can be caused by a deficiency of AADC, 
which converts 5-HTP to serotonin and L-dopa to dopamine (Hyland and Clayton, 
1990; Hyland et al, 1992; see section 1.5).  An inherited deficiency of tyrosine 
hydroxylase, which converts L-tyrosine to L-dopa, has also been described, which leads 
to dopamine deficiency with serotonin metabolism unaffected (Ludecke et al, 1996).  In 
severe forms of autosomal recessive GTPCH, PTPS and DHPR deficiency the common 
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clinical symptoms include mental retardation, convulsions, hypokinesia, oculogyric 
crises, truncal hypotonia, ptosis, irritability, hypersalivation, temperature instability and 
excessive sweating (Hyland, 1999; Blau, 2004).  The majority of these symptoms are 
also shared with AADC deficiency except convulsions which are generally considered 
uncommon in AADC deficiency (Swoboda et al, 1999; Swoboda et al, 2003; Pons et al, 
2004; Brun et al, 2010).  Clinical features of tyrosine hydroxylase deficiency include 
psychomotor delay, truncal hypotonia, hypokinesia, dystonia, rigidity, tremor, 
oculogyric crises, ptosis and hypersalivation (Hoffmann et al, 2003).  Ptosis, 
hypersalivation and excessive sweating are commonly attributed to the consequential 
autonomic dysfunction of noradrenaline and adrenaline deficiency (Swoboda et al, 
2003; Brun et al, 2010).  Movement related deficits are considered to be largely due to 
dopamine deficiency, however in AADC deficiency and BH4 deficiencies there may 
also be a serotonin component, as serotonergic neurons are known to modulate some 
motor functions (Fornal et al, 1996; Jacobs and Fornal, 1997b; Swoboda et al, 2003; 
Brun et al, 2010).  The aetiology of oculogyric crises is not well understood, however as 
they occur in AADC deficiency, BH4 deficiencies and also tyrosine hydroxylase 
deficiency it is likely to involve catecholamine deficiency, rather than indoleamine 
deficiency.  Furthermore as oculogyric crises have not been reported in dopamine β-
hydroxylase deficiency (Robertson et al, 1991) this could suggest that they are 
specifically related to dopamine deficiency.  Serotonin deficiency may manifest as 
relatively subtle but wide ranging functional alterations due to its complex but largely 
modulatory role in many functions.  Examples of symptoms likely to involve serotonin 
include sleeping difficulties, temperature instability and problems with mood (Swoboda 
et al, 2003; Brun et al, 2010). 
1.4.3 Treatment 
GTPCH and PTPS deficiency are treated with BH4. BH4 does not easily cross the blood 
brain barrier and consequently its administration is aimed largely at reducing blood 
phenylalanine levels rather than correcting monoamine neurotransmitter defects 
(Hyland, 2007; Longo, 2009).  Serotonin and dopamine also do not cross the blood 
brain barrier.  Instead, in an attempt to correct the monoamine neurotransmitter 
deficiency 5-HTP and L-dopa are administered (Shintaku, 2002; Blau, 2004). This 
treatment bypasses the metabolic block at tyrosine and tryptophan hydroxylases and 
administered 5-HTP and L-dopa are converted by AADC in the brain to serotonin and 
35 
 
dopamine.  For tyrosine hydroxylase deficiency the main treatment is L-dopa 
(Hoffmann et al, 2003).  Treatment of these conditions with 5-HTP and L-dopa is 
dependent on functioning central AADC, accordingly most cases of AADC deficiency 
cannot be treated in this manner (see section 1.5.4). Treatment with 5-HTP and/or L-
dopa is commonly accompanied by administration of a peripheral AADC inhibitor.  
Peripheral AADC inhibitors such as carbidopa or benserazide prevent peripheral 
decarboxylation of L-dopa and 5-HTP increasing the proportion that reaches the brain 
(Bartholini et al, 1967).  This in turn allows the dosage of L-dopa and 5-HTP to be 
reduced.  Inhibition of MAO and in some cases, COMT are also common treatments for 
these conditions in order to prevent the degradation of monoamines (Hyland, 2007; 
Pearl et al, 2007). 
1.4.4 Related Conditions 
The decarboxylation of 5-HTP and L-dopa performed by AADC requires PLP as an 
obligatory cofactor.  The genetic condition pyridox(am)ine 5‟-phosphate oxidase 
(PNPO) deficiency affects the enzyme that converts the B6 vitamers pyridoxine 5‟-
phosphate and pyridoxamine 5‟-phosphate into the active vitamer PLP (Mills et al, 
2005; see figure 1.5).  This condition presents with PLP responsive seizures that 
develop in the neonatal period.  PLP is also involved in many other enzymatic reactions 
including those involved in γ-amino butyric acid (GABA), glycine and glutamate 
metabolism (reviewed by Clayton, 2006).  It is most likely the alterations of these 
neurotransmitters that lead to seizures.  Serotonin and dopamine metabolism are also 
affected, although this may be variable between individuals (Hoffmann et al, 2007). 
PNPO deficiency is treated by direct replacement of PLP.  A secondary central 
deficiency of monoamines can also occur in phenylalanine hydroxylase deficiency, 
where accumulated blood L-phenylalanine prevents the transport of the monoamine 
precursors L-tryptophan and L-tyrosine into the brain (Surtees and Blau, 2000; Bonafe 
et al, 2001b).  An inherited disorder affecting the breakdown of serotonin and dopamine 
has also been described (Brunner et al, 1993a; Brunner et al, 1993b).  This condition 
affects an isoform of monoamine oxidase, termed MAO-A and is associated with mild 
mental retardation and aggressive behaviour.  24 hour urine analysis revealed increased 
levels of MAO substrates including serotonin. Recently a genetic condition affecting the 
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Figure 1.4 Tetrahydrobiopterin metabolic pathway. GTP: Guanosine triphosphate, BH4: tetrahydrobiopterin, L-dopa: L-3,4-dihydroxyphenylalanine, 
5-HTP:L-5-hydroxytryptophan.
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Figure 1.5 Pyridoxal 5’-phosphate metabolic pathway. ATP: adenosine triphosphate, 
ADP: adenosine diphosphate. PNPO: pyridoxamine 5‟-phosphate oxidase. 
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re-uptake of dopamine via the dopamine transporter has also been described (Kurian et 
al, 2009).  These patients presented with dystonia and parkinsonism and were found to 
have increased levels of the dopamine metabolite homovanillic acid in cerebrospinal 
fluid (CSF).  DAT deficiency patients were not responsive to L-dopa therapy and 
instead dopamine agonists were suggested to be a potential treatment.    
1.5 AADC deficiency 
1.5.1 Clinical Picture 
AADC deficiency was first diagnosed in male monozygotic twins who presented at 2 
months of age with hypotonia, developmental delay, oculogyric crises and 
choreoathetoid limb movements (Hyland and Clayton, 1990; Hyland et al, 1992).  Since 
then cases of AADC deficiency have been identified in Europe, Asia, North America 
and Australia and there are currently 78 cases recorded on the international patient 
database ((http://www.biopku.org/BioPKU_databasesJAKE.asp) curated by N. Blau).  
Hypotonia and oculogyric crises are the two most commonly reported symptoms of 
AADC deficiency (Brun et al, 2010). In addition other common symptoms include 
developmental delay, hypokinesia, choreoathetosis, dystonia, limb hypertonia, 
insomnia, irritability, feeding and speech difficulties (Hyland et al, 1992; Swoboda et 
al, 1999; Swoboda et al, 2003; Pons et al, 2004; Brun et al, 2010).  Autonomic 
symptoms are also common, including nasal congestion, temperature instability, ptosis, 
excessive sweating and hypersalivation.  Hypoglycaemia has been reported in some 
cases and this could also be related to autonomic deficits as noradrenaline and 
adrenaline can play a role in modulation of glucose metabolism (Nonogaki, 2000; 
Swoboda et al, 2003).  Furthermore patients with dopamine β-hydroxylase deficiency 
have been reported to suffer from episodes of hypoglycaemia (Robertson et al, 1991), 
again indicating the role of the autonomic system in this symptom.  Seizures have 
occasionally been reported in AADC deficiency and one case was responsive to 
antiepileptic medication (Swoboda et al, 2003; Hsieh et al, 2005; Anselm and Darras, 
2006; Ito et al, 2008).  Long-term electroencephalogram of one AADC deficient patient 
has demonstrated activity corresponding to epileptic seizures during involuntary 
movements (Ito et al, 2008).  It is unknown if involuntary movements in AADC 
deficiency are commonly associated with epilepsy. 
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1.5.2 Diagnosis 
Once AADC deficiency is suspected from the clinical presentation confirmation of the 
diagnosis requires biochemical analysis of CSF, measurement of plasma AADC enzyme 
activity and finally identification of the mutation (Hyland and Clayton, 1992).  
Abnormalities in dopamine and serotonin metabolism are detected by measurement of 
the concentrations of the major dopamine metabolite HVA, the major serotonin 
metabolite 5-HIAA and 3-O-methyldopa (3-OMD; 3-methoxytyrosine) a major L-dopa 
metabolite using high performance liquid chromatography (HPLC) coupled to 
electrochemical detection (ECD; Hyland and Clayton; 1992; Hyland, 2008).  Due to the 
deficit of dopamine and serotonin in AADC deficiency both HVA and 5-HIAA are 
greatly reduced in patient CSF (Patient range, HVA: <2-128 nM, 5-HIAA: <2-53 nM; 
Reference Range, HVA: 320-955 nM, 5-HIAA: 120-480nM; Hyland and Clayton, 
1992; Fiumara et al, 2002; Brun et al, 2010).  3-OMD is usually elevated in AADC 
deficiency due to the metabolic block at AADC (Patient Range: 54-4293 nM, Reference 
Range: <100nM; Hyland et al, 1992; Maller et al, 1997; Brun et al, 2010).  5-HTP 
accumulation in CSF of AADC deficient patients is also common (Patient Range: 51-
264 nM; Reference Range: <10nM; Abeling et al, 1998; Maller et al, 1997; Brun et al, 
2010).  This CSF metabolite pattern is indicative of AADC deficiency however a 
similar pattern has been found in several patients with PNPO deficiency (Mills et al, 
2005; Hoffmann et al, 2007).  Measurement of AADC activity in plasma can be used to 
confirm the diagnosis.  Plasma is incubated sequentially with PLP and L-dopa and the 
amount of dopamine produced is quantified by HPLC-ECD.  Plasma AADC activity is 
very low in patients with AADC deficiency (Patient Range: <1-5 pmol/min/mL, 
Reference Range 36-129pmol/min/mL; Hyland and Clayton, 1992; Brun et al, 2010).  
Finally, molecular analysis of the AADC gene is generally performed in order to 
determine the pathogenic mutations. 
1.5.3 Inheritance  
AADC deficiency follows an autosomal recessive pattern of inheritance and affected 
individuals have been reported to be homozygous or compound heterozygous (Chang et 
al, 1998; Tay et al, 2007; Lee et al, 2008a).  The human AADC gene is made up of 15 
exons and 14 introns and is mapped to p12.1-p12.3 of chromosome 7 and encodes a 480 
amino acid peptide (Ichinose et al, 1989; Sumi-Ichinose et al, 1992; Nasrin et al, 1992).  
Across the AADC deficient population mutations are heterogeneous, with a high 
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number of novel mutations (Chang et al, 1998; Tay et al, 2007; Haavik et al, 2008).  
Mutations have been identified across the majority of exons, with clusters of mutations 
centring on exons 2, 3 and 14 (see Brun et al, 2010). The most commonly reported 
mutation is the intronic ISV6+4A>T mutation found mainly in the Taiwanese 
population and in individuals with Chinese ancestry (Tay et al, 2007; Lee et al, 2008a; 
Lee et al, 2008b).  Likewise the highest number of cases of AADC deficiency reported 
has been in Taiwan, where at least twelve individuals have been detected (Lee et al, 
2008b).  Of these cases a high proportion are homozygous for the ISV6+4A>T mutation 
which may lead to the production of a truncated protein and all of these cases had a 
severe phenotype (Lee et al, 2008a; Lee et al, 2008b).  This mutation has also been 
reported in two siblings who were compound heterozygous and had a mild disease 
presentation (Tay et al, 2007).  This indicates that in these cases condition severity 
could be directly dependent on the underlying genetic defects.  This is also evident in 
the parents of the two mild siblings, the mother was heterozygous for the ISV6+4A>T 
mutation, while the father was heterozygous for a 853C>T mutation. The father‟s 
AADC activity (11.9 pmol/min/mL) was approximately 50% below the reference range 
while the mother‟s activity (5.3 pmol/min/mL) was approximately 75% below the 
reference range (Adult reference range: 24-43 pmol/min/mL; Tay et al, 2007).    
Heterozygous relatives of AADC deficient children with other mutations have been 
reported to have AADC activity levels as low as 87% below the reference range 
(Verbeek et al, 2007).  Family pedigrees from three patients, constructed on an 
anecdotal basis, indicate a relatively high incidence of psychiatric disorders in relatives 
of these AADC patients (Swoboda et al, 2003).  This could suggest that heterozygosity 
may influence or predispose some individuals to psychiatric conditions, which in turn 
may relate to reduced levels of AADC activity.  However the role of heterozygous 
status in psychiatric disorders has not yet been systematically investigated. 
1.5.4 Treatment 
The first two indentified AADC deficient patients responded well to treatment with the 
MAO inhibitor tranylcypromine, the dopamine agonist bromocriptine and pyridoxine, a 
precursor of PLP (Hyland et al, 1992).  After six months to one year of treatment in this 
manner both twins could perform voluntary movement, were learning to speak, were 
less irritable and oculogyric crises had ceased.  The core treatments for AADC 
deficiency remain the same as those used in the first two cases, a MAO inhibitor, a 
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dopamine agonist and pyridoxine (Swoboda et al, 2003; Pons et al, 2004; Brun et al, 
2010).  However in a survey of 78 patients only approximately 19% were found to 
respond positively to treatment (Brun et al, 2010).  Dopamine agonists are administered 
in AADC deficiency in an attempt to stimulate dopamine receptors and consequently 
replace dopamine neurotransmission.  Dopamine agonists that have been administered 
to patients with AADC deficiency include bromocriptine, pergolide, pramipexole and 
ropinirole, each of which has a differential binding affinity for the different dopamine 
receptors (see section 1.3.3).  However all have greater affinity for D2-like receptors 
rather than D1-like receptors, the efficacy of these drugs for movement disorders is 
considered to be due to action at D2 and D3 receptors (Kvernmo et al, 2006).  In those 
patients that do respond to dopamine agonist treatment the main improvements are 
generally related to voluntary movement (Swoboda et al, 2003; Pons et al, 2004). MAO 
inhibitors (MAOIs) including tranylcypromine, selegiline and moclobemide are given to 
prevent the breakdown of the limited amounts of dopamine and serotonin produced by 
AADC deficient patients.  Again response is variable but MAOIs have, in a few cases, 
been reported to decrease oculogyric crises duration or frequency (Korenke et al, 1997; 
Swoboda et al, 2003; Lee et al, 2008a).   Administered pyridoxine is phosphorylated by 
pyridoxal kinase and then subsequently converted to PLP by PNPO (see figure 1.5; 
reviewed by Clayton, 2006).  The aim of this treatment is to provide an excess of PLP, 
the coenzyme for AADC, which may in turn bolster or enhance residual AADC enzyme 
activity.  Although improvements in the biochemical picture have been noted in some 
patients in response to pyridoxine treatment only rarely has any change been observed 
in the clinical phenotype (Hyland et al, 1992; Korenke et al, 1997; Maller et al, 1997; 
Swoboda et al, 1999; Pons et al, 2004). 
 
A range of other pharmacological interventions have been attempted in patients with 
AADC deficiency.  Several attempts have been made to specifically target the serotonin 
system.  Administration of Zolmitriptan, a 5-HT1B and 5-HT1D selective agonist that is 
commonly used as a treatment for migraine, led to improvement in the mood of one 
patient (Swoboda et al, 2003). Buspirone which is a 5-HT1A receptor agonist but also a 
partial D2 receptor antagonist improved mood and limb rigidity in two patients however 
this treatment was curtailed after tardive dyskinesia developed as a side effect (Swoboda 
et al, 1999). Fluoxetine and paroxetine are inhibitors of serotonin re-uptake into 
neurons.  This form of treatment led to improvement in oculogyric crises in one patient 
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but induced dystonia in another (Swoboda et al, 2003; Manegold et al, 2009).  L-dopa 
therapy has been successful in three siblings with AADC deficiency (Chang et al, 2004; 
Manegold et al, 2009).  Expression of the mutant AADC protein from these patients 
revealed that the mutant had a higher Km for L-dopa than control, indicating a decreased 
affinity for L-dopa (Chang et al, 2004).  L-dopa therapy has been trialled in several 
other patients but without any positive clinical response (Manegold et al, 2009).  The 
hormone melatonin, which is produced from serotonin, is involved in the control of 
circadian rhythm (reviewed by Zawilska et al, 2009) and due to serotonin deficiency 
melatonin is also likely to be deficient in AADC deficiency.  Sleep disturbances have 
been at least partially corrected in two patients following melatonin administration 
(Pons et al, 2004).  Autonomic symptoms have also been treated with some success.  
Oxymetazoline nasal spray has been reported to be beneficial to one patient at reducing 
nasal congestion and trihexyphenidyl an anticholinergic drug has reduced excessive 
sweating in several cases (Pons et al, 2004).   
1.6 Aromatic L-amino acid decarboxylase 
1.6.1 Structure and Reaction Mechanism 
The AADC enzyme is a homodimer consisting of two 480 amino acid monomers each 
with a predicted molecular weight of 54kDa (Ichinose et al, 1989; Nasrin et al, 1992).  
From analysis of the crystal structure each monomer consists of three domains; a large 
central domain of one β-sheet and eight α-helices; a c-terminal small domain of one β-
sheet and three α-helices; and an N-terminal domain containing two α-helices (Burkhard 
et al, 2001).  The homodimer binds two molecules of PLP, one molecule within the 
large domain of each monomer (Ishii et al, 1996; Burkhard et al, 2001).  The active site 
is located close to the monomer-monomer interface and is composed of residues mostly 
of one monomer but with residues iosleucine 101 and phenylalanine 103 contributed 
from the opposing monomer (Burkhard et al, 2001).  The active site contains lysine 
residue 303 which, in common with active site lysine residues of other PLP-dependent 
enzymes, forms the internal aldimine with PLP through a Schiff base linkage.  This 
PLP-lysine linkage undergoes a transaldimination reaction with the substrate forming a 
Schiff base between PLP and the substrate, the external aldimine, leaving the amino 
group of the lysine residue as a free base.  Site directed mutagenesis of lysine 303 
demonstrates that this residue has further roles in the catalytic mechanism of AADC 
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including involvement in the hydrolysis reaction that separates PLP from the 
decarboxylation product (Bertoldi and Voltattorni, 2009). 
To allow decarboxylation to occur in α-decarboxylases such as AADC it is predicted 
that the carboxyl group must lie perpendicular to the plane of the PLP ring (Dunathan, 
1966).  Residues histidine 192, aspartate 271, asparagine 300 and histidine 302 of 
AADC are all predicted to form hydrogen bonds with the external aldimine, maintaining 
its orientation within the active site (Bertoldi et al, 2001; Burkhard et al, 2001).  
Mutation of each of these residues individually produces proteins with greatly reduced 
decarboxylase activity that can also catalyse a decarboxylation dependent 
transamination producing an aldehyde, PMP and CO2 (Bertoldi et al, 2001).  This latter 
reaction can occur in wildtype AADC but only in anaerobic conditions, whereas in the 
mutated proteins it occurs both in the presence and absence of O2 (Bertoldi and 
Voltattorni, 2000; Bertoldi et al, 2001).  This demonstrates that altering residues 
involved in substrate-PLP binding can change the reaction specificity of AADC, 
possibly through alteration of the orientation of the substrate-PLP complex.  Whilst 
none of the above residues have been reported to be altered in AADC deficiency several 
disease causing mutations are positioned close to active site residues (Chang et al, 1998; 
Haarvik et al, 2008).  It is consequently conceivable that these mutations could also 
alter the reaction specificity of AADC.  Therefore potentially the AADC enzyme of 
some patients could catalyse aberrant reactions such as the conversion of PLP to PMP, 
which in turn could lead to PLP deficiency in some tissues.   
The structure of AADC contains a flexible loop region consisting of amino acids 328-
339 (Burkhard et al, 2001).  This region is susceptible to proteolytic cleavage in vitro 
however cleavage is prevented in the presence of PLP and a substrate analog, indicating 
that a conformational change occurs on substrate binding (Ishii et al, 1998; Matsuda et 
al, 2004).  Analogous to structurally similar regions in related enzymes the alteration in 
the conformation of this flexible region may act to enclose the active site (Burkhard et 
al, 2001).  Cleavage of this flexible region produces a protein with greatly reduced 
decarboxylase activity (Ishii et al, 1998).  Furthermore the absence of the flexible 
structure led to a large increase in the formation of Pictet-Spengler adducts between the 
substrate and PLP (Bertoldi et al, 1999).  This could indicate the necessity of enclosing 
the active site during catalysis to allow decarboxylation to proceed to completion.   
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1.6.2 Alternative Reactions 
In addition to decarboxylation wildtype AADC has been demonstrated to catalyse 
several other reactions in vitro.  In aerobic conditions alongside decarboxylation there is 
also the formation of Pictet-Spengler adducts between L-dopa or 5-HTP and PLP 
(Bertoldi and Voltattorni, 2000).  This reaction leads to the removal of the PLP 
coenzyme from the active site and consequently inactivates the protein.  Under 
anaerobic conditions a deamination reaction occurs subsequent to decarboxylation 
producing 3,4-dihydroxyphenylacetaldehyde and pyridoxamine 5‟-phosphate (Oleary 
and Baughn, 1977; Bertoldi and Voltattorni, 2000).  The release of CO2 from the active 
site following decarboxylation is hypothesised to be a prerequisite for the protonation of 
the amine α-carbon.  It has been suggested that O2 acts to positively influence the 
release of CO2 and consequently alters the fate of the reaction intermediate (Bertoldi 
and Voltattorni, 2000).  AADC has also been demonstrated in vitro to directly 
deaminate L-aromatic amines including serotonin, producing ammonia and an aromatic 
aldehyde, which in the case of serotonin was 5-hydroxyindoleactealdehyde (Bertoldi et 
al, 1996).  Alongside the serotonin reaction with AADC there was also found to be an 
irreversible inactivation of the enzyme through the permanent incorporation of serotonin 
and PLP into the structure of AADC.  The physiological relevance of these side 
reactions is unknown however enhancement of side reactions has been demonstrated in 
several artificially generated AADC mutants (Bertoldi et al, 2001).  This could suggest 
that some AADC deficiency pathogenic mutations could also alter the reaction 
specificity and side reactions of AADC.  Biochemical characterisation of only one 
AADC deficiency causing mutated protein has been reported (Chang et al, 2004).  This 
AADC mutant had an increased Km for L-dopa but no alternative reactions were 
investigated.  Characterisation of further mutant proteins could elucidate if alternative 
reactions do occur in AADC deficiency and whether this could have pathogenic 
implications.      
1.6.3 Alternative Substrates 
The name aromatic L-amino acid decarboxylase was originally suggested by Lovenberg 
et al (1962) upon their discovery that in addition to L-dopa and 5-HTP AADC was also 
able to decarboxylate all L-aromatic amino acids including L-tryptophan, L-p-tyrosine 
and L-phenylalanine.  The reported Km apparent of AADC ranges from 120µM to 
620µM for L-dopa and 20μM to 490µM for 5-HTP, measured under various reaction 
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conditions with enzyme preparations of different purity and tissue origin (Lovenberg et 
al, 1962; Voltattorni et al, 1983; Boomsma et al, 1986; Moore et al, 1996; Jebai et al, 
1997; Verbeek et al, 2007).  The Km apparent of AADC with L-p-tyrosine, the natural 
L-dopa precursor, was 13mM, with L-phenylalanine was 20mM and with L-tryptophan 
was 3mM (Lovenberg et al, 1962).  Despite these high Km values, in comparison to L-
dopa and 5-HTP, the products of L-p-tyrosine, L-phenylalanine, and L-tryptophan; p-
tyramine, 2-phenylethylamine and tryptamine respectively, are found at low 
concentrations in multiple brain regions and are termed the trace amines (Hess et al, 
1959; Tallman et al, 1976; Suzuki and Yagi, 1976; Buck et al, 1977).  Trace amines 
have a putative role in neuromodulation and a specific family of trace amine receptors 
has been identified (Borowsky et al, 2001).  The physiological function most associated 
with central trace amines is the modulation of classical monoamine neurotransmission.  
2-phenylethylamine and p-tyramine have been shown to enhance dopamine release, 
whilst tryptamine can enhance serotonin mediated inhibition of neuronal firing (Jones 
and Boulton, 1980; Knoll et al, 1996; Nakamura et al, 1998).  Given that AADC is the 
sole enzyme required for the metabolism of the majority of trace amines it is likely that 
in AADC deficiency the trace amines are also deficient, although this possibility has not 
been investigated.  As the trace amines are known to enhance dopamine and serotonin 
neurotransmission it is possible that a deficit of trace amines could have a secondary 
negative effect on monoamine signalling. 
1.6.4 AADC Splicing 
Multiple splice variants of AADC mRNA have been found in various human and 
animal tissues with alterations in both coding and non-coding regions. Two distinct 
mRNAs were discovered in pheochromocytoma and liver of both rat and human 
(Krieger et al, 1991; Ichinose et al, 1992).  These species arise from alternative splicing 
of untranslated exon 1 and exon 2, and are considered to drive expression in non-
neuronal and neuronal tissues respectively (Albert et al, 1992).  However this 
distinction may be an oversimplification as the neuronal type has been isolated from 
kidney (Vassilacopoulou et al, 2004).  Secondly an alternative splicing event within the 
coding region of AADC mRNA was discovered independently by two groups 
(O‟Malley et al, 1995; Chang et al, 1996).  mRNA isolated from human neuroblastoma 
cell lines was found to exist in two forms, AADC480 and AADC442.  In the latter exon 3 
was omitted and when expressed in COS-7 cells had no 5-HTP or L-dopa decarboxylase 
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activity (O‟Malley et al, 1995).  Vassilacopoulou et al (2004) discovered yet another 
species of AADC mRNA.  This alternative transcript, named alt-DDC, was cloned from 
human placenta and compared to full-length AADC480 mRNA is missing exons 10-15, 
but includes an alternative exon 10.  In humans this splice variant of AADC is only 
found in placenta and kidney (Vassilacopoulou et al, 2004).  The functionality of alt-
DDC was not determined.  This would be particularly interesting with regard to AADC 
deficiency given the multiple reports of hyperdopaminuria in AADC deficient patients 
(see section 1.6.5; Abeling et al, 1998, Abeling et al, 2000, Fiumara et al, 2002 and 
Abdenur et al, 2006; Wassenberg et al, 2010).   
1.6.5 AADC Localisation 
AADC within the brain is localised within both serotonergic and catecholaminergic 
neurons (Hokfelt et al, 1973).  In the mammalian brain the majority of serotonergic 
neuronal cell bodies are found within the raphe nuclei and the brainstem reticular 
formation (reviewed by Baumgarten and Grozdanovic, 1997; Hornung, 2003).  The 
raphe nuclei are located on the midline of the brainstem and are generally classified into 
two main groups, the rostral and caudal (Taber et al, 1960; Dahlstrom and Fuxe, 1964).  
Neuronal pathways from the caudal group project mostly to the brainstem and spinal 
cord whilst those of the rostral group mainly ascend to the forebrain (Bjorklund and 
Skagerberg, 1982).  Ascending serotonergic projections target a wide range of structures 
including the basal ganglia, hippocampus, thalamus, hypothalamus and cortex (Azmitia 
and Segel, 1978).  Spinal serotonergic pathways innervate across the grey matter 
especially laminae I and II of the dorsal horn and have been demonstrated to directly 
modulate motor and sensory neuronal activity (Basbaum and Fields, 1979; Proudfit and 
Hammond, 1981; Bjorklund and Skagerberg, 1982; Heckman et al, 2005).  Central 
dopaminergic neurons project from the substantia nigra pars compacta (SNc) and the 
ventral tegmental area (VTA) of the midbrain (Dahlstrom and Fuxe, 1964; Fuxe, 1965; 
Fuxe et al, 1970).  The dopamine SNc neurons project to the dorsal striatum (caudate 
putuman) forming part of the basal ganglia motor circuit and it is this pathway that 
degenerates during Parkinson‟s disease (Hassler, 1938; Hornykiewicz, 1963; Dahlstrom 
and Fuxe, 1964; Fuxe, 1965).  Two dopaminergic pathways originate from the VTA, 
termed the mesolimbic and mesocortical pathways.  The mesolimbic pathway synapses 
predominantly in the nucleus accumbens and olfactory tubercle, but also to the lateral 
septum, hippocampus and amygdala (Haber, 2002).  This pathway is particularly 
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associated with reward based learning and is implicated as a common pathway in 
addiction (Ikemoto, 2007).  The mesocortical dopaminergic pathway projects to the 
prefrontal cortex and is thought to have a modulatory role in higher functions such as 
working memory, and plays an important role in schizophrenia (Tzschentke, 2001; 
Seamans and Yang, 2004; Toda and Abi-Dargham, 2007; Stone et al, 2007a).   
 
AADC is also located in central noradrenergic neurons.  The cell bodies of 
noradrenergic neurons are grouped in the pons, largely in the locus coeruleus, and in the 
medulla, mostly in the reticular formation (Fuxe, 1965; Hillarp et al, 1966).  Projections 
originating from these cell bodies terminate in a wide range of brain areas including the 
spinal cord, hippocampus, cortex and amygdala.  In addition to monoaminergic neurons 
AADC is also expressed in populations of non-monoaminergic neurons, termed D-cells 
(Jaeger et al, 1983; Jaeger et al, 1984; Kitahama et al, 1990; Eaton et al, 1993; 
Kitahama et al, 2009).  In humans D-cells are detectable in the hypothalamus, striatum, 
forebrain and cortex (Kitahama et al, 2009).  The function of D-cells is unknown, 
however it has been postulated that these cells could be involved in trace amine 
production (Jaeger et al, 1983).  Alternatively it is possible that these neurons sequester 
extracellular substrates such as L-dopa and 5-HTP and convert them to dopamine and 
serotonin. Certainly it has been demonstrated that these neurons are able to 
decarboxylate exogenously administered L-dopa (Tison et al, 1991).   
 
Peripherally AADC has a wide expression including in kidney, liver, lung, the 
gastrointestinal tract and plasma (Berry et al, 1996).  AADC located in the 
enterochromaffin cells of the gastrointestinal tract is responsible for production of the 
majority of peripheral serotonin (Lauweryns and Van Ranst, 1988; Jonnakuty and 
Gragnoli, 2008).  Serotonin in the gut is involved in the control of peristalsis and 
secretion, and the disruption of this function is likely to be involved in at least some of 
the gastrointestinal complications observed in patients with AADC deficiency 
(Swoboda et al, 2003).  The enterochromaffin cells also release serotonin into 
circulation where it is taken up and stored in platelets and is involved in platelet 
aggregation and control of vascular tone (Jonnakuty and Gragnoli, 2008).  The function 
of peripheral AADC in some other areas is not well defined.  For example its function 
in plasma is unknown, but perhaps it could provide a secondary source of serotonin for 
platelets. 
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In the kidney AADC is located in the proximal straight and convoluted tubules of the 
nephron and converts circulating or filtered L-dopa into dopamine (Hayashi et al, 
1990).  Renal dopamine acts to inhibit Na
+
 transport leading to an increase in Na
+
 
excretion (Pestana et al, 2001).  Kidney AADC activity is partially regulated by the 
availability of L-dopa (Soares-Da-Silva and Fernandes, 1990).  This may provide an 
explanation for hyperdopaminuria in some patients with AADC deficiency.  L-dopa 
concentrations have been found to be elevated in urine and plasma of AADC deficient 
patients and L-dopa elevation in urine was accompanied by hyperdopaminuria (Abeling 
et al, 1998; Abeling et al, 2000; Swoboda et al, 1999).  As low levels of HVA and 5-
HIAA are detectable in the CSF of AADC deficient patients it is likely that they retain 
some albeit low levels of AADC activity (Pons et al, 2004).  So although AADC 
activity is low, the high levels of L-dopa reaching the kidney are likely to lead to 
increased production of dopamine, which in some cases may lead to hyperdopaminuria.  
An alternative hypothesis could involve the splice variant of AADC termed alt-dopa 
decarboxylase (alt-DDC) that is only found in kidney and placenta (see section 1.6.4; 
Vassilacopoulou et al, 2004).  Alt-DDC is missing exons 10-15, but includes an 
alternative exon 10.  If alt-DDC is translated into a functional protein it is likely to be 
markedly different to the full-length AADC termed AADC480.  It is possible that alt-
DDC could retain L-dopa decarboxylase activity however the functional properties of 
alt-DDC, including L-dopa decarboxylase activity, have not been determined.  AADC 
has been purified from post-mortem human kidney through sequential chromatography 
steps (Mappouras et al, 1990).  At each stage fractions of the eluate were collected and 
all those containing L-dopa-decarboxylase activity were pooled and further purified.  At 
the end of purification a single approximately 50kDa band was detected by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).  This indicates that in 
human kidney L-dopa-decarboxylation is performed by a single protein and that this 
protein is approximately 50kDa, the same predicted molecular weight as AADC480.  
Alt-DDC would have a lower molecular weight and would appear on SDS-PAGE as a 
separate band.  This evidence therefore suggests that full-length AADC480 alone is 
responsible for L-dopa-decarboxylation in kidney and that alt-DDC is not involved. 
1.6.6 AADC Regulation 
The first indication that AADC may be a regulated enzyme came from studies of the rat 
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retina where L-dopa decarboxylation was found to increase in response to light 
(Hadjiconstantinou et al, 1988; Rossetti et al, 1989; Rossetti et al, 1990).  The 
mechanism for this response was shown to be dependent on D1-dopamine receptors and 
β-adrenergic receptors.  Subsequent investigations of AADC regulation focused on the 
striatum where it was found that D2 dopamine receptor agonists caused a decrease in L-
dopa decarboxylation activity (Zhu et al, 1992; Hadjiconstantinou et al, 1993; Cho et al, 
1999).  Conversely D1 and D2 dopamine receptor antagonists caused an increase in 
activity (Zhu et al, 1992; Hadjiconstantinou et al, 1993; Cho et al, 1999).  This evidence 
implies that AADC activity may be under regulation of dopamine perhaps providing a 
negative feedback mechanism for dopamine production.  Moreover Boomsma et al 
(1989) demonstrated that Parkinson‟s disease patients chronically treated with L-dopa 
and the peripheral AADC inhibitors carbidopa or benserazide had increased plasma 
AADC activity compared to patients treated with L-dopa alone or untreated patients.  
The AADC inhibitor NSD-1015 has also been demonstrated to increase AADC mRNA 
and protein in PC12 cells in a dose-dependent manner (Li et al, 1993).  This evidence 
further suggests a feedback mechanism for AADC activity, such that low activity results 
in increased expression.  Furthermore selegiline when administered to mice at doses that 
would inhibit both MAO-A and MAO-B (10mg/Kg), thereby increasing dopamine 
availability, also decreased striatal AADC activity (Cho et al, 1996).  On the other hand 
administered selegiline also increased AADC mRNA and protein in mouse midbrain.  
Pharmacological agents that antagonise serotonin receptors, particularly 5-HT1A and 5-
HT2A, have also been demonstrated to increase AADC activity in rodent brain (Neff et 
al, 2006).  Taken together the above evidence suggests that negative feedback 
mechanisms control AADC activity and consequently monoamine metabolism in both 
dopaminergic and serotonergic neurons.  It is notable that two of the main treatments of 
AADC deficiency, dopamine agonists and MAO inhibitors, have both been shown to 
decrease AADC activity.  However it is unknown whether these modulations of AADC 
determined in animals with normal levels of AADC would be relevant to AADC 
deficient patients where AADC activity is already minimal (see Allen et al, 2009).  
 
There is also some evidence that PLP, the coenzyme for AADC, could also influence 
the level of AADC protein and possibly expression.  AADC activity, with either L-dopa 
or 5-HTP as substrate, was found to be reduced in rodents fed on a vitamin B6 deficient 
diet or pharmacologically depleted of vitamin B6 (Rahman et al, 1982; Siow and 
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Dakshinamurti, 1985).  In both studies adding PLP to the samples prior to measuring 
AADC activity did not return activity to control levels.  This indicates that the reduction 
in activity was unlikely to be due to a lack of available coenzyme during the assay but 
instead may be due to a reduction in active AADC enzyme.  Matsuda et al (2004) found 
decreased levels of AADC activity and protein in PLP-depleted rat pheochromocytoma 
cells treated with the vitamin B6 antagonist 4-deoxypyridoxine.  The authors proposed 
that the loss of AADC protein could relate to decreased stability of the non-PLP bound 
form of AADC, although no evidence of decreased cellular stability of AADC was 
presented.  In Parkinson‟s disease patients treated with L-dopa the addition of 
pyridoxine has been demonstrated to reverse L-dopa‟s clinical effect, however the 
addition of a peripheral AADC inhibitor prevents this effect of pyridoxine (Duvoisin et 
al, 1969; Klawans et al, 1971). The antagonism of the pyridoxine effect upon L-dopa 
treatment with an AADC inhibitor could suggest that peripheral decarboxylation of L-
dopa by AADC was increased by pyridoxine treatment.   
1.7 AADC Deficiency Pathogenesis   
1.7.1 Pathogenic Mechanism 
The clinical manifestation of AADC deficiency is considered to be largely the result of 
serotonin and dopamine deficiency, with the deficiency of noradrenaline, adrenaline and 
melatonin also involved (Swoboda et al, 2003; Brun et al, 2010). Certainly the majority 
of clinical symptoms can be linked to deficits in the neuronal and non-neuronal systems 
that are ordinarily reliant on these signalling molecules (Hyland et al, 1992; Swoboda et 
al, 2003.  However the lack of response to treatment in the majority of patients is 
perhaps an indication that neurotransmitter deficiency is not the only pathogenic 
mechanism.  In particular the inadequacy with which dopamine agonists replace 
dopamine signalling or receptor activation provides a potential indication that the brains 
of the majority of AADC deficient patients may have an altered reactivity toward these 
chemicals.  There are multiple potential explanations for how this lack of 
responsiveness could arise.  One possibility is that as a result of monoamine deficiency 
developmental changes have taken place in the neuronal pathways that would ordinarily 
be receptive to monoamine replacement therapy.  An alternative could be that, whilst 
these neuronal pathways have developed normally, adaptive changes, such as alteration 
of receptor density at synapses, have taken place in such a way as to make treatment 
ineffective.  A further possibility may be that the state of AADC deficiency is in some 
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way detrimental to neuronal populations and initiates a neurodegenerative process.  No 
investigations of brain pathological specimens from AADC deficient patients have been 
reported and consequently it is difficult to ascertain whether developmental, adaptive or 
degenerative processes have taken place.  Nevertheless there is some evidence that 
neurodegeneration could occur in AADC deficiency.  Firstly there have been reports 
that the disease course is progressive, with some patient‟s symptoms deteriorating over 
time (Fiumara et al, 2002).  Secondly results of magnetic resonance imaging have 
indicated mild brain atrophy and other potentially degenerative changes in several cases 
(Lee et al, 2009; Manegold et al, 2009; Brun et al, 2010).  Thirdly using positron 
emission tomography and the DAT marker 
99m
Tc-TRODAT-1 it has been shown in one 
case of AADC deficiency that DAT expression was reduced (Lee et al, 2009).  This 
alteration may be an adaptive change to dopamine deficiency however reduced DAT 
expression has also been linked to the early stages of degeneration of the nigrostriatal 
pathway (Wullner et al, 2005; Lee et al, 2009). 
1.7.2 Precursor Accumulation  
A metabolic block caused by inborn errors of metabolism can commonly lead to the 
accumulation of precursor molecules or their metabolites.  This accumulation can often 
contribute to the pathogenesis of the condition.  For example this mechanism may 
underlie the pathogenesis of hyperphenylalaninemia.  Here accumulated blood 
phenylalanine, due to either phenylalanine hydroxylase deficiency or BH4 deficiency, 
competes for uptake across the blood-brain barrier through the large neutral amino acid 
transporter (McKean et al, 1968; McKean, 1972; Curtius et al, 1972; Surtees and Blau, 
2000; van Spronsen et al, 2009).  Consequently the uptake of other vital amino acids 
can be inhibited and the brain can become deficient in these amino acids, which include 
L-tyrosine and L-tryptophan.  In AADC deficiency analysis of patient CSF 
demonstrates that there can be an accumulation of both 5-HTP (Patient Range: 51-264 
nM, Reference Range: <10nM) and L-dopa (Patient Range: <2-549 nM, Reference 
Range <25nM; Abeling et al, 1998; Maller et al, 1997; Brun et al, 2010).  In addition 
the L-dopa metabolite 3-OMD is also generally increased in the CSF of AADC 
deficient patients (Patient Range: 54-4293 nM, Reference Range: <100nM; Hyland et 
al, 1992; Maller et al, 1997; Brun et al, 2010).  It is possible that these accumulated 
substrates either directly or through alternative metabolic pathways could contribute to 
the pathogenesis of AADC deficiency.   
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1.7.3 Alternative metabolic pathways for 5-HTP 
Beyond indoleamine metabolism an alternative metabolic route via the kynurenine 
pathway has been identified for 5-HTP (see figure 1.6; Fujiwara et al, 1979).  Through 
this pathway 5-HTP is initially converted to 5-hydroxyformylkynurenine by the enzyme 
indoleamine 2,3-dioxygenase (IDO; EC No. 1.13.11.11; Shimizu et al, 1978; Littlejohn 
et al, 2000) and subsequently converted by arylformamidase (E.C. 3.5.1.9) to 5-
hydroxykynurenine (Tsuda et al, 1974).  5-hydroxykynurenine has been shown to be 
decarboxylated to 5-hydroxykynuramine in rat intestine and brain (Noguchi et al, 1970; 
Tsuda et al, 1972).  The enzyme responsible for this decarboxylation is not known, 
however the reaction is PLP dependent.  Given its broad substrate specificity it is 
possible that AADC could catalyse this reaction.  5-hydroxykynuramine can also be 
produced directly from serotonin by the actions of IDO and arylformamidase.  5-
hydroxykynurenine can alternatively be metabolised to 6-hydroxykynurenic acid, while 
5-hydroxykynuramine can be converted to 4, 6-dihydroxyquinoline (see figure 1.6; 
Tsuda et al, 1972).  The enzymes responsible for these latter stages have not been 
identified.  Physiological and pathophysiological roles for the 5-HTP kynurenine 
metabolites have largely remained uninvestigated.  However it has been demonstrated 
that 5-hydroxykynuramine can act as a serotonin agonist in arterial smooth muscle 
(Toda et al, 1974; Toda, 1975; Kitamura et al, 1979).   
 
Whilst the 5-HTP-kynurenine metabolites are relatively uncharacterised the metabolites 
of tryptophan via the kynurenine pathway have received more attention (see figure 1.6).  
Three of these metabolites are known to have neuroactive or neurotoxic properties.  
Quinolinic acid has been demonstrated to be neurotoxic through glutamate N-methyl D-
aspartate (NMDA) receptor activation leading to excitotoxicity and free radical 
production (Foster et al, 1983; Garthwaite and Garthwaite, 1987; Santamaria et al, 
2001).  Conversely kynurenic acid is an NMDA receptor antagonist and may protect 
against neuronal cell death (Lehmann, 1987; Stone et al, 2007b; Lee et al, 2008c). 3-
hydroxykynurenine is an intermediate of tryptophan-kynurenine metabolism which can 
undergo oxidation leading to neurotoxicity through the generation of reactive oxygen 
species and hydrogen peroxide (Okuda et al, 1998; Guidetti and Schwarcz, 1999).    
Metabolites of tryptophan via the kynurenine pathway have been associated with 
disorders such as Huntington‟s disease, Alzheimer‟s disease and many infective and
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Figure 1.6 Kynurenine metabolic pathway. IDO: indolamine 2,3-dioxygenase, TPH: tryptophan hydroxylase, AADC: aromatic L-amino acid 
decarboxylase, KA: kynureninase, K 3-H: kynurenine 3-hydroxylase, KAT: kynurenine aminotransferase, 3-HAO: 3-hydroxyanthranilic acid oxidase, 
AADC: aromatic L-amino acid decarboxylase, PLP: pyridoxal 5-phosphate, L-Ala: L-alanine, BH4: tetrahydrobiopterin, *unknown enzyme(s).
54 
 
inflammatory conditions (Bruyn and Stoof, 1990; Guillemin et al, 2003; Guillemin et 
al, 2005a; Leonard, 2007).  It is possible that 5-HTP-kynurenine metabolites could have 
similar neurotoxic properties to tryptophan-kynurenine metabolites, although this 
possibility has not been investigated.  For example 5-hydroxykynurenine differs from 3-
hydroxykynurenine only in the position of the hydroxyl group and conceivably could 
also be susceptible to oxidation.  The accumulation of 5-HTP in AADC deficiency 
could lead to an increase in the levels of 5-HTP-kynurenine metabolites and 
consequently may contribute to the pathogenesis of this disorder. 
1.7.4 Alternative Metabolic Pathways for L-dopa 
The main alternative metabolic pathway to catecholamine metabolism for L-dopa is 
initiated by COMT which methylates L-dopa to 3-OMD with SAM acting as a methyl 
donor (see figure 1.7; Alexrod and Tomchick, 1958; Pletscher et al, 1967; Fellman et al, 
1971). 3-OMD is subsequently converted to vanilpyruvic acid in a reaction catalysed by 
tyrosine aminotransferase, requiring 2-oxoglutarate as an amino group acceptor and 
pyridoxal 5‟-phosphate as a co-enzyme (Miller and Litwack, 1971; Maeda et al, 1978).  
Vanilpyruvic acid is reduced to vanillactic acid (VLA) by aromatic α-ketoacid 
reductase, although this reaction can also be catalysed by lactate dehydrogenase, both 
reactions require reduced nicotinamide adenine dinucleotide (NADH) as an electron 
donor (Zannoni and Weber, 1966; Meada et al, 1978).  Tyrosine aminotransferase and 
α-ketoacid reductase have been detected in human liver, heart, kidney and brain 
(Fellman et al, 1969; Donald, 1982). VLA is excreted in urine, and is commonly found 
in high levels in the urine of patients with AADC deficiency (Goodwin et al, 1978; 
Hyland and Clayton, 1992; Abeling et al, 1998).  Studies in rats have suggested that 3-
OMD at high concentrations competes with L-dopa for transport across the blood-brain 
barrier, consequently reducing L-dopa accumulation and dopamine turnover (Wade and 
Katzman, 1975; Reches and Fahn, 1982; Lee et al, 2008d).  However 3-OMD, at 
plasma concentrations replicating those found in Parkinson‟s disease patients treated 
with L-dopa (39 ± 4 μM), was not found to inhibit the uptake of 6-[18F]fluorodopa in 
Macaques (Guttman et al, 1992). These plasma concentrations are higher than those 
found in AADC deficiency (Patient Range: 9-10.5μM; Hyland et al, 1992; Maller et al, 
1997), indicating that 3-OMD is unlikely to block blood-brain barrier transport in 
AADC deficient patients. 
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L-dopa is also a substrate for the biosynthesis of the pigment melanin (reviewd by 
Riley, 1997; Pattison et al, 2002).  The initial enzyme in melanin synthesis is tyrosinase, 
a bifunctional enzyme that catalyses the hydroxylation of tyrosine to L-dopa and the 
oxidation of L-dopa to dopaquinone (Hearing and Ekel, 1976). Dopaquinone 
subsequently undergoes a series of spontaneous and enzymatically catalysed reactions 
to form the indolic polymer melanin (Riley, 1997; Pattison et al, 2002).  The reactions 
of melanin formation occur within specialised membrane bound organelles termed 
melanosomes (Seiji and Fitzpatrick, 1961; Seiji et al, 1963).  Tyrosinase is not 
expressed in the brain (Gimenez et al, 2003; Tribl et al, 2007), however L-dopa can also 
readily undergo auto-oxidation producing dopaquinone via a free radical intermediate, 
dopa-semiquinone (Monder et al, 1957a; Felix and Sealy, 1981; Pattison et al, 2002).  
The oxidation of L-dopa to dopa-semiquinone and its subsequent oxidation to 
dopaquinone can be catalysed by transition metal ions (Monder et al, 1957b).  
Furthermore dopa-semiquinone can react with O2 and H2O2 producing O2
•-
 and the OH
•-
 
respectively (Pattison et al, 2002).    Dopamine can undergo a similar auto-oxidation 
process.  Auto-oxidation of dopamine, and to a lesser extent L-dopa, is thought to lead 
to the production of neuromelanin, a characteristic feature of dopaminergic nigrostriatal 
neurons (Wakamatsu et al, 2003).  Neuromelanin is a dark pigment contained within a 
membrane bound autophagic vacuole.  The production of neuromelanin may be driven 
by excess cytosolic catecholamines (Sulzer et al, 2000).  If excess cytosolic L-dopa can 
drive neuromelanin production then patients with AADC deficiency, in whom L-dopa 
accumulates, may have increased levels of neuromelanin.  L-dopa as well as dopamine 
have been demonstrated to be toxic in vitro due to auto-oxidation, leading to the 
production of hydrogen peroxide and melanin, the induction of apoptotic pathways and 
lipid peroxidation (Mena et al, 1993; Basma et al, 1995; Lai and Yu, 1997; Nakao et al, 
1997; Offen et al, 2001; Pedrosa and Soares-Da-Silva, 2002; Haque et al, 2003), 
however in vivo experiments indicate that L-dopa may not be toxic (Mytilineou et al, 
2003; LeWitt and Nyholm, 2004; Muller et al, 2004).  Furthermore L-dopa has been 
demonstrated to have some neurotrophic and neuroprotective effects at sub-toxic 
concentrations (Mytilineou et al, 1993; Han et al, 1996; Mena et al, 1997a; Jia et al, 
2008a).  The accumulation of L-dopa seen in AADC deficiency leads to an 
accumulation of 3-OMD, which can be seen in CSF of AADC patients.  This excess of 
L-dopa may also undergo auto-oxidation with potential neurotoxic and neuroprotective 
effects that could influence the pathogenesis of AADC deficiency.  
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1.7.5 Oxidative Stress 
Both 5-HTP and L-dopa accumulation has the potential to produce reactive oxygen 
species (ROS) either via direct oxidation or through metabolism (Monder et al, 1957a; 
Felix and Sealy, 1981; Ng et al, 2000; Pattison et al, 2002; Smith et al, 2009).  ROS is a 
collective term for oxygen derived reactive molecules including both free radicals such 
as O2
•-
 and non-radicals such as hydrogen peroxide (H2O2; Halliwell, 1992).  Reactions 
involving ROS can lead to cellular damage such as adduct formation with DNA guanine 
nucleotides or lipid peroxidation (Halliwell and Gutteridge, 1984; Steenken, 1989). 
Oxidative stress refers to a circumstance where the generation of ROS outweighs a cells 
capability to detoxify ROS and repair damage generated by ROS.  The central nervous 
system (CNS) may be particularly susceptible to oxidative stress due to its unique 
physiological functions (reviewed by Halliwell, 1992; Halliwell, 2006).  The 
mammalian brain has an especially high requirement for O2 which in turn is due to the 
high usage of adenosine triphosphate (ATP). For example ATP is utilised to maintain 
ion concentration gradients across membranes required for essential neuronal functions 
such as maintaining membrane potentials and neurotransmitter transport such as via 
SERT, DAT and VMAT2 (Dunham and Glynn, 1961; Tissari et al, 1969; Xie and 
Stone, 1986; Moriyama and Nelson, 1987; Cidon and Sihra, 1989; Skou, 1998).  The 
vast majority of O2 is reduced to H2O by cytochrome c oxidase (complex IV) of the 
mitochondrial electron transport chain (Sas et al, 2007).  However also at the 
mitochondrial electron transport chain approximately 1-2% of O2 is reduced to O2
•-
 due 
to electron „leakage‟ mostly at complex I, but also at complex III (Kudin et al, 2005). 
O2
•-
 can be reduced to H2O2 by manganese-containing superoxide dismutase (MnSOD) 
in the mitochondrial matrix or copper and zinc containing superoxide dismutase 
(CuZnSOD) in the rest of the cell (Okado-Matsumoto and Fridovich, 2001).  H2O2 is 
also produced in the brain by MAO during the degradation of serotonin, dopamine and 
noradrenaline (McEwen, 1965; Spina and Cohen, 1989).  Catalase and glutathione 
peroxidase (GPx) can detoxify H2O2 however both may only be present at low 
concentrations within some brain tissues (de Marchena et al, 1974; Mavelli et al, 1982; 
Halliwell, 2006; see section 1.7.6).  The brain may also be more susceptible to oxidative 
stress due to a relatively high iron content and potentially a low iron bind capacity in the 
CSF, increasing the possibility of OH
•-
 production via the Fenton reaction (Harrison et 
al, 1968; Bleijenberg et al, 1971; reviewed by Gutteridge, 1994; Bradbury, 1997).  
Furthermore neuronal membranes are rich in polyunsaturated fatty acids increasing their 
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Figure 1.7 L-dopa catabolism. AADC: aromatic L-amino acid decarboxylase, PLP: 
pyridoxal 5‟-phosphate, SAM: S-adenosylmethionine, SAH: S-adenosylhomocysteine, 
α-KAR: α-ketoacid reductase. 
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susceptibility to lipid peroxidation (reviewed by Farooqui and Horrocks, 1998). 
1.7.6 Glutathione 
One of the most important cellular defences against oxidative stress is reduced 
glutathione (GSH) which is the most abundant non-protein cellular thiol (reviewed by 
Ballatori et al, 2009).  GSH is synthesised through the action of γ-glutamylcysteine 
ligase that forms the dipeptide γ-glutamylcysteine from glutamate and cysteine, and 
subsequently glutathione synthase which adds glycine to γ-glutamylcysteine to form the 
tripeptide GSH (see figure 1.8; Mandeles and Bloch, 1955; Snoke and Bloch, 1955).  
Both stages of GSH synthesis require ATP and γ-glutamylcysteine ligase is the rate 
limiting enzyme for the formation of GSH.  The antioxidant capability of GSH is two-
fold; firstly GSH can be directly oxidised by ROS to form glutathione disulphide 
(GSSG); secondly GSH can act as an electron donor for the conversion of H2O2 to 
2H2O by GPx, again producing GSSG (reviewed by Martin and Teismann, 2009; 
Ballatori et al, 2009).  GSSG is reduced back to form two molecules of GSH by the 
enzyme glutathione reductase using reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) as an electron donor (Rall and Lehninger, 1952; Scott et al, 1963).  
This redox cycling between GSH and GSSG, in combination with other redox couples 
such as thioredoxin, allows the cell to maintain a redox balance and detoxify reactive 
oxygen species (reviewed by Kalinina et al, 2008). 
Within the brain and in cell culture the GSH content of astroglial cells is higher than 
that of neurons (Slivka et al, 1987; Raps et al, 1989; Bolanos et al, 1995).  The 
intracellular GSH concentration in primary neurons cultured separated from glia was 
found to decrease over time (Sagara et al, 1993).  This decrease is considered to be due 
to the inability of neurons to utilise cystine to form reduced cysteine as a precursor of 
GSH (Sagara et al, 1993; Kranich et al, 1996).  Conversely glial cells are able to utilise 
cystine in the generation of GSH (Kranich et al, 1998).  In neuronal-glial co-cultures 
neuronal GSH content is maintained, demonstrating that glial cells provide a source of 
cysteine for neuronal GSH synthesis (see figure 1.9; Sagara et al, 1993; Dringen et al, 
1999).  It has been shown that astrocytes release GSH (Yudkoff et al, 1990; Sagara et 
al, 1996) and in addition astrocytes release superoxide dismutase (SOD) which prevents 
the extracellular oxidation of GSH (Stone et al, 1999; Stewart et al, 2002; Pope et al, 
2008). Released GSH can be subsequently broken down by the enzyme γ-glutamyl 
transpeptidase (γ-GT), expressed on the cell surface of astrocytes, to form 
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cysteinylglycine (CysGly) whilst transferring the γ-glutamyl group to an acceptor 
(Dringen et al, 1997).  Inhibiting γ-GT prevented the increase in neuronal GSH content 
seen when these cells were co-cultured with astrocytes (Dringen et al, 1999). It has been 
further demonstrated that CysGly is hydrolysed by aminopeptidase N, expressed on the 
surface of neurons, to give cysteine and glycine (Dringen et al, 2001).  The action of 
aminopeptidase N is also required for the astrocyte-dependent increase in neuronal 
GSH.  This release and subsequent breakdown of GSH from astrocytes may provide 
much of the amino acids, particularly cysteine for GSH synthesis within neurons 
(reviewed by Dringen and Hirrlinger, 2003).   It is possible that the accumulation of L-
dopa and/or 5-HTP in AADC deficiency could increase the production of ROS in the 
brain of AADC deficient patients.  This proposed increase in ROS production could in 
turn disrupt GSH homeostasis potentially leading to oxidative stress.  
1.7.7 Mitochondrial Respiratory Chain  
The mitochondrial electron transport chain consists of four multi-subunit complexes 
bound to the inner mitochondrial membrane (see figure 1.10). Complex I 
(NADH:ubiquinone oxidoreductase) transfers two electrons from NADH via flavin 
mononucleotide and iron-sulfur prosthetic groups to reduce ubiquinone to ubiquinol 
(reviewed by Hirst, 2010). This electron transfer drives the transport of 4H
+
 across the 
mitochondrial inner membrane from the matrix to the intermembrane space.  Complex 
II (succinate:ubiquinone oxidoreductase) oxidises succinate to fumarate as part of the 
citric acid cycle, transferring the electrons to covalently bound flavin adenine 
dinucleotide (FAD) to generate FADH2 (reviewed by Cecchini, 2003).  Electrons are 
then transferred from FADH2 via iron-sulphur clusters to reduce ubiquinone to 
ubiquinol.   
Complex III (ubiquinol:cytochrome c oxidoreductase) contains three heme centres 
termed cytochrome bL, cytochrome bH and cytochrome c1 as well as two ubiquinone 
binding sites, Qo that binds one molecule of reduced ubiquinol and Qi that binds one 
molecule of oxidised ubiquinone (De Vries et al, 1982; reviewed by Crofts, 2004).  One 
electron from bound ubiquinol is transferred via an iron sulphur cluster and cytochrome 
c1 to reduce cytochrome c, a small water soluble heme- containing protein. This reduced 
cytochrome c can then diffuse away from complex III.  The remaining electron from 
ubiquinol is transferred via cytochrome bL and cytochrome bH to the oxidised 
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Figure 1.8 Glutathione synthesis and recycling. GSH: reduced glutathione, GSSG: 
glutathione disulphide. 
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ubiquinone bound at Qi producing a ubisemiquinone.  This process is then repeated with 
a second molecule of reduced ubiquinol binding at Qo, transferring one electron to a 
cytochrome c molecule and a second electron to ubisemiquinone at Qi to give ubiquinol.  
With each reduction of a ubiquinol molecule 2H
+
 are released to the intermembrane 
space.  In addition 2H
+
 from the mitochondrial matrix are utilised by the reduction of 
ubiquinone at Qi. 
Complex IV (cytochrome c oxidase) catalyses the final step in the electron transport 
chain, the reduction of O2 to 2H2O using four molecules of oxidised cytochrome c 
(reviewed by Brzezinski and Gennis, 2008).  This complex contains two copper centres 
(CuA and CuB) and two heme centres (Hemea and Hemea3).  An electron from the first 
molecule of oxidised cytochrome c is transferred via CuA and both heme centres to CuB, 
reducing Cu
2+
 to Cu
+
. An electron from a second molecule of cytochrome c is 
transferred via CuA and Hemea to Hemea3, reducing Fe
3+
 to Fe
2+
.  Oxygen then binds 
initially to hemea3 and then additionally to CuB, forming a peroxide bridge between 
these two centres.  Third and fourth electrons from two oxidised cytochrome c 
molecules and 2H
+
 from the mitochondrial matrix sequentially break this bond and 
produce hydroxyl groups bound to the copper and iron in CuB and hemea3 respectively.  
The final addition of 2H
+
 from the mitochondrial matrix generates 2H2O from the 
hydroxyl groups.  In addition 4H
+
 are transferred from the matrix to the intermembrane 
space during this process (Wikstrom, 1977). 
Complexes I, III and IV all contribute during electron transport to the H
+
 gradient across 
the mitochondrial inner membrane.  This H
+
 gradient is used to drive the final stage in 
oxidative phosphorylation, ATP generation via ATP synthase (complex V).  ATP 
synthase is a multi-subunit complex consisting of two main domains F1 and F0.  F0 is a 
transmembrane domain tranversing the mitochondrial inner membrane, whilst F1 is 
soluble and positioned on the matrix side of the inner membrane (reviewed by von 
Ballmoos et al, 2008).  Binding and transloction of H
+
 ions at F0 from the 
intermembrane space to the matrix generates rotation in the structure of the complex 
(Walker et al, 1998; Stock et al, 1999; Stock et al, 2000).  This rotation changes the 
conformational state of subunits within the F1 domain altering the binding affinity for 
adenine nucleotides and driving ATP synthesis.  However the reaction is reversible and 
when the H
+
 gradient across the mitochondrial inner membrane decreases ATP synthase 
can utilise ATP hydrolysis to transfer H
+
 ions in the opposite direction.   
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The mitochondrial respiratory chain as well as being a potential source of ROS (see 
section 1.7.5) may also be sensitive to oxidative stress.  An accumulation of substrates 
in AADC deficiency could hypothetically increase the production of ROS in the brain, 
which in turn may lead to damage to the mitochondrial respiratory chain.  ROS have 
been demonstrated to damage all components of the respiratory chain in vitro and 
induction of oxidative stress or depletion of GSH can affect activity of the complexes in 
vivo (Zhang et al, 1990; Benzi et al, 1991; Bolanos et al, 1994; Heales et al, 1995; 
Bolanos et al, 1996; Merad-Boudia et al, 1998; Merad-Saidoune et al, 1999; Chinta and 
Andersen, 2006).  Furthermore inhibition of complex I can in turn increase O2
•-
 
production potentially exacerbating oxidative stress (Lambert and Brand, 2004).  
Damage to the mitochondrial respiratory chain could reduce ATP synthesis, decreasing 
energy supply to the cell.  This may be particularly detrimental to neurons as glycolysis 
is actively downregulated in these cells and consequently cannot compensate for the 
loss of oxidative phosphorylation (Almeida et al, 2001; Herrero-Mendez et al, 2009). In 
addition decreased respiratory chain function can lead to dissipation of the 
mitochondrial membrane potential, altered Ca
2+
 homeostasis, opening of the 
mitochondrial permeability transition pore and cell death through the release of pro-
apoptotic proteins including cytochrome c into the cytoplasm (Wu et al, 1990; Bernardi 
and Petronilli, 1996; Packer et al, 1996; Chernyak and Bernardi, 1996; Clayton et al, 
2005; Wu et al, 2007; Oppenheim et al, 2009).   
1.8 Hypotheses 
1) 5-HTP accumulation in AADC deficiency is toxic to neurons or glial cells either 
directly or via the kynurenine pathway through the induction of oxidative stress. 
2) The accumulation of L-dopa in AADC deficiency leads to the induction of 
oxidative stress and neuronal cell death. 
3) The availability of the AADC cofactor PLP influences the stability or expression 
of the AADC enzyme.  
1.9 Aims 
1) To establish the plasma AADC activity assay as a diagnostic test in the UK. 
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2) To investigate the effect of 5-HTP accumulation on neuronal cell viability and 
oxidative stress by determining cellular GSH levels and mitochondrial 
respiratory chain function in cell culture. 
3) To investigate the potential role of L-dopa accumulation in the generation of 
oxidative stress by examining cell viability, GSH homeostasis and mitochondrial 
respiratory chain function in cell culture. 
4) To investigate the role of PLP in the regulation of AADC availability. 
 
 6
4
 
 
Figure 1.9 Glutathione trafficking from astrocytes to neurons. γ-GCL: γ-glutamylcysteine ligase, GS: glutathione synthase, GSH: reduced 
glutathione, MRP1: multidrug resistance protein 1, γ-GT: γ-glutamyltranspeptidase, ApN: aminopeptidase N, SOD: superoxide dismutase
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Figure 1.10 Mitochondrial respiratory chain. Ubi: ubiquinone, C: cytochrome C
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Chapter 2 
2 Material and methods 
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2.1 Materials 
The following were purchased from VWR International Ltd (Lutterworth, UK): 
Disodium hydrogen orthophosphate; sodium dihydrogen orthophosphate; potassium 
dihydrogen phosphate; dipotassium hydrogen phosphate;  ethylenediaminetetraacetic 
acid (EDTA); hydrochloric acid (12.2M); methanol HiPerSolv for HPLC; potassium 
hydroxide; sodium hydroxide; sodium bicarbonate; sodium chloride; calcium chloride; 
magnesium sulfate and D-glucose. 
The following were purchased from Sigma Aldrich (Poole, UK): 
1,4-Dithioerythritol; pyridoxal 5‟-phosphate; L-3,4-dihydroxyphenylalaine; perchloric 
acid; sodium-L-ascorbate; dopamine; 1-octanesulfonic acid; L-5-hydroxytryptophan; 
serotonin; 5-hydroxyindoleacetic acid; homovanillic acid; 3,4-dihydroxyphenylacetic 
acid; 3-O-methyldopa; noradrenaline;  trichloroacetic acid; 3-hydroxybenzylhydrazine 
dihydrochloride (NSD-1015); tranylcypromine; Ro-41-0960; SCH-23390; sulpiride; 
superoxide dismutase; catalase; cyclohemimide; pyridoxal; 4-deoxypyridoxine; 
sulforhodamine B monosodium salt; tris base; tris HCl; Sterile modified Hank‟s 
balanced salt solution with sodium bicarbonate, without phenol red, calcium chloride 
and magnesium sulphate (HBSS); sodium dodecyl sulphate (SDS); tween 20; triton X-
100; sodium deoxycholate; mammalian protease inhibitor cocktail; sucrose; sterile 
4mL/L trypan blue; dimethyl sulfoxide; fusaric acid; reduced glutathione; β-
nicotinamide adeneine dinucleotide reduced; potassium cyanide; ubiquinone; 
cytochrome c; antimycin A; rotenone; ferricyanide; acetyl-coenzyme A; 5, 5‟-dithio-bis 
(2-nitrobenzoic acid); oxaloacetate  and sodium pyruvate. 
850mL/L Orthophosphoric acid HPLC electrochemical grade was purchased from 
Fisher Scientific UK Ltd (Loughborough, UK). 
Sterile cell culture products: Dulbecco‟s modified eagles medium (DMEM); 
DMEM/Ham‟s F-12 Nutrient Mixture (DMEM/F-12) (1:1); L-glutamine;; foetal bovine 
serum, heat inactivated; 2.5mL/L trypsin-EDTA; recombinant human interferon-γ; Nu-
PAGE sample buffer; Nu-PAGE MES SDS running buffer, Nu-PAGE  4-12% Bis-Tris 
gel were purchased from Invitrogen Ltd (Paisley, UK). 
HPLC vials and caps were purchased from Chromacol (Welwyn Garden City, UK). 
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Mini trans-blot filter paper and DC total protein assay kit were purchased from Bio-Rad 
Laboratories Ltd (Hemel Hempstead, UK). 
Pierce ECL western blotting substrate was purchased from Thermo Fisher Scientific 
Inc. (Rockford, IL, USA). 
All other reagents were analytical grade and purchased from Sigma Aldrich, Fisher 
Scientific or VWR International except where stated. 
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2.2 High performance liquid chromatography 
Catecholamines, indoleamines and GSH were quantified using reversed-phase high 
performance liquid chromatography (HPLC) coupled to electrochemical detection 
(ECD).  Reversed-phase HPLC utilises a non-polar stationary phase and an aqueous 
mobile phase to separate analytes.  Non-polar molecules tend to adsorb to the stationary 
phase and so are retained on the column longer than polar molecules (Molnar and 
Horvath, 1976).    ECD uses an electrical potential to oxidise or reduce analytes flowing 
past the surface of electrodes, generating a current that can be used to quantify the 
analyte (reviewed by Mefford, 1981).  Throughout this thesis coulometric 
electrochemical detection was utilised, where the total amount of analyte present is 
oxidised and consequently the current is directly proportional to the concentration of the 
analyte (Mefford, 1981; Marsden and Joseph, 1986). 
2.2.1 Catecholamine HPLC 
2.2.2 Equipment 
HPLC equipment: PU-2080 Plus pump (Jasco (UK) Ltd., Great Dunmow, UK); AS-
2057 Plus autosampler (Jasco); Coulochem III electrochemical detector and 5010 
analytical cell (ESA Analytical Ltd., Aylesbury, UK) assembled as in figure 2.1. The 
electrochemical detector was coupled to a computer and data recorded using AZUR 
version 4.6 chromatography data capture and analysis software (Datalys, Saint Martin 
D‟Heres, France). The mobile phase was degassed using a Degasys populaire inline 
degasser (Degasys, Japan). 
2.2.2.1 Procedure 
This method is based on that of Hyland and Clayton (1992) adapted here for the 
simultaneous determination of L-dopa, 3-OMD, dopamine, DOPAC and HVA.  The 
mobile phase consisted of 50mM potassium phosphate (pH 3.12), 1.4mM 
octanesulfonic acid, 0.05mM EDTA, 170mL/L methanol in HPLC grade water.  The 
flow rate was 1.0mL/min. Samples were thawed at +20˚C, transferred to vials and 
loaded into the autosampler, maintained at +4˚C.  50µL of each sample was injected and 
separated on a C18 reversed phase 250 x 4.6mm i.d. HiQSil C18W column (KYA Tech. 
Corp. Tokyo, Japan), maintained at +35˚C.  Analytes were detected by coulometric 
electrochemical detection.  The screening electrode (E1) was set to +20mV to oxidise 
analytes of low oxidation potential.  A voltamogram was used to determine the 
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optimum potential for the detector electrode (E2) by measuring the peak area of 500nM 
L-dopa, 3-OMD, dopamine, DOPAC and HVA at electrode potentials ranging from 
+30mV to +520mV (see figure 2.2a). An E2 electrode potential of +450mV was chosen 
for determination of all five analytes.  Samples were quantified against external 
standards of 250nM L-dopa, 3-OMD, dopamine, DOPAC and HVA in 0.4M perchloric 
acid (see figure 2.2b). 250nM noradrenaline was run with each standard to ensure it did 
not co-elute with the L-dopa peak.  Noradrenaline was not quantified due to co-eluting 
peaks within samples. Calibration curves were performed to determine the linearity 
between current amplitude and standard concentration (see figure 2.3a).  Linearity was 
demonstrated for L-dopa between 1nM and 4000nM and for 3-OMD, dopamine, 
DOPAC and HVA 5nM and 5000nM (r
2
 = 1.000 for each analyte).  An example of a 
sample chromatogram is presented in figure 2.3b. 
2.2.2.2 Data Analysis 
Catecholamines were identified and quantified using the AZUR Version 4.6 software 
package (Datalys) using the following equation: 
Conc. (nM) = (sample peak area /external standard peak area) x calibration standard 
conc. (nM) 
For intracellular determination of catecholamines the conc. (nM) was divided by total 
protein (mg/mL) and expressed as pmol/mg of protein. 
2.2.3 Measurement of Indoleamines by HPLC 
2.2.3.1 Equipment 
The equipment used was as described for catecholamine measurement, see section 2.2.2 
and figure 2.1 
2.2.3.2 Procedure 
This method is based on the method of Alvarez et al (1999) with some minor 
modifications.  The mobile phase consisted of 50mM potassium phosphate (pH 2.6), 
1mM OSA, 50µM EDTA, 170mL/L methanol in HPLC grade H2O run at 1.3mL/min.  
Samples were transferred to vials and loaded into the autosampler and maintained at 
 7
1
 
Figure 2.1 Flow diagram of HPLC-ECD system.  Used for quantitation of catecholamines, indoleamines and GSH 
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a. 
 
b. 
 
Figure 2.2 Caetcholamine HPLC voltamogram and external standard 
Chromatogram.  a. Voltamogram of 250nM L-dopa, 3-OMD, dopamine, DOPAC and 
HVA. b. Representative chromatogram of an external catecholamine standard of 250nM 
L-dopa, 3-OMD, dopamine, DOPAC, HVA and noradrenaline. 
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a. 
 
b. 
 
Figure 2.3 Catecholamine HPLC calibration curve and sample chromatogram. a. 
Caibration curve of L-dopa, 3-OMD, dopamine, DOPAC and HVA. b. Example of a 
SH-SY5Y sample chromatogram. 
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+4°C.  50µL of each sample was injected and separated on a C18 reversed phase 
column (HiQ sil C18W) at +35°C over a run time of ~16 minutes. Serotonin, 5-HTP 
and 5-HIAA were detected by coulometric electrochemical detection. The screening 
electrode (E1) was set to +20mV to oxidize analytes with a low oxidation potential.  A 
voltammogram of 500nM serotonin, 5-HTP and 5-HIAA was performed by varying the 
potential of electrode 2 (E2), the detector electrode, from +150mV to +400mV and 
determining peak areas (see figure 2.4a).  The optimum voltage for the measurement of 
all three chemicals simultaneously was determined to be +350mV.  Serotonin, 5-HTP 
and 5-HIAA were quantified against an external standard containing 500nM serotonin, 
500nM 5-HTP, 500nM 5-HIAA in HPLC grade water with 2 drops 12.2M HCl (see 
figure 2.4b).  A calibration curve for serotonin, 5-HTP and 5-HIAA was also performed.  
The relationship between indoleamine concentration and current amplitude was found to 
be linear across the concentration range tested (see figure 2.5a, 5-HIAA r
2
 = 1.000, 5-
HTP r
2
 = 1.000, serotonin r
2
 = 1.000).  See figure 2.5b for an example of a sample 
chromatogram.  Peaks were identified and quantified using the AZUR Version 4.6 
software package (Datalys) as for catecholamines (see section 2.2.2.2).  
2.2.4 GSH HPLC 
2.2.4.1 Equipment 
HPLC equipment: PU-1580 pump (Jasco); AS-2055 Plus autosampler (Jasco); 
Coulochem II electrochemical detector (ESA) and 5010 analytical cell (ESA) assembled 
as in figure 2.1. For data recording the electrochemical detector was coupled to a 
Thermo Finnigan Chromjet integrator (Thermo Fisher Scientific, Rockford, IL, USA). 
The mobile phase was degassed using a DG-980-50 inline degasser (Jasco). 
2.2.4.2 Procedure 
GSH was measured using reversed-phase HPLC with coulometric electrochemical 
detection using the method of Reiderer et al (1989).  The mobile phase consisted of 
15mM orthophosphoric acid in HPLC grade H2O.  The flow rate was 0.5mL/min. 
Samples were thawed at +20˚C, transferred to vials and loaded into the autosampler and 
maintained at +20˚C.  50µL of each sample was injected and separated on a C18 
reversed phase 250 x 4.6mm i.d. Techsphere ODS column (HPLC Technology, Welwyn 
Garden City, UK), maintained at +30˚C.  The screening electrode (E1) was set to 
+50mV to oxidise analytes of low oxidation potential.  Optimum potential for the 
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detector electrode (E2) was determined by voltamogram, measuring peak height of 5µM 
GSH at electrode potentials from +60mV to +650mV (see figure 2.6a).  A maximum 
response was achieved with 600mV, however due to a high background current at this 
potential an E2 electrode potential of 550mV was chosen for the measurement of GSH.  
Samples were quantified against an external standard of 5µM GSH in 15mM 
orthophosphoric acid (see figure 2.6b).  A calibration curve was performed to determine 
the linearity between GSH concentration and current amplitude (see figure 2.7a).  
Linearity was demonstrated between 0.1µM and 10µM (r
2
 = 1.000).  An example of a 
sample chromatogram is presented in figure 2.7b. 
2.2.4.3 Data analysis 
GSH was identified using a Thermo Finnigan Chromjet integrator (Thermo Fisher 
Scientific) and quantifed using the following equation: 
Conc. (µM) = (sample peak height /external standard peak height) x calibration standard 
conc. (µM) 
For intracellular determination of GSH the conc. (µM) was divided by total protein 
(mg/mL) and expressed as nmol/mg of protein. 
2.2.5 Measurement of PLP by HPLC 
Cell samples were processed as described for AADC activity measurement (see section 
3.3.2).  PLP was measured by Viruna Neergheen and Marcus Oppenheim 
(Neurometabolic Unit, National Hospital) using a commercial kit (Chromsystems, 
Munich, Germany).  200µL sample was mixed with 300µL precipitation reagent 
(Chromsystems) and incubated at +4˚C for 10 minutes.  Samples were then centrifuged 
at 12000xg for 5min at room temperature.  200µL of supernatant was diluted with 
200µL neutralisation reagent (Chromsystems), and 80µL derivatisation reagent 
(Chromsystems) was subsequently added.  Samples were then incubated at +60˚C for 
20min and subsequently incubated at +4˚C for 10min.  Samples were then centrifuged 
for 2min at 12000xg for 5min at room temperature.  Supernatant was transferred to 
autosampler vials ready for injection onto HPLC. 
HPLC equipment was as follows: PU-980 pump (Jasco); AS-950 autosampler (Jasco); 
FP-920 fluorescence detector (Jasco) assembled as in figure 2.1. The fluorescence 
detector was coupled to a computer and data recorded using AZUR version 4.6 
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chromatography data capture and analysis software (Datalys).   The mobile phase 
(Chromsystems) was run at a flow rate of 1.3mL/min.  50µL of each sample was 
injected onto the column (Chromsystems) which was maintained at +20˚C.  PLP was 
detected by fluorescence detection with an excitation wavelength of 320nm and an 
emission wavelength of 415nm.  Sample PLP was quantified against an external plasma 
calibration standard (Chromsystems), which varied between batches but was between 
47 and 53nM PLP, using AZUR version 4.6 software. 
Tissue Culture 
2.2.6 SH-SY5Y neuroblastoma cell culture 
2.2.6.1 Cell line 
The SK-N-SH cell line was established from a bone-marrow biopsy of a four year old 
female patient with a neuroblastoma of the chest (Biedler et al, 1973).  This line 
contained two distinct cell groups a neuroblast-like cell and an epithelial-like cell.  The 
neuroblast-like cell group was sub-cloned sequentially three times as SH-SY, then SH-
SY5 and finally SH-SY5Y (Biedler et al, 1978).  The SH-SY5Y cell line has a 
neuroblast-like morphology (see figure 2.8a), with neurite-like processes, has 
previously been demonstrated to express tyrosine hydroxylase, dopamine β-
hydroxylase, contain AADC mRNA and dopamine (Biedler et al, 1978; Ross et al, 
1980; Oyarce and Fleming, 1991; Gomez-Santos et al, 2002; McLaughlin et al, 2006).  
Additionally the kynurenine pathway enzymes can be inducibly expressed in the 
parental cell line SK-N-SH by the addition of interferon-γ (Guillemin et al, 2007).     
2.2.6.2 Cell Storage 
SH-SY5Y cells were obtained from the European Collection of Cell Cultures (Health 
Protection Agency, Salisbury, UK) and cultured in accordance with supplier‟s 
instructions.  Cells were seeded at a density of 1 x 10
4
 cells/cm
2
 in 75cm
2
 tissue culture 
flasks in Dulbecco‟s modified Eagle‟s medium/ Ham‟s F-12 nutrient mixture (1:1; 
DMEM/F-12; Invitrogen) supplemented with 100mL/L foetal bovine serum (FBS).  
Cells were grown at +37°C in 5% CO2, culture medium was replaced the day after 
seeding and every other day thereafter.  Cells were passaged at 80-90% confluence.  For 
passage each flask was washed once with 10mL Hank‟s balanced salt solution (HBSS) 
at +37°C.  Cells were lifted with 6mL/flask 2.5g/L trypsin, 0.38g/L EDTA in HBSS 
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a. 
 
b. 
 
Figure 2.4 Indoleamine HPLC voltamogram and external standard chromatogram. a. 
Voltamogram of 500nM 5-HTP, serotonin and 5-HIAA. b. Representative 
chromatogram of an external catecholamine standard of 500nM 5-HTP, serotonin and 5-
HIAA.
78 
 
a. 
 
b. 
 
Figure 2.5 Indoleamine HPLC calibration curve and sample chromatogram. a. 
Caibration curve of 5-HTP, serotonin and 5-HIAA. b. Example of an SH-SY5Y cell 
sample chromatogram of indoleamine HPLC 
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a. 
 
b. 
 
 
Figure 2.6 Glutathione voltamogram and external standard chromatogram. a. 
Voltamogram of 5µM GSH. b. Representative chromatogram of an external standard of 
5µM GSH. 
80 
 
 
a. 
 
b. 
 
Figure 2.7 Glutathione HPLC calibration curve and sample chromatogram a. 
Calibration curve of GSH. b. Example of a sample chromatogram of GSH HPLC.
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(trypsin-EDTA; Invitrogen) incubated at +37°C for 3min.  Cells were collected by 
centrifugation at 500xg for 5min at +20˚C.  Supernatant was removed and cells 
resuspended in DMEM/F-12 + 100mL/L FBS.  100µL cell suspension was mixed 1:1 
with 4g/L trypan blue and cells counted using a Neubauer improved hemocytometer.  
Cells of passage number 17 to 19 were stored at a density of 1 x 10
6
 cells/mL in 
300mL/L FBS, 100mL/L dimethyl sulfoxide (DMSO) and 700mL/L DMEM/F-12 as 
1mL aliquots.  Cells were frozen to -80°C using an isopropanol freezing vessel for 24hr 
and then transferred to liquid nitrogen for storage.    
2.2.6.3 Cell Recovery and Passage 
Cells were recovered from liquid nitrogen and seeded at a density of 6.7 x 10
3
 cells/cm
2
 
in 75cm
2
 flasks. Cells were grown at +37°C in 5% CO2 in DMEM/F-12 + 100mL/L 
FBS.  Cell medium was replaced the day after seeding and every other day thereafter. 
Cells were passaged at 80-90% confluence. For passage cells were washed once with 
10mL/flask HBSS.  Cells were lifted with 6mL/flask trypsin-EDTA incubated at +37°C 
for 3min.  Cells were collected by centrifugation at 500xg for 5min at +20˚C.  
Supernatant was removed and cells resuspended in DMEM/F-12 + 100mL/L FBS.  
100µL cell suspension was mixed 1:1 with 4g/L trypan blue and cells counted on a 
Neubauer improved hemocytometer.  Cells were seeded at a density of 1 x 10
4
 cells/mL 
in 75cm
2
 or 175 cm
2 
flasks and grown in DMEM/F-12 + 100mL/L FBS at +37°C in 5% 
CO2.  Cell medium was replaced the day after seeding and every other day thereafter. 
Cells were passaged as above at 80-90% confluence approximately every 6 days.  To 
maintain consistency cells of passage number 19 to 24 were used for experiments. 
2.2.7 1321N1 astrocytoma cell culture 
2.2.7.1 Cell line 
The 1321N1 cell line was originally derived from a human brain glioblastoma culture 
designated 118 MG that was extracted from a 50 year old male (Ponten and Macintyre, 
1968).  118 MG was subcloned as 1181N1 and finally as 1321N1 (Macintyre et al, 
1972; Foster and Perkins, 1977).  1321N1 cells have an astrocyte-like morphology (see 
figure 2.8b) and express the glial specific marker vimentin as well as the astrocyte 
specific markers glial fibrillary acidic protein and S-100 (Mead and Pentreath, 1998). 
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2.2.7.2 Cell storage 
1321N1 cells were obtained from the European Collection of Cell Cultures (Health 
Protection Agency) and cultured in accordance with supplier‟s instructions.  Cells were 
seeded at a density of 3.4 x 10
4
 cells/cm
2
 in 75cm
2
 tissue culture flasks in Dulbecco‟s 
modified Eagle‟s medium (DMEM) supplemented with 100mL/L FBS.  Cells were 
grown at +37˚C in 5% CO2, the culture medium was replaced the day after seeding and 
every other day thereafter.  Cells were passaged at 70-80% confluence.  For passage 
each flask was washed once with 10mL HBSS at +37°C.  Cells were lifted with 
6mL/flask trypsin-EDTA incubated at +37°C for 3min.  Cells were collected by 
centrifugation at 500xg for 5min at +20˚C.  Supernatant was removed and cells 
resuspended in DMEM + 100mL/L FBS.  100µL cell suspension was mixed 1:1 with 
4g/L trypan blue and cells counted using a Neubauer improved hemocytometer.  Cells 
of passage number 6 to 8 were stored at a density of 2 x 10
6
 cells/mL in 300mL/L FBS, 
100mL/L DMSO and 700mL/L DMEM as 1mL aliquots.  Cells were frozen to -80°C 
using an isopropanol freezing vessel for 24hr and then transferred to liquid nitrogen for 
storage. 
2.2.7.3 Cell Recovery and Passage 
Cells were recovered from liquid nitrogen and seeded at a density of 1.4 x 10
4
 cells/cm
2
 
in 75cm
2
 flasks in DMEM + 100mL/L FBS. Cells were grown at +37°C in 5% CO2.  
Cell medium was replaced the day after seeding and every other day thereafter. Cells 
were passaged at 70-80% confluence.  For passage cells were washed once with 
10mL/flask HBSS.  Cells were lifted with 6mL/flask trypsin-EDTA incubated at +37°C 
for 3min.  Cells were collected by centrifugation at 500xg for 5min at +20˚C.  
Supernatant was removed and cells resuspended in DMEM + 100mL/L FBS.  100µL 
cell suspension was mixed 1:1 with 4g/L trypan blue and cells counted on a Neubauer 
improved hemocytometer.  Cells were seeded at a density of 1 x 10
4
 cells/mL in 75cm
2
 
or 175 cm
2 
flasks and grown in DMEM + 100mL/L FBS at +37°C in 5% CO2.  Cell 
medium was replaced the day after seeding and every other day thereafter. Cells were 
passaged as above at 80-90% confluence approximately every 3 days.  To maintain 
consistency cells of passage number 7 to 12 were used for experiments. 
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a. 
 
b. 
 
Figure 2.8 Cell images. a. SH-SY5Y neuroblastoma cells b. 1321N1 astrocytoma cells 
viewed under a light microscope 
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2.2.8 Cell sample collection 
2.2.8.1 SH-SY5Y cell and media harvesting for catecholamine and indoleamine  
HPLC 
Following treatment 500μL cell culture media was sampled and centrifuged at 500xg 
for 5min at +4°C.  Supernatant was stored at -80°C.  Immediately prior to analysis 
samples were thawed at +20˚C, diluted 1:1 in 0.8M perchloric acid and incubated at 
+4°C for 10min.  Samples were centrifuged at 12000xg for 5min at +4°C.  Supernatant 
was analysed by HPLC as described in section 2.2.1 or section 2.2.3.  Subsequent 
dilutions where required were made using HBSS. 
Cells were washed once with HBSS, lifted with trypsin-EDTA at +37°C for 3 min.  
Trypsin was quenched by the addition of FBS.  Cells were collected by centrifugation at 
500xg for 5min at +4˚C.  The supernatant was removed and the cells washed by 
resuspension in HBSS at +4˚C. Samples were centrifuged at 500xg for 5min at +4˚C.  
The supernatant was removed and cells were resuspended in isolation buffer: 10mM tris 
(pH7.4), 1mM EDTA, 320mM sucrose in HPLC grade H2O.  Cell samples were stored 
at -80°C. Immediately prior to analysis samples were thawed at +37°C and 
subsequently snap frozen in liquid nitrogen and thawed at +37°C twice to lyse cells.  
Samples were diluted 1:1 in 0.8M perchloric acid and incubated at +4°C for 10min and 
subsequently centrifuged at 12000xg for 5min at +4°C.  Supernatant was analysed by 
HPLC as described in section 2.2.1. or section 2.2.3 
2.2.8.2 SH-SY5Y and 1321N1 cell harvesting for GSH HPLC 
Following treatment cells were washed once with HBSS and lifted with trypsin-EDTA 
at +37°C for 3 min.  Trypsin was quenched by the addition of FBS.  Cells were 
collected by centrifugation at 500xg for 5min at +4˚C.  The supernatant was removed 
and the cells washed by resuspension in HBSS at +4˚C. Samples were centrifuged at 
500xg for 5min at +4˚C.  The supernatant was removed and cells were resuspended in 
isolation buffer: 10mM tris (pH7.4), 1mM EDTA, 320mM sucrose in HPLC grade H2O.  
Cell samples were stored at -80°C. Immediately prior to analysis samples were thawed 
at +37°C and subsequently snap frozen in liquid nitrogen and thawed at +37°C twice to 
lyse cells.  Samples were diluted 1:1 in 15mM orthophosphoric acid and incubated at 
+4°C for 15min and subsequently centrifuged at 14000xg for 5min at +4°C.  
Supernatant was analysed by HPLC as described in section 2.2.4. 
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2.2.8.3 Minimal medium harvesting for GSH HPLC 
Minimal medium consisted of 44mM sodium bicarbonate, 110mM sodium chloride, 
1.8mM calcium chloride, 5.4mM magnesium sulfate, 0.92mM sodium phosphate 
monobasic and 5mM D-glucose, adjusted with CO2 to pH7.4.  Following incubation 
with cells minimal medium was removed and transferred to +4˚C.  Samples were 
centrifuged at 500xg for 5min at +4˚C to remove any cells.  Supernatant was diluted 1:1 
with 15mM orthophosphoric acid and incubated at +4˚C for 15min to precipitate 
protein.  Samples were then centrifuged at 14000xg for 5min at +4˚C.  Supernatants 
were stored at -80˚C until analysis by HPLC as described in section 2.2.4. 
2.2.8.4 SH-SY5Y cell harvesting for western blotting 
Following treatments SH-SY5Y cells were transferred to ice and washed once with 
HBSS at +4˚C.  Cells were collected by scraping into 10mM tris (pH8.0), 150mM 
NaCl, 20g/L CHAPS buffer containing protease inhibitor cocktail at manufacturer‟s 
recommended concentration (Sigma) at +4˚C and subsequently snap frozen in liquid 
nitrogen and stored at -80°C.  Immediately prior to analysis samples were thawed and 
agitated for 1hr at +4°C and then centrifuged at 12000xg for 10min at +4°C.  
Supernatant was analysed as described in section 2.5. 
2.2.8.5 SH-SY5Y cell harvesting for mitochondrial respiratory chain complex assays 
Following treatment cells were washed once with HBSS and lifted with trypsin-EDTA 
at +37°C for 3min.  Trypsin was quenched by the addition of FBS.  Cells were collected 
by centrifugation at 500xg for 5min at +4˚C.  The supernatant was removed and the 
cells washed by resuspension in HBSS at +4˚C. Samples were centrifuged at 500xg for 
5min at +4˚C.  The supernatant was removed and cells were resuspended in isolation 
buffer: 10mM tris (pH7.4), 1mM EDTA, 320mM sucrose in HPLC grade H2O.  Each 
cell sample was stored at -80°C in five aliquots, one for each complex, one for citrate 
synthase  and one for total protein. Immediately prior to analysis an aliquot was thawed 
at +37°C and subsequently snap frozen in liquid nitrogen and thawed at +37°C twice to 
lyse cells.  Samples were analysed as described in section 2.7. 
2.3 Sulforhodamine B cell proliferation assay 
The Sulforhodamine B (SRB) cytotoxicity assay is based on the published methods of 
Skehan et al (1990) and Vichai and Kirtikara (2006).   In this assay cells are grown and 
treated in 96 well plates.  Following treatment cells are fixed and dyed with the protein 
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dye SRB.  The dyed cells are then solubilised and absorbance is measured at 490nm.  
The absorbance is proportional to the quantity of cells following treatment.  This is then 
compared to cells that were plated at the same time as the treated cells but were fixed at 
the beginning of treatment (time 0).  The advantage of this assay is that it allows for 
quantitation of the change in the amount of cell material over the treatment period, 
rather than measurement only of the end point following treatment. 
2.3.1 SRB assay procedure   
Time 0 and treated 96-well plates were seeded concurrently at the same density.  Blank 
wells were performed on each plate where only DMEM/F-12 + 100mL/L FBS was 
added to the wells.  Treatments were added 24hr after seeding and at this time point 
100µL 100g/L trichloroacetic acid (TCA) at +4°C was added to all wells of time 0 
plates only and time 0 plates were incubated at +4°C for 1hr. Time 0 plates were then 
washed four times with HPLC grade H2O and left to air dry.  Treated plates were treated 
and incubated as indicated (see section 4.4.2 and 5.4.2). Following treatment 100µL 
100g/L TCA at +4°C was added to all wells of treated plates and incubated at +4°C for 
1hr. Treated plates were washed four times with water and left to air dry for 16hr.  
100µL 0.57g/L SRB was added to each well including wells of time 0 plates and 
incubated at +20˚C for 1hr.  Plates were washed four times with 10g/L acetic acid and 
left to air dry for 16hr.  200µL 10mM tris base unbuffered in HPLC grade H2O was 
added to each well and agitated for 15min at +20˚C.  Plates were read at 490nm using a 
FLUOstar omega plate reader (BMG Labtech Ltd, Aylesbury, UK).  Results are 
expressed as the change in absorbance at 490nm following treatment compared to that 
at time 0 (ΔA490), calculated using the following equation: 
ΔA490 = (mean treated – mean blank) – (mean time 0 – mean time 0 blank) 
Where all values are mean absorbance units measured at 490nm. 
2.3.2 Validation 
This assay has not previously been reported to have been used with SH-SY5Y cells and 
so consequently some validation was undertaken.  For validation cells were plated in 96 
well plates and allowed to adhere for two hours at +37°C in 5% CO2 before being fixed, 
dyed and measured as described above (see section 2.3.1). It is essential for the SRB 
assay that a supramaximal dye concentration and a sufficient dye incubation time are 
used to ensure that all cell protein is dyed.    Six different amounts of SRB were tested 
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Figure 2.9 SRB assay validation of dye amount and time. a. Effect of different 
percentages of SRB on absorbance at 490nm with different densities of cells b. Effect of 
SRB incubation time on absorbance at 490nm with different cell densities. 
88 
 
across a single plate from 0.1g/L to 4.0g/L, at four different cell densities from 2.0 x 10
4
 
cells/well to 1.6 x 10
5
 cells/well, each well was performed in quadruplicate and dyed for 
1hr.  0.57g/L SRB was chosen for future experiments as cells were saturated across the 
range at this dye level (see figure 2.9a).  Six different dye incubation times were tested 
from 0.5hr to 4hr using 0.57g/L SRB, at three different cells densities from 2.0 x 10
4
 to 
1.6 x 10
5
 across a single plate.  Wells were performed in quadruplicate.  A dye 
incubation time of 1hr was chosen for future experiments, as cells appeared to be 
saturated by this time (see figure 2.9b).  The linearity of the relationship between cell 
number and absorbance was also established by testing from 2500 cells/well to 2 x 10
5
 
cells/well.  Seven wells were performed per cell density across one plate. Using 0.57g/L 
SRB and incubating for 1hr the relationship was linear across the cell density range 
tested (see figure 2.10a; r
2
 = 0.9881). 
2.4 Lactate dehydrogenase release assay 
The release of the cytosolic enzyme lactate dehydrogenase (LDH) into cell culture 
media can be used as a measure of membrane integrity or cell lysis.  This method 
measures the oxidation of NADH, as the reduction in absorbance at 340nm, during the 
conversion of pyruvate to lactate by LDH.  This method is based on that of Decker and 
Lohmann-Matthes (1988) where LDH activity in cell culture media as a proportion of 
total LDH activity in cells and media combined is used to give a quantitative measure of 
cell lysis. 
2.4.1 LDH Release assay procedure 
For each plate 10g/L triton X-100 was added to 4 wells at the same time as treatments 
as a positive control. Following treatment 50µL of media was removed from each well 
of 96 well plate and transferred to a new plate (plate A). 50µL 40mL/L triton X-100 was 
added to original plate and plate agitated for 30min at +20˚C to lyse cells.  Meanwhile 
50µL 80mM Tris (pH7.2), 200mM NaCl was added to each well of plate A.  100µL 
80mM Tris (pH7.2), 200mM NaCl, 0.4mM β-NADH, 3.2mM sodium pyruvate was 
added to each well of plate A and plate read at 340nm over 20min at 1min intervals at 
+30˚C using FLUOstar omega plate reader (BMG Labtech Ltd).  After the 30min 
incubation with triton X-100, 50µL from each well of original plate was transferred to a 
new plate (plate B).  50µL 80mM Tris (pH7.2), 200mM NaCl was added to each well of 
plate B.  100µL 80mM Tris (pH7.2), 200mM NaCl, 0.4mM β-NADH, 3.2mM pyruvate 
was added to each well of plate B and plate read at 340nm over 20min at 1min intervals 
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at +30˚C using a FLUOstar omega plate reader (BMG Labtech Ltd).  For each assay a 
linear portion of the reaction was chosen between 6 and 10min in length.  The same 
time frame was used for plate A and plate B within each assay.  The change in 
absorbance at 340nm was calculated for each plate.  To take account of the dilution 
factor of the triton X-100 plate B ΔA340 was multiplied by 1.25.  Mean values from 
blank wells containing only media performed on each plate were then subtracted from 
each mean value. Results are expressed as LDH activity in cell culture medium as a 
percentage of total LDH activity following complete cell lysis (% LDH release). 
2.4.2 Validation 
The LDH release assay has been used previously with SH-SY5Y cells (Lai and Yu, 
1997) however the linearity of LDH activity with cell number was determined to ensure 
the assay was fit for purpose.  Cells were diluted to the appropriate density and seeded 
in 96 well plates and allowed to adhere for two hours at +37˚C in 5% CO2. 50µL of cell 
culture media was removed from each well and 50µL 40mL/L triton X-100 was added 
to each well.  The plate was agitated at +20˚C for 30min to lyse cells.  The LDH assay 
was performed as described above for plate B and LDH activity calculated.  The 
relationship between cell number and LDH activity was found to be linear from 0.05 x 
10
5
 to 1.2 x 10
5
 cells/well (r
2
 = 0.991; see figure 2.10b). 
2.5 Western Blotting 
Samples were diluted to 10µg of protein/30µL + 10µL of 4xNuPAGE sample buffer 
(Invitrogen) containing 1mM dithiothreitol.  All samples were boiled for 5min at 
+100°C.  Samples were separated on a 4-12% Bis-Tris gel in NuPAGE MES SDS 
running buffer (Invitrogen) at +150V on ice for ~2hr. Protein was transferred to 
immobilon-P polyvinylidene fluoride (PVDF) membrane 0.45µm (Millipore, Billerica, 
MA, USA) by electrotransfer, in 25mM Tris (pH8.3), 192mM glycine, 200mL/L 
methanol transfer buffer at +80V for 70min.  All antibodies were diluted in blocking 
buffer (30g/L non-fat dry milk in phosphate buffered saline with 0.5mL/L tween-20 
(PBST)). Following blocking for 1hr in blocking buffer, membranes were probed with 
primary goat polyclonal to human AADC (Abcam, Cambridge, UK; 1:5000) or β-actin 
mouse monoclonal (Sigma; 1:10000) for 16hr at +4°C, washed 3 x 20min in PBST, then 
re-blocked for 20min in blocking buffer.  Membranes were then incubated with 
secondary antibody either horseradish peroxidise (HRP) conjugated polyclonal to goat  
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Figure 2.10 Linearity with cell number for SRB and LDH release.  a. Relationship 
between cell density and absorbance at 490nm during the SRB assay, b. Relationship 
between cell density and LDH activity measured as the change in absorbance at 340nm 
during the LDH release assay.  
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IgG (Abcam; 1:2000) for AADC or HRP conjugated anti-mouse IgG (Sigma; 1:2000) 
for β- actin and subsequently washed 3 x 20min in PBST.  The membranes were 
incubated with enhanced chemiluminescence HRP substrate (Thermo Fisher Scientific) 
according to manufacturer‟s instructions and visualised by exposure to x-ray film.  
Quantification was performed using the Bio-Rad (Hemel Hempstead, UK) Molecular 
Imager and Quantity One software.  
2.6 RNA analysis 
2.6.1 Cell preparation for RNA analysis 
Cells were washed once with HBSS, lifted with 2.5mL/L trypsin-EDTA at +37°C for 3 
min.  Cells were collected by centrifugation at 500xg for 5min at +4˚C.  The supernatant 
was removed and the cells washed by resuspension in HBSS at +4˚C. Samples were 
centrifuged at 500xg for 5min at +4˚C.  The supernatant was removed and cell pellets 
were stored at -80˚C. 
2.6.2 Total RNA extraction 
Total RNA was extracted using the RNeasy minikit (Qiagen, Crawley, UK) according 
to manufacturer‟s instructions.  Cell pellets were resuspended in 300µL RLT buffer 
(Qiagen) containing 10µL/mL β-mercaptoethanol and applied to qiashredder spin 
columns (Qiagen).  Columns were centrifuged at 16000xg for 2min at +20˚C to lyse 
cells.  The eluate was mixed with 300µL 700mL/L ethanol and applied to RNeasy spin 
columns (Qiagen).  Columns were centrifuged at 12000xg for 30sec at +20˚C.  Eluate 
was discarded, 700µL RW1 buffer (Qiagen) was added to the column and centrifuged at 
12000xg for 5min at +20˚C.  Eluate was discarded, 500µL RPE buffer (Qiagen) was 
added to the column and centrifuged at 12000xg for 5min at +20˚C.  This step was 
repeated once.  Eluate was discarded and columns were centrifuged at 16000xg for 
2min at +20˚C.  35µL RNase free water was added to the column, incubated for 2min at 
+20˚C and centrifuged at 16000xg for 2min at +20˚C.  Total RNA concentration in the 
eluate was measured by absorbance at 260nm using a nanodrop spectrophotometer 
(Thermo-Fisher Scientific). 
2.6.3 Reverse Transcription 
RNA samples were diluted to a concentration of 0.2µg/µL in RNase free water.  1µL 
dNTPs (Invitrogen) and 1µL Oligod(T)18 (New England Biolabs, Herts, UK) was 
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added to 10µL of each sample.  Samples were heated for 5min at +95˚C and 
subsequently transferred to ice. 4µL 5x RT-buffer (Invitrogen), 2µL 0.1M dithiothritol 
and 1µL RNasin (Promega, Madison, WI, USA) added to each sample and heated for 
2min at +42˚C. 1µL superscript II (Invitrogen) added to each sample to start reverse 
transcription and samples were incubated at +42˚C for 70min followed by +70˚C for 
15min. Samples were stored at -20˚C until analysis. 
2.6.4 Agarose gel electrophoresis 
Reverse transcribed samples were separated on a 10mL/L agarose gel containing 
0.2mL/L ethidium bromide in 40mM Tris-acetate, 1mM EDTA (Invitrogen) at 90V for 
approximately 30min.  Samples were run against a 1kb DNA ladder (Promega) and 
visulised by exposure to UV. 
2.6.5 Quantitative polymerase chain reaction (PCR) 
Glyceraldehyde 3‟-phosphate dehydrogenase (E.C. 1.2.1.9; GAPDH) mRNA was used 
as a control gene as its expression is not known to be influenced by pyridoxal 5‟-
phosphate (see section 6.5.2) and is commonly used as a reference gene including in 
neuroblastoma cells (Dotsch et al, 2000; Janssens et al, 2004).    AADC or GAPDH 
mRNA expression was quantified against a standard curve ranging from 1 x 10
3
 to 1 x 
10
8
 molecules of GAPDH mRNA in 10mM tris-HCl (pH 8.00), 15mM KCl, 0.6mM 
MgCl2 in HPLC grade H2O.  The GAPDH mRNA standard was a kind gift from Dr 
Julia Fitzgerald (Department of Molecular Neuroscience, UCL Institute of Neurology, 
London).  Quantitative PCR was carried out using the Rotor-Gene 6000 system 
(Qiagen). 5µL iQSybr green supermix (Bio-Rad), 0.3µL each of 10µM forward and 
reverse primer and 3.4µL HPLC grade H2O was added to each standard or reverse 
transcribed sample.  The primers used were as follows AADC, 5‟-TTC CTT TCT TTA 
TGG TTG CC-3‟, 3‟-TGT TGG AAC CCT TTA GCC GA-5', GAPDH, 5‟-CCA TCA 
CCA TCT TCC AGG AGC GA-3‟, 5‟-GGA TGA CCT TGC CCA CAG CCT TG-3‟. 
The PCR conditions were denaturation at +95°C for 3min, followed by 45 cycles of 
denaturation at +94°C for 20sec, annealing at +55°C for 30sec and elongation +72°C 
for 30sec (see figure 2.11). Data was analysed using rotor-gene software (Qiagen) and 
AADC mRNA expression is given as arbitrary units/molecule of GAPDH DNA. 
93 
 
a. 
 
b. 
 
Figure 2.11 Quantitative PCR amplification plot and melt curve. a. A representative 
amplification plot of fluorescence (ex.470/em.510nm) against PCR cycle number from 
a quantitative PCR run, red (AADC) and green (GAPDH).  Demonstrating 
accumulation of product across PCR cycles measured by change in dye fluorescence 
intensity.  b. A representative melt curve plotting [change in fluorescence 
(ex.470/em.510nm)/change in temperature in ˚C (dF/dT)] by temperature in ˚C (deg.). 
This is a measure of change in dye fluorescence when double stranded DNA dissociates 
to single stranded DNA, PCR products should be distinguishable as each product 
dissociates at a specific temperature.  Therefore this melt curve demonstrates that only 
two PCR products were produced, red (AADC) and green (GAPDH), indicating that 
there was no contamination during the PCR reaction.  
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2.7 Mitochondrial Respiratory Chain Complex Assays 
2.7.1 Complex I 
This assay is based on that described by Ragan et al (1987) and measures the oxidation 
of NADH, as the decrease in absorbance at 340nm, during the reduction of ubiquinone 
to ubiquinol by complex I.  The specific complex I inhibitor rotenone is used to 
determine the proportion of NADH oxidation which is independent of complex I.  20µL 
of each sample was added to a cuvette containing at final concentration 2.5mg/mL 
bovine serum albumin (BSA), 0.15mM β-NADH, 1mM potassium cyanide (KCN) in 
20mM potasium phosphate (pH 7.2), 8mM magnesium chloride in HPLC grade H2O.   
The reaction was started by the addition of 10µL 5mM ubiquinone (final conc. 50µM), 
the final volume in each cuvette was 1mL.  The reaction was measured at 340nm at 
30sec intervals for 5min at +30˚C using a Uvikon 941 spectrophotometer (Northstar 
Scientific, Potton, UK).  20µL 1mM rotenone (final conc. 20µM) was added to each 
sample cuvette and measurement was continued for 5min.  Each sample was run against 
a reference cuvette containing all components of the sample cuvette except ubiquione.  
To produce a specific value for complex I the change in absorbance at 340nm following 
rotenone addition was subtracted from that before rotenone inhibition.  Absorbance was 
converted to molar concentration using the NADH extinction coefficient 6.81 x 10
3
 M
-1
 
cm
-1
 (path length 1cm, total volume 1mL), taking account of ubiquinone, using a re-
arrangement of Beer-Lambert law: 
ΔA = c 
ε 
Where ΔA is the specific change in absorbance; ε = extinction coefficient; and c = 
mole/min/mL.  Results are expressed as nmol/min/mg of protein or as a ratio to citrate 
synthase activity. 
2.7.2 Complex II/III 
Complex II/III was measured by the method of King (1967).  Complex II reduces 
ubiquinone to ubiquinol during the oxidation of succinate to fumarate.  Ubiquinol 
subsequently acts as an electron donor during the reduction of cytochrome c catalysed 
by complex III.  This assay measures the succinate dependent reduction of cytochrome c 
by measuring the increase in absorbance at 550nm.  The complex III inhibitor antimycin 
A is used to determine the proportion of cytochrome c oxidation which is independent 
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of complexII/III activity.  20µL of each sample was added to a cuvette containing at 
final concentration 0.3mM EDTA, 1mM KCN, 0.1mM cytochrome c in 100mM 
potassium phosphate (pH 7.4) in HPLC grade H2O.  The reaction was started by the 
addition of 40µL 0.5M succinate (final conc. 20mM), the final volume in each cuvette 
was 1mL. The reaction was measured at 550nm at 30sec intervals for 5min at +30˚C 
using a Uvikon 941 spectrophotometer (Northstar Scientific). 10µL 1mM antimycin A 
(final conc. 10µM) was added to each sample cuvette and measurement was continued 
for 5min.  Each sample was run against a reference cuvette containing all components 
of the sample cuvette except succinate.  To produce a specific value for complex II/III 
the change in absorbance at 550nm following antimycin A addition was subtracted from 
that before antimycin A inhibition.  Absorbance was converted to molar concentration 
using Beer-Lambert law (see section 2.7.1) and the extinction coefficient of cytochrome 
c, 19.2 x 10
3
 M
-1
 cm
-1
 (path length 1 cm, total volume 1mL). Results are expressed as 
nmol/min/mg of protein or as a ratio to citrate synthase activity. 
2.7.3 Complex IV 
Complex IV was measured by the method of Wharton and Tzagoloff (1967).  This assay 
measures the reduction of cytochrome c catalysed by complex IV.  0.8M oxidised 
cytochrome c is first reduced by the addition of a few crystals of ascorbic acid.  A PD10 
desalting column equilibrated with 10mM potassium phosphate (pH7.0) in HPLC grade 
H2O was used to remove ascorbate from the reduced cytochrome c. 50µL reduced 
cytochrome c was added to 950µL H2O in a sample and a reference cuvette and the 
sample cuvette was blanked against the reference at 550nm using a Uvikon 941 
spectrophotometer (Northstar Scientific). Cytochrome c in the reference cuvette was 
then oxidsed by the addition of 10µL 100mM ferricyanide (final conc. 1mM).  The 
absorbance was recorded after 1min and used to determine the concentration of reduced 
cytochrome c using beer-lambert law and the extinction coefficient for cytochrome c, 
19.2 x 10
3
 M
-1
 cm
-1
 (path length 1cm, total volume 1mL).  Cytochrome c to a final 
concentration of 50µM was then added to sample and reference cuvettes containing at 
final concentration 10mM potassium phosphate (pH7.0) in HPLC grade H2O. The 
sample cuvette was blanked against the reference at 550nm using a Uvikon 941 
spectrophotometer (Northstar Scientific) and 10µL 100mM ferricyanide (final conc. 
1mM) was added to the reference cuvette to oxidise cytochrome c.  The reaction was 
started by the addition of 20µL sample to the sample cuvette and the change in 
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absorbance at 550nm was recorded over 3min at +30˚C.  The reaction of complex IV 
with cytochrome c follows first-order kinetics as it is dependent on the concentration of 
cytochrome c.  Activity is therefore expressed as a first order rate constant (k). k is 
calculated by plotting the natural log of absorbance against time and determining the 
slope.  Results are expressed as k/min/mg of protein or k/mol when divided by citrate 
synthase activity.  
2.7.4 Citrate synthase  
Citrate synthase catalyses one step of the the citric acid cycle within the mitochondrial 
matrix and is commonly used as a measure of mitochondrial enrichment (Almeida and 
Medina, 1998; Hargreaves et al, 1999).  This enzyme catalyses the condensation of 
oxaloacetate and acetyl-coenzyme A to form citric acid and coenzyme A.  The assay of 
Shepherd and Garland (1969) was used to measure citrate synthase activity.  This assay 
measures the production of coenzyme A through a reaction of free coenzyme A with 5, 
5‟-dithio-bis (2-nitrobenzoic acid) (DNTB). 20µL of each sample was added to a 
cuvette containing at final concentration 0.1mM acetyl-coenzyme A, 0.2mM DNTB in 
100mM tris (pH 8.0), 1g/L triton X-100 in HPLC grade H2O.  The reaction was started 
by the addition of 10µL 20mM oxaloacetate (final conc. 0.2mM) and the reaction 
measured at 412nm for 5min at 30sec intervals at +30˚C using a Uvikon 941 
spectrophotometer (Northstar Scientific).  Absorbance was converted to molar 
concentration using Beer-Lambert law (see section 2.7.1) and the extinction coefficient 
of DNTB, 13.6 x 10
3
 M
-1
 cm
-1
 (path length 1 cm, total volume 1mL). Results are 
expressed as nmol/min/mg of protein. 
2.8 Total protein determination 
Total protein was determined by the Bio-Rad DC-protein assay (Bio-Rad Laboratories 
Ltd, Hemel Hempstead, UK).  This assay is a modified method based on that of Lowry 
et al (1951).  The assay was performed as per manufacturer‟s instructions.  Briefly all 
samples were diluted in HPLC grade H2O.  A 6-point standard line was prepared with 
BSA in distilled water from 0 to 1mg/mL. 5µL of each standard and sample were added 
to 3 wells of a 96 well plate. 25µL reagent A (alkaline copper tartrate) and 200µL 
reagent B (Folin-Ciocalteau phenol) was added to each sample. Samples were incubated 
for 5min at +20˚C, in the dark.  After incubation absorbance of samples was measured 
at 750nm using a FLUOstar omega plate reader (BMG Labtech Ltd).  Total protein was 
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determined from linear regression of sample absorbance units against the BSA standard 
line. 
2.9 Statistical analysis 
With the exception of individual patient data all results are expressed as mean ± 
standard error of the mean (SEM).  Individual comparison of means was made using 
Student‟s t-test and was carried out using Graphpad Prism software (Graphpad Software 
Inc. San Diago, CA, USA).  Multiple comparisons were made using ANOVA. 
Independent variables found to be significant by ANOVA were further analysed by least 
significant difference (LSD) multiple range test using SPSS (SPSS Inc. Chicago, Il, 
USA).  In all cases p <0.05 was considered significant.  Prior to statistical analysis % 
LDH release and complex activites when expressed as a ratio to citrate synthase were 
transformed by the following calculation: 
 
Arcsin √ (ratio) 
Where percentage values were first divided by 100 to give a ratio.  This transformation 
yielded data with a normal distribution to enable statistical analysis to be performed 
(Gegg et al, 2003). 
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Chapter 3 
3 Aromatic L-amino acid 
decarboxylase activity assay 
method 
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3.1 Background 
AADC activity was originally determined through measurement of CO2 evolution from 
tissue extracts upon addition of L-dopa (Holtz et al, 1938; Blaschko, 1942).  However 
non-enzymatic reactions involving L-dopa that do not produce dopamine were also 
found to produce CO2 and so this method was considered to be inaccurate (Mackowiak 
et al, 1972).  Alternative methods measured the product of decarboxylation of various 
L-aromatic amino acids spectrophotometrically or fluorometrically, or through 
radioisotopic measurement after the addition of [
14
C]-DL-dopa (Lovenberg et al, 1962; 
Mackowiak et al, 1972; Sherald et al, 1973; Charteris and John, 1975).   Nagatsu et al 
(1979) used HPLC-ECD to measure L-dopa and dopamine to improve the sensitivity of 
AADC activity measurement for use with brain homogenates.  A similar method 
measuring dopamine by HPLC-ECD was later developed for determination of AADC 
activity in human plasma (Boomsma et al, 1986).  These two HPLC-ECD methods were 
adapted for use as a diagnostic tool for investigation of AADC deficiency measuring L-
dopa or 5-HTP decarboxylation in liver samples or L-dopa decarboxylation in plasma 
(Hyland and Clayton, 1992).  
3.2 Principle 
This assay measures the conversion of L-dopa to dopamine or 5-HTP to serotonin.  The 
sample is initially incubated with excess PLP to ensure available AADC is in the PLP-
bound form.  The reaction is subsequently initiated by the addition of substrate and 
terminated after a set incubation time by protein precipitation.  HPLC-ECD is then used 
to quantify dopamine or serotonin. 
3.3 Method 
3.3.1 Patient Plasma Samples 
Patient samples were lithium heparin plasma. All patient samples were tested as part of 
diagnostic investigations requested by the patient‟s clinician and after informed consent.  
Anonymised control samples were from patients found not to have conditions relating 
to vitamin B6 or monoamine metabolism used in accordance with accredited 
Neurometabolic Unit (National Hospital for Neurology and Neurosurgery) procedures.   
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3.3.2 Cell Homogenate Preparation 
Cells were washed once with HBSS, lifted with 2.5mL/L trypsin-EDTA at +37°C for 3 
min.  Cells were collected by centrifugation at 500xg for 5min at +4˚C.  The supernatant 
was removed and the cells washed by resuspension in HBSS at +4˚C. Samples were 
centrifuged at 500xg for 5min at +4˚C.  The supernatant was removed and cells were 
resuspended in protein isolation buffer: 10mM tris (pH 7.4), 1mM EDTA, 320mM 
sucrose buffer containing protease inhibitor cocktail (Sigma) at manufacturers 
recommended concentration.  Samples were stored at -80°C until analysis. Immediately 
prior to analysis samples were thawed at +37°C and subsequently snap frozen in liquid 
nitrogen and thawed at +37°C twice to lyse cells. 
3.3.3 L-dopa decarboxylation 
3.3.3.1 Sample incubation 
L-dopa decarboxylation was measured using the method of Hyland and Clayton (1992) 
with minor modifications.  50μL of plasma or cell lysate was incubated with 70μM PLP 
in assay buffer (500mM sodium phosphate pH 7.0, 0.167mM EDTA, 39mM 
dithioerythrietol) for 120min at +37°C.  25μL 20mM L-dopa (final conc. in reaction 
2mM), except where stated, in 6mM HCl (final conc. in reaction 0.6mM) was added to 
the reaction mixture and after mixing was incubated for a further 90min (plasma 
samples) or 5min (cell lysate) at +37°C.  The reaction was stopped with 250μL 0.8M 
perchloric acid (final volume 500μL). Samples were incubated at room temperature for 
10min before centrifugation at 12000xg for 5min at +4°C. A substrate blank was also 
performed, where each sample was treated in exactly the same manner except that no L-
dopa was added during the incubations.  Within each assay a sample blank was also 
incubated in exactly the same manner except that the sample was omitted from the 
reaction mixture. All samples and blanks were stored at -80°C until analysis of 
dopamine by HPLC as described below (see section 3.4).   
3.3.4 5-HTP decarboxylation 
3.3.4.1 Sample incubation 
5-HTP decarboxylation was only measured in cell lysates not in plasma samples.   This 
method is also based on that of Hyland and Clayton (1992).  Incubations were 
performed in exactly the same manner as for L-dopa decarboxylation except the assay 
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buffer consisted of 167mM sodium phosphate pH 8.0, 0.167mM EDTA, 39mM 
dithioerythrietol and in place of L-dopa 25µL 5mM 5-HTP (final conc. in reaction 
0.5mM), except where stated, was added at the same time point.  Samples and blanks 
were stored at -80°C before analysis of serotonin by HPLC as described below. 
3.4 HPLC 
3.4.1 Equipment 
The equipment used was as described for catecholamine measurement see section 2.2.2 
3.4.2 Procedure 
The chromatography procedure was based on the method of Hyland and Clayton 
(1992).  The mobile phase consisted of 50mM sodium phosphate (pH 3.60), 5mM 
octanesulfonic acid, 67µM EDTA, 43mM orthophosphoric acid, 230mL/L methanol in 
HPLC grade water.  Samples were thawed at room temperature, 200µL of each sample 
was transferred to a vial, loaded into the autosampler and maintained at +4°C.  The flow 
rate was 1.2mL/min and column temperature was maintained at +25°C or +35°C for 
dopamine or serotonin measurement respectively. 50μL of each sample was injected 
and separated on a 250 x 4.6mm i.d. HiQSil C18W column (KYA Tech. Corp. Tokyo, 
Japan).  Dopamine and serotonin were detected by coulometric electrochemical 
detection.  The screening electrode (E1) was set to +20 mV to oxidize analytes with a 
low oxidation potential.  The optimum voltage of the detector electrode (E2) was 
determined by voltamogram by measuring the peak area of 1000 nM dopamine or 
1000nM serotonin at varying E2 potentials from +50mV to +400mV (see figure 3.1a).  
A potential of +350mV was chosen for the detection of dopamine or serotonin.  
Samples were quantified using an external standard of 1000nM dopamine or serotonin 
in 60mM HCl (see figure 3.2).  Calibration curves were performed to ensure linearity 
between current amplitude and concentration (see figure 3.1b).  Linearity was 
demonstrated across all concentrations tested, from 5nM to 4000nM of dopamine (r
2
 = 
1.000) and 5nM to 5000nM of serotonin (r
2
 = 1.000).  Examples of sample 
chromatograms are presented in figure 3.3. 
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Figure 3.1 Dopamine and serotonin voltamogram and calibration curve for AADC 
activity assay. a. Voltamogram of 1000nM dopamine and 1000nM serotonin. b. 
Calibration curve of dopamine and serotonin. 
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a. 
 
b. 
 
 
Figure 3.2 External dopamine and serotonin standards for AADC activity assay. 
Representative chromatogram of an external standard of a. 1000nM dopamine and b. 
1000nM serotonin. 
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a. 
 
b. 
 
 
Figure 3.3 Example chromatograms of AADC activity assay samples. Representative 
chromatogram of a sample of a. L-dopa decarboxylation and b. 5-HTP decarboxylation. 
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3.4.3 Data Analysis 
Dopamine and serotonin were identified and quantified using the AZUR Version 4.6 
software package (Datalys) using the following equation: 
Conc. (nM) = (sample peak area /external standard peak area) x calibration standard 
conc. (nM) 
The concentration of dopamine or serotonin in the substrate and sample blanks was 
subtracted from the sample concentration to give the final concentration produced 
during the incubation period.  AADC activity, either L-dopa or 5-HTP decarboxylation, 
was calculated using the following equation: 
AADC activity = (final sample conc. (nM) x dilution factor) / incubation time (min) 
These results are expressed as pmol/min/mL.  Results for cell homogenates are 
expressed as pmol/min/mg of protein.  
3.5 Validation 
3.5.1 Plasma L-dopa decarboxylation 
The relationship between incubation time with substrate and dopamine production was 
determined to be linear across the incubation times tested (20 to 120min; r
2
 = 0.990; see 
figure 3.4a).  An incubation time of 120min was chosen for future assays to allow 
adequate dopamine formation during the assay.  The relationship between plasma 
volume and dopamine production was also determined to be linear across tested 
volumes (10 to 50µL; r
2
 = 0.989; see figure 3.4b).  A plasma volume of 50µL was 
chosen for future assays.  Percentage recovery of dopamine from the reaction mixture 
containing plasma was 103.2 ± 0.8% (n = 3). 
The plasma L-dopa decarboxylation assay was further validated by measuring the 
kinetics of AADC by varying the concentration of L-dopa added to the reaction between 
0.025 and 2mM.  L-dopa decarboxylation appeared to follow classical Michaelis-
Menten kinetics with the reaction saturated by 1mM L-dopa (see figure 3.5a).  Km 
apparent and Vmax were determined using a Lineweaver-Burk plot (Lineweaver and 
Burk, 1934; see table 1 and figure 3.5b).  A concentration of 2mM L-dopa was used for 
all subsequent assays. The kinetics of the coenzyme PLP was also determined by 
measuring AADC activity at different concentrations of PLP between 0.5 and 70μM.   
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Figure 3.4 Linearity of L-dopa decarboxylation with time and plasma volume. Plasma 
AADC activity assay using L-dopa as substrate, relationship between a. incubation time 
and dopamine concentration and b. plasma volume and dopamine concentration.  
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Figure 3.5 Kinetics of AADC activity with L-dopa in plasma. a. Relationship between 
L-dopa concentration and plasma AADC activity. b. Lineweaver-Burk double-
reciprocal plot with L-dopa and plasma AADC activity. 1/V: 1/L-dopa decarboxylase 
activity (pmol/min/mL), 1/S: 1/L-dopa (µM).  
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Figure 3.6 Kinetics of AADC activity and PLP in plasma. a. Relationship between PLP 
concentration and plasma AADC activity with L-dopa as substrate. b. Lineweaver-Burk 
double-reciprocal plot with PLP and plasma AADC activity with L-dopa as substrate. 
1/V: 1/L-dopa decarboxylase activity (pmol/min/mL), 1/S: 1/PLP (µM). 
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Again the reaction appeared to follow Michaelis-Menten kinetics, saturating by 35μM 
PLP and Km apparent and Vmax were determined by Lineweaver-Burk plot (see figure 
3.6 and table 3.1). A concentration of 70μM PLP was used for future assays.  Plasma 
Km apparent values were similar to those previously reported for L-dopa, 360µM and 
620µM, and for PLP, 1.66μM (Boomsma et al, 1986; Verbeek et al, 2007). 
3.5.2 SH-SY5Y cell samples L-dopa decarboxylation  
The L-dopa decarboxylation assay was adapted for use with homogenates of the SH-
SY5Y cell line.  The relationship between dopamine production and incubation time 
with substrate was found to be linear from 1 to 30min (r
2
 = 1.000; see figure 3.7a) but 
non-linear above 30min.  Consequently incubation time was reduced to 5min for all 
experiments with SH-SY5Y homogenates.  The relationship between dopamine 
production and homogenate total protein was found to be linear across all total protein 
final concentrations tested from 0.02 to 0.66mg/mL (r
2
 = 0.997; see figure 3.7b).  For all 
further experiments with SH-SY5Y homogenates total protein was within this range.  
Recovery of dopamine from the reaction mixture containing cell homogenate was 105.3 
± 0.7% (n = 3).  Both dopamine β-hydroxylase and MAO were likely to be present in 
SH-SY5Y cell homogenates.  Consequently it was tested whether inhibition of these 
enzymes affected the measurement of L-dopa decarboxylation.  Dopamine production 
after addition of the non-selective MAO inhibitor nialamide (100µM) was 111.3 ± 8.4% 
of control (p = 0.611, n = 3).  Consequently a MAO inhibitor was considered 
unnecessary and was not used for all subsequent determinations of L-dopa 
decarboxylation.   Dopamine production after the addition of the dopamine β-
hydroxylase inhibitor fusaric acid (100µM) was 119.4 ± 1.9% of control (p = 0.366, n = 
3).  Although the difference from control was not statistically significant it was 
considered large enough to justify the addition of 100µM fusaric acid to all subsequent 
assays.  The kinetics of AADC was again determined by varying the concentration of L-
dopa added to the reaction between 0.025 and 2mM.  The reaction followed Michaelis-
Menten kinetics, saturating at 1mM L-dopa, and Km and Vmax were determined by 
Lineweaver-Burk plot (see figure 3.8 and table 3.1).  A concentration of 2mM L-dopa 
was used for all future assays.  The SH-SY5Y L-dopa Km apparent was not significantly 
different from the plasma Km apparent (p = 0.212) and was within the range of 
previously reported Km values in different tissues (120µM to 620µM; Lovenberg et al, 
1962; Voltattorni et al, 1983; Boomsma et al, 1986; Moore et al, 1996; Jebai et al, 
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1997; Verbeek et al, 2007).  The kinetics of PLP for L-dopa decarboxyation in SH-
SY5Y homogenates could not be determined due to the high proportion of AADC that 
was already bound to PLP (see below section 3.5.3).   
3.5.3 5-HTP decarboxylation cell samples 
The 5-HTP decarboxylation assay was adapted for use in SH-SY5Y homogenates from 
the method using liver homogenates described by Hyland and Clayton (1992).  The 
relationship between serotonin production and incubation time with substrate was tested 
from 1 to 30min and was found to be linear across this range (r
2
 = 0.999; see figure 
3.9a). An incubation time of 5min was selected for all further assays.  The relationship 
between serotonin production and homogenate total protein was found to be linear 
across the range of final protein concentrations tested from 0.02 to 0.33mg/mL (r
2
 = 
1.000; see figure 3.9b).  SH-SY5Y homogenate total protein was within this range for 
all subsequent experiments.  Recovery of serotonin from the reaction mixture 
containing cell homogenate was 104.9 ± 1.5% (n = 5).  It was next determined whether 
degradation of serotonin by MAO in the cell homogenate would affect the assay. 
Serotonin production in homogenates treated with 100µM of the non-selective MAO 
inhibitor nialamide was found to be 102.3 ± 7.4% of control (p = 0.747, n = 3).  
Consequently the addition of a MAO inhibitor to the reaction mixture was not 
considered necessary for determination of 5-HTP decarboxylation. 
The kinetics of the 5-HTP decarboxylation reaction by AADC was also determined. The 
concentration of 5-HTP added to the reaction was varied between 5 and 500µM.  The 
reaction followed classical Michaelis-Menten kinetics and saturated by a 5-HTP 
concentration of 250µM (see figure 3.10a.  Km and Vmax were determined by 
Lineweaver-Burk plot (see figure 3.10b; table 3.1).  The 5-HTP Km apparent determined 
here was within the range of previously reported values from other tissues (20μM to 
490µM; Lovenberg et al, 1962; Voltattorni et al, 1983; Boomsma et al, 1986; Moore et 
al, 1996; Jebai et al, 1997; Verbeek et al, 2007).  The proportion of AADC bound to 
PLP in the samples was estimated by measuring 5-HTP decarboxylation in both the 
presence and absence of added PLP.  Using this method the proportion of AADC bound 
to PLP was found to be 62 ± 2% (n = 8).  The proportion of AADC bound to PLP was 
not determined using L-dopa decarboxylation as side reactions consuming PLP have 
previously been demonstrated to lead to underestimation of PLP binding (Kawasaki et 
al, 1992). The proportion of AADC bound to PLP measured by 5-HTP decarboxylation 
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may also be an underestimation as side reactions consuming PLP could potentially 
occur during 5-HTP decarboxylation.  Nevertheless due to the majority of AADC 
already being bound to PLP the kinetics of PLP for 5-HTP decarboxylation in SH-
SY5Y cell homogenates could not be determined.   
 
 
Sample Varied substrate or 
coenzyme 
Km Vmax 
Plasma L-dopa 460.9 ± 96.2 27.1 ± 5.7 
Plasma PLP 3.0 ± 0.4 19.0 ± 1.3 
SH-SH5Y L-dopa 332.6 ± 62.0 4452.6 ± 587.5 
SH-SY5Y 5-HTP 47.4 ± 4.9 425.6 ± 22.6 
 
Table 3.1 Km and Vmax of AADC in plasma and SH-SY5Y cell samples. Km (µM) and 
Vmax (plasma: pmol/min/mL; SH-SY5Y: pmol/min/mg) values for AADC.  The kinetics 
of PLP was tested using 2mM L-dopa as substrate.  Values determined from 3 to 6 
independent measurements. 
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Figure 3.7 Linearity of L-dopa decarboxylation with time and cell homogenate total 
protein. AADC activity assay in SH-SY5Y homogenate using L-dopa as substrate, 
relationship between a. incubation time and dopamine concentration and b. plasma 
volume and dopamine concentration. 
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Figure 3.8 Kinetics of AADC activity with L-dopa in SH-SY5Y cell homogenate. a. 
Relationship between L-dopa concentration and SH-SY5Y homogenate AADC activity. 
b. Lineweaver-Burk double-reciprocal plot with L-dopa and SH-SY5Y homogenate 
AADC activity. 1/V: 1/L-dopa decarboxylase activity (pmol/min/mg), 1/S: 1/L-dopa 
(µM).  
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Figure 3.9 Linearity of 5-HTP decarboxylation with time and cell homogenate total 
protein.  SH-SY5Y homogenate AADC activity assay using 5-HTP as substrate, 
relationship between a. incubation time and serotonin concentration and b. plasma 
volume and serotonin concentration. 
 
115 
 
 
Figure 3.10 Kinetics of AADC activity with 5-HTP in SH-SY5Y cell homogenate. a. 
Relationship between 5-HTP concentration and SH-SY5Y homogenate AADC activity. 
b. Lineweaver-Burk double-reciprocal plot with 5-HTP and SH-SY5Y homogenate 
AADC activity. 1/V: 1/5-HTP decarboxylase activity (pmol/min/mg), 1/S: 1/5-HTP 
(µM).  
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Chapter 4 
4 The effect of 5-HTP and serotonin 
on cell viability, antioxidant status 
and mitochondrial function 
117 
 
4.1 Introduction 
Due to the metabolic block at AADC there is an accumulation of the serotonin 
precursor 5-HTP in AADC deficient patients including in CSF (Hyland et al, 1992; 
Maller et al, 1997; Brun et al, 2010).  An endogenous accumulation of 5-HTP is 
relatively unique to AADC deficiency however 5-HTP has been administered in a 
number of neurological conditions, including disorders of tetrahydrobiopterin 
metabolism (Ramaekers et al, 2001; Turner et al, 2006; Longo et al, 2009).  
Furthermore treatment with 5-HTP has been demonstrated to increase the 
concentrations of 5-HTP present in CSF (Ramaekers et al, 2001).  5-HTP 
administration in animals has been reported to have some side-effects, however these 
side-effects are commonly considered to relate to increases in serotonin rather than to 
direct effects of 5-HTP (Colpaert et al, 1989; Mokler et al, 1992; Gwaltney-Brant et al, 
2000; Nisijima et al, 2001; Turner et al, 2006).  This “serotonin syndrome” is 
characterised by a range of behavioural phenotypes including head twitching, flat body 
posture, tremors and hypolocomotion.  These behaviours can be potentiated by 
serotonin re-uptake inhibitors and MAO inhibitors and prevented with serotonin 
receptor antagonists, demonstrating the role of increased serotonin availability in these 
effects (Colpaert et al, 1989; Izumi et al, 2006).  A similar syndrome has been reported 
in humans after administration of serotonin re-uptake inhibitors (Mills, 1995; Lane and 
Baldwin, 1997).  However this syndrome in humans has not been reported to be induced 
by 5-HTP administration alone or in combination with serotonin re-uptake inhibitors 
(Nardini et al, 1983; Meltzer et al, 1997; Turner et al, 2006).  Consequently 5-HTP 
administration is accompanied by relatively few safety concerns (Turner et al, 2006), 
however the direct cellular toxicity of 5-HTP has not been previously reported.  
Furthermore the toxicity of 5-HTP has not been assessed in the absence of AADC-
catalysed production of serotonin. 
5-HTP toxicity could potentially arise through alternative metabolism leading to the 
accumulation of toxic metabolites.  A possible alternative metabolic route for 5-HTP 
could be via the kynurenine pathway (see section 1.7.3).  The kynurenine pathway is 
involved in the de novo synthesis of NAD
+
 using L-tryptophan as an initial substrate 
(Beadle et al, 1947; Mitchell and Nyc, 1948; Bonner, 1948; Nishizuka and Hayaishi, 
1963; Ikeda et al, 1965).  The first and rate limiting step in this pathway is the 
conversion of L-tryptophan to N-formyl-L-kynurenine (Knox and Mehler, 1950).  This 
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step is catalysed by tryptophan 2,3-dioxygenase in liver and IDO (indoleamine 2,3-
dioxygenase) in other tissues (reviewed by Badawy, 1977; Rafice et al, 2009).  In 
mouse constitutive IDO expression has been detected in the digestive tract, spleen, 
thymus and respiratory system (Dai and Zhu, 2010). IDO expression can be induced in 
response to inflammatory mediators, particularly interferon-γ (IFN-γ), but also 
interferon-α, interferon-β and lipopolysaccharide (Yoshida et al, 1981; Yoshida et al, 
1986; Takikawa et al, 1988; Wang et al, 2010a).  In the brain IDO expression can be 
induced by IFN-γ in neurons, astrocytes, microglia and macrophages (Heyes et al, 1993; 
Alberati-Giani et al, 1996; Alberati-Giani and Cesura, 1998; Guillemin et al, 2003; 
Guillemin et al, 2005b; Kwidzinski et al, 2005; Roy et al, 2005; Connor et al, 2008).  
Induction of IDO is considered to play a dual role in the immune response.  Firstly 
activation of the rate limiting step of the kynurenine pathway can deplete L-tryptophan, 
depriving the invading pathogen of this essential amino acid (Byrne et al, 1986; Beatty 
et al, 1994).  Secondly IDO induction can suppress T-cell proliferation and 
consequently acts to limit the immune response, potentially preventing damage to 
uninfected tissue (Munn et al, 1999; Hwu et al, 2000).  This latter function is also 
mediated by L-tryptophan depletion, but additionally by production of pro-apoptotic 
kynurenine metabolites (Munn et al, 1999; Hwu et al, 2000; Morita et al, 2001).  
Several kynurenine metabolites of L-tryptophan are also known to have neuroactive 
properties including the putative neurotoxins quinolinic acid and 3-hydroxykynurenine 
(see section 1.7.3; Foster et al, 1983; Garthwaite and Garthwaite, 1987; Okuda et al, 
1998; Guidetti and Schwarcz, 1999; Santamaria et al, 2001).  These kynurenine 
metabolites have been implicated in Huntington‟s disease, dementia associated with 
HIV infection and ischaemic brain damage (Moroni et al, 1999; Guidetti and Schwarcz, 
2003; Guillemin et al, 2005c; Samikkannu et al, 2010; Sathyasaikumar et al, 2010). 
5-HTP is also known to be a substrate for IDO (Hirata and Hayaishi, 1972; Shimizu et 
al, 1978; Fujiwara et al, 1979).  Human IDO purified from placenta had a Km for 5-HTP 
of 400µM, whilst the Km for L-tryptophan was 21µM, indicating that L-tyrptophan is 
likely to be the preferred substrate (Takikawa et al, 1988). However the 5-HTP-
kynurenine pathway products 5-hydroxykynurenine and 4,6-dihydroxyquinoline (see 
figure 1.6) have been detected in the urine of hens after an L-tryptophan load, 
demonstrating that 5-HTP-kynruenine metabolites can be produced in vivo (Kido et al, 
1967a Kido et al, 1967b).  Furthermore the conversion of 5-HTP to 5-
hydroxyformylkynurenine and subsequently 5-hydroxykynruenine has been suggested 
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to occur in rat brain homogenates and consequently the CNS may also produce 5-HTP-
kynruenine metabolites (Tsuda et al, 1972; Tsuda et al, 1974). Very little has been 
reported as to the physiological effects or functions of the 5-HTP-kynurenine pathway 
metabolites.  5-hydroxykynuramine, which can be produced from 5-HTP or directly 
from serotonin, has been demonstrated to interact with serotonin receptors (Watts et al, 
1995).  This metabolite can induce contraction of smooth muscle and increase prolactin 
release although with less potency than serotonin (Toda et al, 1974; Toda, 1975; 
Iwasaki et al, 1978; Kitamura et al, 1979; Fu and Toda, 1979).  5-hydroxykynuramine 
has also been shown to antagonise serotonin induced platelet aggregation (Okuma et al, 
1976). 5-hydroxyanthranillic acid is a potential 5-HTP kynurenine metabolite that can 
also be produced from L-tyrptophan metabolism via the kynurenine pathway (Noguchi 
et al, 1969; Naito et al, 1984).   It has recently been demonstrated that 5-
hydroxyanthranillic acid can induce oxidative stress, H2O2 production and neuronal cell 
death in culture (Smith et al, 2009).  The accumulation of 5-HTP in AADC deficiency 
may potentially also lead to the accumulation of 5-HTP-kynurenine metabolites.  These 
kynurenine metabolites or 5-HTP itself could potentially induce oxidative stress.  Two 
potential consequences of oxidative stress could be decreases in the level of neuronal 
GSH and decreased activity of the mitochondrial respiratory chain (see section 1.7.6 and 
section 1.7.7; Bolanos et al, 1994; Desole et al, 1995; Heales et al, 1995; Bolanos et al, 
1996; Merad-Boudia et al, 1998; Merad-Saidoune et al, 1999; Chinta and Andersen, 
2006).  Consequently it may be of importance for understanding the pathogenesis of 
AADC deficiency to investigate the role played by the kynurenine pathway when 5-
HTP availability is increased. 
4.2 Aims 
1) To determine the toxicity of 5-HTP and serotonin in neuronal and astrocyte cell 
lines 
2) To examine the effect of IFN-γ on 5-HTP and serotonin toxicity and metabolism 
3) To determine the effect of increased levels of 5-HTP and serotonin on 
intracellular GSH and mitochondrial respiratory chain activity in a neuronal cell 
line 
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4.3 Methods 
4.3.1 Treatment solutions 
20mM NSD-1015, 40mM 5-HTP, 40mM serotonin were made up as stock solutions in 
HPLC grade H2O, 0.2µm sterile filtered and stored at -20˚C.  Sterile IFN-γ was 
reconstituted to 2000U/mL in DMEM/F-12 + 100mL/L FBS and stored at -80°C in 
1mL aliquots.  
4.3.2 Cell culture 
Routine cell culture was performed as described in section 2.2.6 for SH-SY5Y cells and 
in section 2.2.7 for 1321N1 cells. 
4.3.3 Measurement of Indoleamines 
Cell homogenates and cell culture medium were prepared as described in section 2.2.8.1 
and indoleamines were measured as described in section 2.2.3. 
4.3.4 AADC activity 
Cell homogenates were prepared as described in section 3.3.2 and AADC activity was 
measured as described in section 3.3.3. 
4.3.5 Western Blotting 
Cells were prepared as described in section 2.2.8.4 and western blot was performed as 
described in section 2.5. 
4.3.6 RT-PCR 
RNA was isolated as decribed in section 2.6.2.  RT-PCR was performed as described in 
section 2.6.3 and agarose gel electrophoresis was performed as described in section 
2.6.4. 
4.3.7 Measurement of GSH 
Cells and minimal medium were prepared as described in section 2.2.8.2 and section 
2.2.8.3 and GSH measured as described in section 2.2.4. 
4.3.8 SRB cell proliferation assay 
The SRB cell proliferation assay was performed as described in section 2.3. 
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4.3.9 LDH Release assay 
The LDH release assay was performed as described in section 2.4 
4.3.10 Mitochondrial respiratory chain complex assays and citrate synthase 
The activity of complex I, II/III, IV and citrate synthase were determined by the 
methods described in section 2.7  
4.4 Experimental Protocol 
4.4.1 Indoleamine measurement 
SH-SY5Y cells were seeded in 12.5mL DMEM/F-12 + 100mL/L FBS at a density of 
5.00 x 10
4
 cells/cm
2
 in 56.7cm
2
 cell culture dishes.  6.25µL NSD-1015 (20mM: final 
conc. 10µM; 2mM: final conc. 1µM; 0.2mM: final conc. 0.1µM) and/or 312.5µL 
2000U/mL IFN-γ (final conc. 50U/mL) were added to appropriate dishes and 6.25µL 
sterile HPLC grade H2O was added to untreated dishes.  Cells were incubated for 24hr 
at 37˚C in 5.0% CO2 to allow cells to adhere.  15.63µL  5-HTP (40mM: final conc. 
50µM; 8mM: final conc. 10µM) or 40mM serotonin (final conc. 50µM) were added to 
appropriate dishes and cells incubated for 48hr at +37˚C in 5.0% CO2. Cells and cell 
culture medium were then processed as indicated in section 4.3.3. 
4.4.2 Toxicity testing 
For SRB and LDH release assays SH-SY5Y cells or 1321N1 cells were seeded in 96-
well plates at a density of 1.80 x 10
4
 cells/well in DMEM/F-12 + 100mL/L FBS or 
DMEM + 100mL/L FBS respectively.  10µL NSD-1015 (200µM: final conc. 10µM or 
20µM: final conc. 1µM) was added to treated wells, 10µL sterile HPLC grade H2O was 
added to untreated wells.  10µL 1000U/mL IFN-γ (final conc. 50U/mL) was added to 
wells where indicated. Plates were incubated for 24hr to allow cells to adhere at +37˚C 
in 5.0% CO2.  10µL 5-HTP or serotonin (concentration range: 40mM to 2mM: final 
conc. 2000µM to 100µM) were added to appropriate treated wells.  10µL sterile HPLC 
grade H2O was added to control wells. Final volume of all wells was 200µL. Cells were 
then incubated for 48hr at +37˚C in 5.0% CO2.  Cells were then processed as indicated 
for the appropriate assay (see section 4.3.8 for the SRB assay and section 4.3.9 for LDH 
release assay).   
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4.4.3 GSH measurement 
SH-SY5Y cells were seeded in 3mL DMEM/F-12 + 100mL/L FBS at a density of 5.00 
x 10
4
 cells/cm
2
 in 6-well cell culture dishes, the surface area of each well was 9.6cm
2
. 
30µL 1mM NSD-1015 (final conc. 10µM) and/or 75µL 2000U/mL IFN-γ were added to 
appropriate treated wells.  30µL sterile HPLC grade H2O was added to untreated wells.  
Plates were incubated at +37˚C in 5.0% CO2 for 24hr to allow cells to adhere.  75µL 5-
HTP or serotonin (40mM: final conc. 1mM; 2mM: final conc. 50µM) were added to 
appropriate treated wells. 75µL sterile HPLC grade H2O was added to untreated wells.  
Plates were then incubated at +37˚C in 5.0% CO2 for the indicated length of time.  Cells 
were processed as indicated for determination of intracellular GSH (see section 4.3.7).   
4.4.4 Mitochondrial respiratory chain and citrate synthase 
SH-SY5Y cells were seeded in 30mL DMEM/F-12 + 100mL/L FBS at a density of 5.00 
x 10
4
 cells/cm
2
 in 145cm
2
 cell culture dishes.  15µL 20mM NSD-1015 (final conc. 
10µM) was added to treated dishes and 15µL sterile HPLC grade H2O was added to 
untreated dishes.  Cells were incubated for 24hr at +37˚C in 5.0% CO2 to allow cells to 
adhere.  37.5µL 40mM 5-HTP (final conc. 50µM) or 40mM serotonin (final conc. 
50µM) were added to appropriate dishes, 37.5µL sterile HPLC grade H2O was added to 
control dishes.  Cells were incubated for 48hr at +37˚C in 5.0% CO2.  Cells were then 
processed as indicated for respiratory chain complex assays (see section 4.3.10). 
4.5 Results 
4.5.1 AADC in SH-SY5Y and 1321N1 cells 
The activity of AADC in SH-SY5Y cells and 1321N1 cells was first determined.  The 
AADC activity with L-dopa as substrate was found to be 3462.7 ± 319.2 pmol/min/mg 
for SH-SY5Y cells, whilst in 1321N1 cells activity was below the limit of detection (n = 
7). This result indicates that 1321N1 cells do not contain active AADC.  As a further 
test 1321N1 cell homogenate was incubated for up to 3hr with L-dopa without any 
detectable increase in dopamine (see figure 4.1a).  To confirm that the AADC activity 
of SH-SY5Y cells was related to AADC expression both AADC mRNA and protein 
were determined by RT-PCR and western blot respectively (see figure 4.1b). 
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Figure 4.1 AADC activity, mRNA and protein in cells. a. The AADC activity of SH-
SY5Y neuroblastoma cells, human plasma and 1321N1 astrocytoma cells plotted as 
incubation time with L-dopa against dopamine. b. SH-SY5Y cells expression of AADC 
mRNA and protein.  Representative images from 3 independent experiments. 
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4.5.2 NSD-1015 concentration for inhibition of AADC 
The appropriate concentration range for inhibition of AADC activity in SH-SY5Y cells 
was determined.  Cells were incubated with NSD-1015 from 0 to 10µM for 24hr.   
10µM 5-HTP was added and cells were incubated for 48hr before measurement of 
indoleamines in the cell culture medium.  Serotonin and 5-HIAA were significantly 
decreased and 5-HTP was significantly increased following treatment with 1µM or 
10µM NSD-1015 in comparison to control (see figure 4.2).  This indicates that AADC 
was inhibited at these concentrations with the greater inhibition seen at 10µM. 0.1µM 
NSD-1015 treatment had no significant effect upon 5-HIAA, serotonin or 5-HTP in 
comparison to control.  Concentrations of 1µM or 10µM NSD-1015 were chosen for all 
future experiments. For further investigations of indoleamine metabolism the 
concentration of 5-HTP was increased to 50µM in order to increase the availability of 
substrate during the incubation. 
4.5.3 Indoleamine metabolism 
SH-SY5Y cells were cultured either in the presence or absence of 10µM NSD-1015 for 
24hr and then subsequently 50µM 5-HTP was added for 48hr.  Treatment with NSD-
1015 led to a significant decrease in intracellular 5-HIAA and extracellular serotonin 
and 5-HIAA in comparison to untreated control (see table 4.1).  Furthermore 5-HTP 
was increased both intracellularly and in the cell culture media, indicating that AADC 
was partially inhibited, however intracellular serotonin was not significantly affected by 
NSD-1015 treatment.  IFN-γ was used throughout these experiments to potentially 
activate IDO and consequently the kynurenine pathway.  A concentration of 50U/mL 
IFN-γ was chosen for experiments based on previous investigations (Martin et al, 1993; 
Chiarugi et al, 2000). In order to assess the effect of IFN-γ stimulation on indoleamine 
metabolism SH-SY5Y cells were cultured in the presence of IFN-γ with or without 
10µM NSD-1015 and indoleamines were measured following a 48hr incubation with 
50µM 5-HTP.  IFN-γ treatment led to a 1.4-fold increase in the intracellular level of 5-
HIAA in comparison to untreated control (p <0.05).  However this effect of IFN-γ was 
not observed in NSD-1015 treated cells in comparison to those treated with NSD-1015 
only.  Conversely in NSD-1015 treated cells intracellular levels of 5-HTP were 
increased by approximately 1.6-fold (p <0.01) following IFN-γ treatment in comparison 
to cells treated with NSD-1015 alone. This effect was not observed in cells treated with 
IFN-γ alone in comparison to untreated control.  Intracellular serotonin and extracellular 
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5-HTP, serotonin and 5-HIAA were unaffected by IFN-γ treatment both in the presence 
and absence of NSD-1015.  Following treatment with 50µM serotonin for 48hr IFN-γ 
treatment did not affect the intracellular or extracellular levels of 5-HTP, serotonin or 5-
HIAA in comparison to cells treated with serotonin alone 
4.5.4 5-HTP and serotonin toxicity in SH-SY5Y cells 
The SRB cell proliferation assay was utilised to investigate the effect of 5-HTP and 
serotonin on SH-SY5Y cell growth.  Treatment for 48hr with 5-HTP at concentrations 
>500µM and serotonin at concentrations >1000µM led to significant reductions in cell 
growth (see figure 4.3a).  Comparing the effect on cell growth of 5-HTP to that of 
serotonin there was an overall difference (p <0.001), however by individual comparison 
this difference was only significant at 250µM (p <0.05).  The addition of 1µM and 
10µM NSD-1015 did not have an effect on the decrease in cell growth seen with 5-HTP 
treatment alone (p = 0.735; see figure 4.3b).  The effect of 5-HTP and serotonin on 
membrane integrity was investigated using the LDH release assay. 5-HTP treatment for 
48hr led to a small but significant increase in LDH release at concentrations >1000µM 
(see figure 4.4a).  48hr treatment with 2000µM serotonin significantly increased LDH 
release by approximately 2-fold above the level of untreated control (p <0.05).  
Concentrations of serotonin below 2000µM had no effect on LDH release.  The overall 
effect of 5-HTP and serotonin on LDH release was not significantly different (p 
<0.107), however by individual comparison the effect of serotonin on LDH release was 
significantly different from that of 5-HTP at 2000µM (p <0.01).  NSD-1015 at a 
concentration of 1µM or 10µM had no significant effect on LDH release observed 
following 5-HTP treatment (p = 0.234; see figure 4.4b). 
As an activator of IDO the influence of IFN-γ on 5-HTP and serotonin treatment of SH-
SY5Y cells was also investigated.  Cells were treated with 50U/mL IFN-γ for 24hr prior 
to the addition of 5-HTP and then incubated for 48hr.  Using the SRB assay IFN-γ 
treatment alone decreased cell growth to approximately 37% of untreated control (p 
<0.001).  5-HTP was found to significantly affect cell growth of IFN-γ treated cells at 
concentrations >500µM (see figure 4.5a).  At concentrations >1000µM 5-HTP 
treatment led to some cell loss relative to the amount of cells present at time 0. The 
effect of 5-HTP on cell growth in the presence and absence of IFN-γ was found to be 
significantly different (p <0.001).  Cell growth following treatment with 1µM NSD-
1015 was less affected by 5-HTP (p <0.01) however this effect was not significant with  
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Figure 4.2 NSD-1015 concentration for inhibition of AADC in SH-SY5Y cells. 
Extracellular concentration of a. 5-HTP b. serotonin and c. 5-HIAA in SH-SY5Y cells 
following 48hr treatment with 10µM 5-HTP in the presence of different concentrations 
of NSD-1015. All values are mean ± SEM of 8 independent experiments . ***
 
p <0.001 
in comparison to 5-HTP alone treatment determined by ANOVA followed by least 
significant difference test. 
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10µM NSD-1015 (p = 0.120).  Serotonin treatment in the presence of IFN-γ also had a 
significant effect on SH-SY5Y cell growth at concentrations >500µM (see figure 4.5b).  
Cell loss relative to the amount of cells present before treatment was observed at 
concentrations >750µM.  The effect of serotonin on cell growth in the presence of IFN-
γ was found to be different from the effect of serotonin alone (p <0.001). Furthermore in 
the presence of IFN-γ serotonin treatment induced cell loss at lower concentrations 
(750µM) than 5-HTP (1000µM; p <0.05). 
IFN-γ treatment alone increased LDH release from SH-SY5Y cells by approximately 
1.4-fold in comparison to untreated control (p <0.01).  In the presence of IFN-γ 5-HTP 
had no significant effect on LDH release at concentrations <2000µM (see figure 4.6a).  
Comparing cells treated with 5-HTP alone to those treated with 5-HTP and IFN-γ LDH 
release was increased (p <0.001). 1µM or 10µM NSD-1015 treatment did not alter LDH 
release after treatment with <2000µM 5-HTP in the presence of IFN-γ (p = 0.386; see 
figure 4.6a).  Serotonin treatment in combination with IFN-γ led to significant increases 
in LDH release at serotonin concentrations >1000µM in comparison to control treated 
with IFN-γ alone (see figure 4.6b).  The effect of 1000μM and 2000μM serotonin upon 
LDH release was significantly increased in the presence of IFN-γ in comparison to SH-
SY5Y cells treated with serotonin alone.  The effect of serotonin in the presence of IFN-
γ was also found to be increased in comparison to 5-HTP in the presence of IFN-γ (p 
<0.01).  
4.5.5 Effect of 5-HTP and serotonin on LDH release in astrocytoma cells 
The LDH release assay was used to investigate the effect of 5-HTP and serotonin on 
membrane integrity of the human astrocytoma cell line 1321N1.  Cells were treated 
with 5-HTP or serotonin for 48hr before measurement of LDH release.  5-HTP 
treatment did not change LDH release across the concentration range tested (p = 0.720; 
see figure 4.7).  2000µM serotonin treatment led to an approximately 3.3-fold increase 
in LDH release (p <0.05) with no significant effect observed at lower concentrations of 
serotonin (see figure 4.7).  The effect of IFN-γ upon LDH release from 1321N1 cells 
was also investigated.  Cells were treated for 24hr with IFN-γ before the addition of 5-
HTP or serotonin.  IFN-γ treatment alone had no effect on LDH release (p = 0.763).  In 
the presence of IFN-γ 5-HTP at a concentration of 1000µM increased LDH release by
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TREATMENT 5-HTP Serotonin 5-HIAA 
INTRACELLULAR 
5-HTP 1 ± 0 1584 ± 198 281 ± 21 
5-HTP + IFNγ 9 ± 1 2244 ± 344 399 ± 54* 
5-HTP + NSD-1015 194 ± 11*** 1278 ± 155 39 ± 8*** 
5-HTP + NSD-1015 +IFN-γ 308 ± 46***++ 1508 ± 180 24 ± 4*** 
serotonin ND 1868 ± 238 291 ±37  
Serotonin + IFN-γ ND 1911 ± 208 326 ± 64 
EXTRACELLULAR 
5-HTP 5968 ± 350 2280 ± 78 1928 ± 336 
5-HTP + IFNγ 5387 ± 505 2422 ± 99 1578 ± 280 
5-HTP + NSD-1015 10840 ± 199** 188 ± 5*** 205 ± 39*** 
5-HTP + NSD-1015 +IFN-γ 10470 ± 331*** 185 ± 2*** 156 ± 36*** 
serotonin ND 9361 ± 396 1910 ± 405 
Serotonin + IFN-γ 1.62 ± 1.62 9763 ± 499 2075 ± 335 
 
Table 4.1 Effect of NSD-1015 and IFN-γ on indoleamine metabolism.  Indoleamine 
levels following treatment with 50µM 5-HTP or Serotonin.  Cells treated with 10µM 
NSD-1015 and/or 50U/mL IFN-γ for 24hr before the addition of 5-HTP or serotonin.   
Intracellular values expressed as pmol/mg of protein and extracellular values expressed 
as nM. All values are mean ± SEM of 5 independent experiments. ND: not detectable.  
++ 
p <0.01 in comparison to 5-HTP + NSD-1015 treatment, *p <0.05, **p <0.01, ***
 
p 
<0.001 in comparison to 5-HTP alone treatment determined by ANOVA followed by 
least significant difference test. 
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Figure 4.3 SH-SY5Y cell proliferation following 5-HTP, serotonin and NSD-1015 
treatment. a. The effect of 5-HTP and serotonin treatment on cell proliferation of SH-
SY5Y cells as measured by SRB assay. b. The effect of NSD-1015 on 5-HTP induced 
changes in cell proliferation of SH-SY5Y cells measured by SRB assay.  ΔA490: 
Change in absorbance at 490nm compared to cells prior to treatment.  Results are mean 
± SEM of 6 independent experiments. ** p <0.01, ***p <0.001 difference in 
comparison to 0 by ANOVA followed by least significant difference test. 
#
 p <0.05 
determined by Student‟s t-test. 
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Figure 4.4 SH-SY5Y LDH release following 5-HTP, serotonin and NSD-1015 
treatment. a. The effect of 5-HTP and serotonin on membrane integrity of SH-SY5Y 
cells measured by the LDH release assay. b. LDH release from SH-SY5Y cells in 
response to 5-HTP following treatment with NSD-1015.  % LDH release: LDH activity 
in cell culture medium as a percentage of total LDH activity following complete cell 
lysis.  Results are mean ± SEM of 5 independent experiments.  * p <0.05, ***p <0.001 
difference in comparison to 0 by ANOVA followed by least significant difference test. 
# 
#
 p <0.01 determined by Student‟s t-test. 
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approximately 1.3-fold in comparison to cells treated with IFN-γ alone (p <0.01; see 
figure 4.8a), however this effect was not significantly different from treatment with 5-
HTP alone (p = 0.09).  Higher and lower concentrations of 5-HTP had no significant 
effect on LDH release in the presence of IFN-γ.  IFN-γ also had no significant effect 
upon LDH release from 1321N1 cells treated with serotonin in comparison to cells 
treated with serotonin alone (p = 0.880; see figure 4.8b). 
4.5.6 Intracellular GSH in SH-SY5Y cells 
To investigate whether the effects of 5-HTP on cell growth were related to oxidative 
stress intracellular GSH in SH-SY5Y cells was measured. Cells were incubated in the 
presence or absence of IFN-γ and/or 10µM NSD-1015 for 24hr before the addition of 5-
HTP.  IFN-γ and NSD-1015 (p = 0.509 and p = 0.159 respectively) had no significant 
effect on intracellular GSH with 5-HTP treatment (see figure 4.9a).  5-HTP treatment 
led to a small but significant increase in GSH concentration at both 50µM and 1000µM 
(p <0.05, p <0.01 respectively), although comparing these two concentrations this effect 
did not appear to be dose-dependent (p = 0.523).  Similarly small increases in 
intracellular GSH with both 50µM and 1000µM of serotonin were observed (p <0.05, p 
<0.01 respectively; see figure 4.9b) again with no significant difference between the 
two concentrations (p = 0.378).  IFN-γ had no effect upon the changes in GSH levels 
following serotonin treatment (p = 0.244). 
4.5.7 Mitochondrial respiratory chain activity following 5-HTP or serotonin 
treatment   
As GSH was increased with 5-HTP and serotonin treatment at a sub-toxic concentration 
of 50µM this indicates that there may be cellular alterations at lower and potentially 
more physiologically relevant concentrations.  Furthermore alterations in GSH levels 
can lead to changes in the activity of the mitochondrial respiratory chain complexes 
(Heales et al, 1995). The effect of 50μM 5-HTP and serotonin on the mitochondrial 
respiratory chain was therefore also investigated.  50µM 5-HTP or serotonin alone 
produced no change in complex I, II/III or IV activity in comparison to untreated 
control (see figure 4.10 and table 4.2).  Similarly 50µM 5-HTP in the presence of NSD-
1015 did not alter the activity of any of the complexes in comparison to cells treated 
with NSD-1015 alone. Treatment with 5-HTP and IFN-γ did result in an increase in 
complex II activity in comparison to cells treated with 5-HTP alone (see figure 4.10 and 
table 4.2). This effect was apparent both when activity was expressed as a ratio to
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Figure 4.5 SH-SY5Y cell proliferation following 5-HTP, serotonin and NSD-1015 
treatment with IFN-γ. a. The effect of NSD-1015 on 5-HTP induced changes in cell 
proliferation following treatment with 50U/mL IFN-γ measured by SRB assay b. The 
effect of serotonin treatment in the presence of 50U/mL IFN-γ on cell proliferation as 
measured by SRB assay.  ΔA490: Change in absorbance at 490nm compared to cells 
prior to treatment.  Results are mean ± SEM of 6 independent experiments. * p <0.05, 
** p <0.01, ***p <0.001 difference in comparison to 0 by ANOVA followed by least 
significant difference test.  
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Figure 4.6 SH-SY5Y LDH release following 5-HTP, serotonin and NSD-1015 
treatment with IFN-γ. a. The effect 5-HTP following treatment with NSD-1015 in the 
presence of 50U/mL IFN-γ on membrane integrity of SH-SY5Y cells measured by the 
LDH release assay. b. LDH release from SH-SY5Y cells in response to serotonin 
treatment in the presence of 50U/mL IFN-γ.  % LDH release: LDH activity in cell 
culture medium as a percentage of total LDH activity following complete cell lysis.  
Results are mean ± SEM of 5 independent experiments.  ** p <0.01, ***p <0.001 
difference in comparison to 0 by ANOVA followed by least significant difference test. 
# 
p < 0.05,
 # #
 p <0.01 determined by Student‟s t-test. 
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citrate synthase or as nmol/min/mg of protein.  However the activity of each complex 
was not significantly different between cells treated with 5-HTP and IFN-γ and those 
treated with IFN-γ alone.  Complex IV activity was also found to be increased following 
treatment with 5-HTP and IFN-γ in comparison to 5-HTP alone, however this was only 
significant when expressed as nmol/min/mg of protein (p <0.05) and not significant as a 
ratio to citrate synthase activity.  Combined treatment with 5-HTP, NSD-1015 and IFN-
γ led to a significant increase in complex II/III activity in comparison to cells treated 
with 5-HTP and NSD-1015. However this effect was only significant when results were 
expressed as nmol/min/mg (p <0.05), not when expressed as a ratio to citrate synthase.  
Furthermore complex activities were not significantly different between cells treated 
with 5-HTP, NSD-1015 and IFN-γ and those treated with NSD-1015 and IFN-γ.  In 
comparison to serotonin alone, serotonin with IFN-γ treatment did lead to a significant 
increase in complex II/III activity when expressed as nmol/min/mg (p <0.05), but not 
when expressed as a ratio to citrate synthase.  However the activity of each of the 
complexes was not significantly different between serotonin and IFN-γ treated cells and 
cells treated with IFN-γ alone.  Citrate synthase activity was not changed between any 
of the treatment conditions (p = 0.999; see table 4.2).  Total protein levels were also not 
significantly different between any of the treatments (p = 0.483). 
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Figure 4.7 1321N1 LDH release following 5-HTP and serotonin treatment. The effect 
of 5-HTP and serotonin treatment on membrane integrity of 1321N1 cells measured by 
the LDH release assay. % LDH release: LDH activity in cell culture medium as a 
percentage of total LDH activity following complete cell lysis.  Results are mean ± 
SEM of 3 - 5 independent experiments.  * p <0.05 difference in comparison to 0 by 
ANOVA followed by least significant difference test. 
# 
p < 0.05 determined by 
Student‟s t-test. 
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Figure 4.8 1321N1 LDH release following 5-HTP and serotonin treatment with IFN-
γ. a. The effect of 5-HTP treatment in the presence or absence of 50U/mL IFN-γ on 
membrane integrity of 1321N1 cells measured by the LDH release assay. b. LDH 
release from 1321N1 cells in response to serotonin in the presence or absence of 
50U/mL IFN-γ. % LDH release: LDH activity in cell culture medium as a percentage of 
total LDH activity following complete cell lysis.  Results are mean ± SEM of 3 - 5 
independent experiments.  ** p <0.01 difference in comparison to 0 by ANOVA 
followed by least significant difference test.  
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Figure 4.9 Intracellular GSH following 5-HTP or serotonin treatment in SH-SY5Y 
cells. a. Intracellular GSH in SH-SY5Y cells following treatment with 5-HTP in the 
presence or absence of 10µM NSD-1015 and/or 50U/mL IFN-γ. b. Intracellular GSH in 
SH-SY5Y cells following treatment with serotonin in the presence or absence of 
50U/mL IFN-γ. Results are mean ± SEM of 3 independent experiments.  *p <0.05, ** p 
<0.01 difference in comparison to 0 by ANOVA. 
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Figure 4.10 SH-SY5Y cell activity of mitochondrial respiratory chain after serotonin 
and 5-HTP treatment. a. complex I, b. complex II/III and c. complex IV expressed as a 
ratio to citrate synthase.  Cells were treated with 50µM 5-HTP or serotonin as indicated 
for 48hr.  10µM NSD-1015 and/or 50U/mL IFN-γ was added 24hr before other 
treatments.  Results are mean ± SEM from 3 - 4 independent experiments. * p <0.05 
determined by ANOVA followed by least significant difference test. 
 1
3
9
 
 
 Complex I Complex II/III Complex IV Citrate 
synthase 
 Activity % inhibition Activity % inhibition   
Control 8.6 ± 3.5 54 ± 5 8.2 ± 1.0 98 ± 5 55.1 ± 6.4 146.1 ± 59.4 
5-HTP 7.4 ± 1.9 60 ± 10 6.7 ± 1.3 104 ± 3 58.9 ± 9.0 162.7 ± 22.5 
5-HTP + NSD-1015 4.9 ± 1.7 50 ± 27 6.2 ± 0.8 99 ± 6 64.1 ± 12.5 158.4 ± 46.2 
5-HTP + IFN-γ 9.9 ± 2.1 63 ± 14 12.5 ± 1.0+ 103 ± 3 85.9 ± 7.9+ 136.9 ± 36.4 
5-HTP + NSD-1015 + IFN-γ 9.9 ± 0.8 71 ± 6 10.8 ± 0.8$ 100 ± 2 75.5 ± 5.5 126.3 ± 28.6 
Serotonin 5.9 ± 1.3 48 ± 15 6.2 ± 0.7 100 ± 1 61.0 ± 8.5 134.6 ± 31.8 
Serotonin + IFN-γ 11.0 ± 2.9 72 ± 7 9.8 ± 2.5@ 96 ± 6 56.2 ± 9.9 131.0 ± 53.2 
NSD-1015 10.7 ± 1.8 73 ± 3 8.4 ± 0.3 99 ± 5 55.1 ± 14.6 159.0 ± 50.6 
IFN-γ 14.0 ± 2.6 78 ± 0 11.0 ± 1.7 101 ± 1 73.8 ± 12.7 144.0 ± 25.3 
NSD-1015 + IFN-γ 10.3 ± 2.2 55 ± 0 12.2 ±1.1 100 ± 1 68.3 ± 5.5 123.7 ± 39.1 
 
Table 4.2 SH-SY5Y cell activity of mitochondrial respiratory chain after serotonin and 5-HTP treatment. Activity of complex I (nmol/min/mg of 
protein); complex II/III (nmol/min/mg of protein) and  complex IV (k/min/mg of protein) as well as citrate synthase activity (nmol/min/mg).  Complex 
I % inhibition following addition of rotenone and complex II/III % inhibition following addition of antimycin A.  Cells were treated with 50µM 5-HTP 
or serotonin as indicated for 48hr. 10µM NSD-1015 and/or 50U/mL IFN-γ was added 24hr before other treatments.  Results are mean ± SEM from 3 - 
4 independent experiments. 
+
 p <0.01 difference from 5-HTP alone, 
$
 p <0.05 difference from 5-HTP + NSD-1015, 
@
 p <0.05 difference from 
serotonin alone all determined by ANOVA followed by least significant difference test. 
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4.6 Discussion 
4.6.1 5-HTP and serotonin metabolism 
Due to the lack of indoleaminergic cell lines the catecholaminergic SH-SY5Y cell line, 
which was found to express AADC mRNA, protein and activity was used to investigate 
the role of 5-HTP in AADC deficiency pathogenesis.  The addition of 5-HTP to SH-
SY5Y cells led to the production of serotonin and 5-HIAA demonstrating that serotonin 
could be produced and degraded in these cells.  The degradation of serotonin to 5-HIAA 
is most likely via MAO-A that is known to be expressed in SH-SY5Y cells (Fitzgerald 
et al, 2007).  Taken together these results suggest that indoleamine metabolism can be 
successfully reproduced in SH-SY5Y cells following the addition of 5-HTP.  
Furthermore following the extracellular addition of serotonin to SH-SY5Y cells 
intracellular serotonin was detected demonstrating that this cell line was capable of 
serotonin uptake.  Additionally mRNA from the 5-HT2B receptor has been isolated from 
SH-SY5Y cells, suggesting that this receptor type may be present at the cell membrane 
(Schmuck et al, 1994).  Together these results suggested that SH-SY5Y cells could 
provide a useful model of some aspects of indoleamine physiology and could be used 
for initial testing of the hypotheses of this chapter.  
NSD-1015 was used to inhibit AADC which, following 5-HTP treatment, led to 
reductions in the level of 5-HIAA and increases in 5-HTP, in a similar pattern to what is 
observed in the CSF of patients with AADC deficiency (Hyland and Clayton, 1990; 
Brun et al, 2010).   Extracellular serotonin was also decreased following NSD-1015 
treatment however intracellular serotonin was unaffected.  This could suggest that 
intracellular serotonin was preserved in these cells at the expense of extracellular 
serotonin. Consequently this indicates that one possible adaptation to reduced serotonin 
biosynthesis in AADC deficiency could be to decrease serotonin release or increase re-
uptake.  Through measurement of quantal release of serotonin from presynaptic 
membranes it has been demonstrated that the amount of neurotransmitter contained 
within each small synaptic vesicle may be proportional to the size of the vesicle (Bruns 
et al, 2000).  Potentially then serotonin deficiency could lead to less vesicles being 
filled and consequently serotonin release would be reduced.  Alternatively serotonin 
deficiency could lead to an upregulation of SERT, increasing reuptake and recycling of 
serotonin, supporting this chronic blockade of serotonin re-uptake with cocaine leads to 
upregulation of SERT in humans (Mash et al, 2000).  
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IFN-γ was utilised throughout this study to activate IDO and consequently the 
kynurenine pathway.  It has been shown previously that IFN-γ can activate IDO in 
neuronal cell lines including the parental cell line to SH-SY5Y cells, SK-N-SH 
(Guillemin et al, 2007).  Activation of IDO would be expected to lead to an increase in 
the metabolism of 5-HTP and serotonin via the kynurenine pathway.  However IFN-γ 
treatment did not lead to any decrease in 5-HTP or serotonin potentially indicating that 
they were not being degraded via this alternative metabolic route.  This could suggest 
that either IDO was not active in this cell line or 5-HTP and serotonin were not 
degraded via the kynurenine pathway at the concentration used in these experiments.  
Treatment of SH-SY5Y cells with IFN-γ alone led to a reduction in cell growth, 
indicating that IFN-γ has an inhibitory effect on SH-SY5Y cell proliferation.  This 
could relate to tryptophan depletion due to IDO activation, which has previously been 
shown to inhibit cell proliferation (Munn et al, 1999).    Therefore this could indicate 
that IDO was active. IFN-γ treatment has also been demonstrated to lead to 
differentiation of some neuroblastoma cell lines, which in the mouse N103 cell line was 
dependent on NO
•
  production (Munoz-Fernandez et al, 1994; Ridge et al, 1996).  IFN-γ 
is known to be a potent inducer of nitric oxide synthase (NOS) (Kilbourn and Bellomi, 
1990; Petit et al, 1990) and both neuronal NOS (nNOS) and inducible NOS (iNOS) 
have previously been demonstrated to be expressed in SH-SY5Y cells (Russo et al, 
2004; Guo et al, 2005).  It is possible therefore that IFN-γ treatment increased NO• 
production in SH-SY5Y cells during the current study.  NO
•
 has been demonstrated to 
be an inhibitor of IDO (Thomas et al, 1994; Alberati-Giani et al, 1997) and therefore it 
is possible that while IDO expression was induced by IFN-γ treatment of SH-SY5Y 
cells, iNOS could also have been induced leading to inhibition of IDO via NO
•
 .   
The Km of purified human IDO for 5-HTP is approximately 20-fold greater than that of 
tryptophan (Takikawa et al, 1988), indicating that 5-HTP would need to be in a great 
excess to compete with tryptophan as a substrate for IDO.  The cell culture medium 
used with SH-SY5Y cells in the current study contains 44µM L-tryptophan 
(Invitrogen), almost equimolar with the concentration of 5-HTP (50µM).  However if 
IDO was active it would seem likely, given its proposed physiological role in L-
tryptophan depletion (Byrne et al, 1986; Beatty et al, 1994; Munn et al, 1999), that this 
initial concentration of L-tryptophan would undergo a relatively rapid degradation.  
Furthermore an L-tryptophan load in hens has been demonstrated to lead to the 
production of 5-hydroxykynurenine, demonstrating that in a physiological setting 5-
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HTP can still be metabolised via IDO even under conditions of high L-tryptophan (Kido 
et al, 1967a Kido et al, 1967b).  It is possible that at the 48hr time point, when 
indoleamines were measured in the current study, the levels of 5-HTP and serotonin 
could have been below the level required for IDO metabolism.  Potentially at earlier 
time points, when 5-HTP and serotonin concentrations were likely to have been higher, 
there could have been some observable differences in indoleamine levels as a result of 
IFN-γ treatment.  5-hydroxykynurenine metabolites could not be directly measured as 
no synthetic 5-hydroxykynurenines were available for use as standards.  For future work 
labelled [
14
C-3]-5-HTP could be used to follow the metabolic fate of 5-HTP and 
identify if kynurenine metabolites do accumulate in an AADC deficient cell model 
(Zamboni and Sauer, 2009; Hiller et al, 2010).     
4.6.2 5-HTP and serotonin toxicity 
Greater than 500µM 5-HTP was found to be growth inhibitory to SH-SY5Y cells and 
LDH release was also slightly increased at higher concentrations of 5-HTP.  Together 
these results indicate that 5-HTP may be mildly toxic to SH-SY5Y cells.  Both the 
effect on cell growth and LDH release were unaffected by NSD-1015 demonstrating 
that these effects were not dependent on conversion to serotonin.  However serotonin 
itself was demonstrated to be growth inhibitory and to increase LDH release to a greater 
extent than 5-HTP, however this was only observed at a concentration of 2000µM.  This 
possible toxicity of 5-HTP and serotonin could relate to an increase in oxidative stress 
as both are capable of undergoing oxidation, however both 5-HTP and serotonin have 
been suggested to act as antioxidants (Ng et al, 2000; Herraiz and Galisteo, 2004; 
Munoz-Castaneda et al, 2005; Munoz-Castaneda et al, 2006).  Alternatively it has been 
suggested that activation of serotonin 5-HT2 receptors may lead to activation of 
apoptosis through increased intracellular Ca
2+
 (Schmidt et al, 1990; Azmitia, 2001).  
Consequently the increase in LDH release observed following serotonin treatment could 
relate to Ca
2+
 influx and excitotoxicity similar to that described for glutamate (reviewed 
by Fan and Raymond, 2007).   
IFN-γ alone reduced cell growth and led to a small increase in cell lysis as measured by 
LDH release.  This treatment has previously been demonstrated to inhibit SH-SY5Y cell 
growth (Martin et al, 1993; Ridge et al, 1996). SH-SY5Y cell populations contain two 
morphologically distinct but interconvertable cellular phenotypes neuroblast-like cells 
and epithelial-like cells (Biedler et al, 1978; Ciccarone et al, 1989).  Ridge et al (1996) 
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demonstrated that IFN-γ treatment of SH-SY5Y cells induces differentiation of both 
phenotypes and also noted the presence of small-round cells in suspension in the media 
which the authors described as dead cells.  In the present study combined treatment with 
>1000µM 5-HTP and IFN-γ led to a loss of cells, but with no concomitant increase in 
LDH release.  This suggests that SH-SY5Y cells are detaching from the growth surface, 
but may not be dying as no change in membrane integrity was observed.   This could 
indicate that the combined treatment of 5-HTP and IFN-γ causes differentiation of SH-
SY5Y cells into a cell type that grows in suspension. Alternatively the cells may have 
been undergoing a cell death process but membrane integrity had not been disrupted at 
the time point when LDH release was measured.  In support of this combined treatment 
of serotonin and IFN-γ led to both a decrease in cell growth and increased cell lysis, 
indicating that this treatment is toxic to SH-SY5Y cells.  Furthermore NSD-1015 at 
1µM but not 10µM decreased the effect of 5-HTP and IFN-γ on cell loss, suggesting 
that cell loss was partially dependent on conversion to serotonin and consequently may 
be related to cellular toxicity.   
As measurement of indoleamines following IFN-γ treatment indicate that 5-HTP and 
serotonin may not have been degraded by the kynurenine pathway (see section 1.7.3) it 
seems unlikely that the toxicity of serotonin and 5-HTP following IFN-γ treatment 
could be related to the production of 5-hydroxykynurenine metabolites.  However IFN-γ 
could have induced the production of L-tryptophan kynurenine metabolites and 
consequently there may potentially have been a synergistic effect between these 
metabolites and serotonin and 5-HTP.  For example the L-tryptophan kynruenine 
metabolite quinolinic acid is a glutamate NMDA receptor agonist that causes 
excitotoxicity through calcium influx via NMDA receptors (Garthwaite and Garthwaite, 
1986, Garthwaite and Garthwaite, 1987; Schurr et al, 1991).  Additionally quinolinic 
acid induces oxidative stress through production of the OH
•-
 (Santamaria et al, 2001).  
Likewise another L-tryptophan kynurenine metabolite 3-hydroxykynurenine induces 
oxidative stress and cellular toxicity through the production of reactive oxygen species 
and also potentiates quinolinic acid induced toxicity (Eastman and Guilarte, 1989; 
Okuda et al, 1998; Guidetti and Schwarcz, 1999).  Alternatively IFN-γ treatment could 
have led to IDO activation and consequently L-tryptophan depletion (Munn et al, 1999), 
leading to the observed inhibition of SH-SY5Y cell growth.  In this state the cells may 
have been more vulnerable to high concentrations of serotonin or 5-HTP.  An 
alternative explanation could possibly relate to increased NO
•
  production following 
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IFN-γ treatment (Bolanos et al, 1994; Bolanos et al, 1996; Minc-Golomb et al, 1996) 
which could potentially occur in SH-SY5Y cells as they are known to express iNOS 
(Russo et al, 2004; Guo et al, 2005).  Increased levels of NO
•
 could increase the cellular 
oxidative burden and potentially make the cells more susceptible to damage induced by 
serotonin or 5-HTP treatment.   
In contrast to SH-SY5Y cells LDH release from the human astrocytoma cell line 
1321N1 was not increased following IFN-γ treatment.  Furthermore although treatment 
with high concentrations of serotonin led to increases in LDH release from 1321N1 
cells this effect was not changed by IFN-γ. This could indicate that neuronal-like cells 
are more susceptible than astrocyte-like cells to the mechanisms of combined IFN-γ and 
serotonin toxicity, although both may be equally susceptible to the effects of serotonin 
alone.  5-HTP treatment alone also had no effect on LDH release from 1321N1 cells. 
Combined treatment with IFN-γ and 1000µM 5-HTP led to a small increase in LDH 
release perhaps indicating some toxicity of this treatment which again may relate to the 
kynurenine pathway or NO
•
.  The same treatment led to a greater increase in LDH 
release in SH-SY5Y cells, perhaps indicating increased neuronal susceptibility to this 
treatment.  In AADC deficiency the level of 5-HTP in the CSF is generally in the 
nanomolar range (patient range: 51-264 nM; Brun et al, 2010).  The concentration of 5-
HTP has not been measured in close proximity to serotoninergic neurons though it is 
likely to be somewhat higher than in the CSF.   This concentration may still not reach 
the level that was mildly toxic in the current experiments, however the neurons of 
patients with AADC deficiency are chronically exposed to 5-HTP, whereas in these 
experiments only acute effects were measured.  Consequently the chronic effects of 5-
HTP exposure require further investigation. Furthermore Guillemin et al (2005b) 
demonstrated that while neurons and astrocytes were able to express IDO, they were 
unable to produce quinolinic acid, a product of L-tryptophan kynurenine metabolism.  
In contrast microglial cells were able both to express IDO and produce quinolinic acid.  
This suggests that microglial cells rather than neurons or astrocytes, may be required for 
metabolism of 5-HTP via the kynurenine pathway.  A co-culture system utilising both 
neuronal cells and microglial cells could therefore be an important future experiment to 
investigate the potential role of microglia in 5-HTP kynruenine metabolism and possible 
toxicity. 
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4.6.3 Glutathione and mitochondrial respiratory chain activity 
GSH acts as a major cellular antioxidant acting as both a free radical scavenger as well 
as a substrate for glutathione peroxidise (reviewed by Martin and Teismann, 2009; 
Ballatori et al, 2009).  5-HTP and serotonin treatment led to small increases in the 
intracellular level of GSH in SH-SY5Y cells.  This could be an indication of oxidative 
stress as GSH can increase in response to ROS (Gegg et al, 2003).  γ-glutamylcysteine 
ligase can be upregulated by the activation of the transcription factor nuclear factor 
erythroid 2-related factor (Nrf2) that binds to promoter sequences termed antioxidant 
response elements (AREs; Rushmore et al, 1991; Venugopal et al, 1996; Itoh et al, 
1997; Wild et al, 1999).  Nrf2 activity is partly regulated by the cytosolic protein kelch-
like ECH associating protein 1 (Keap1; Itoh et al, 1999; Zipper and Mulcahy, 2002; 
Itoh et al, 2003).  Keap1 can act as a sensor for ROS and under oxidative stress this can 
lead to activation of Nrf2 (reviewed by Motohashi and Yamamoto, 2004).  It is possible 
therefore in the current experiments that serotonin and 5-HTP led to an increase in ROS 
production that activated this pathway resulting in an upregulation of γ-
glutamylcysteine ligase and the observed increase in GSH levels.  However it has 
previously been demonstrated that serotonin is unable to activate Nrf2 at concentrations 
<100µM in astrocytes and meningeal cells (Shih et al, 2007).  Conversely serotonin and 
5-HIAA are able to inhibit lipid peroxidation and OH
•-
 formation in vitro (Ng et al, 
2000).  5-HTP, serotonin and a range of other indolic compounds can also act as free 
radical scavengers in an in vitro system (Herraiz and Galisteo, 2004). This property of 
indoles is suggested to relate to the ability of the indolic nitrogen to accept a single 
electron.  Depletion of serotonin led to a decrease in GSH levels in rats, which could be 
restored by subsequent administration of 5-HTP (Munoz-Castaneda et al, 2006).  
Additionally during serotonin depletion catalase and SOD activities were reduced and 
lipid peroxidation increased.  Serotonin depletion has also been demonstrated to 
exacerbate lipid peroxidation, as well as catalase and SOD depletion in rats treated with 
the antibiotic gentamicin, which is known to induce oxidative stress (Munoz-Castaneda 
et al, 2005). It is possible therefore in the present study that serotonin and 5-HTP 
directly contributed to the antioxidant potential of SH-SY5Y cells thereby leading to the 
observed increases in GSH.  Alternatively 5-HTP and 5-HIAA, but not serotonin, have 
been shown to inhibit glutathione S-transferase (Sawicki et al, 2001).  Inhibition of this 
enzyme could reduce the consumption of GSH in conjugate formation potentially 
leading to an increase in intracellular GSH concentrations.   Glutathione S-transferases 
146 
 
are involved in the detoxification of a range of endogenous and xenobiotic compounds 
by forming conjugates between GSH and the compound (reviewed by Hayes et al, 
2005).  It is possible therefore that whilst 5-HTP could increase GSH via inhibiting 
glutathione S-transferase, this would have a negative impact on cell survival and 
potentially redox status by reducing clearance of toxic compounds. 
The mitochondrial respiratory chain is known to be susceptible to oxidative damage due 
to increased cellular ROS (Zhang et al, 1990; Benzi et al, 1991; Bolanos et al, 1994; 
Heales et al, 1995; Bolanos et al, 1996; Merad-Boudia et al, 1998; Merad-Saidoune et 
al, 1999; Chinta and Andersen, 2006). Mitochondria are also known to play a major role 
in cell survival, calcium signalling and apoptosis (Carafoli and Crompton et al, 1978; 
Miller, 1991; Neame et al, 1998; Nicholls and Budd, 2000; Pena et al, 2001).  
Consequently the activity of the respiratory chain enzyme complexes were investigated 
to determine whether 5-HTP or serotonin can induce changes in mitochondrial function. 
Combined treatment of SH-SY5Y cells with IFN-γ and 5-HTP or serotonin appeared to 
lead to an increase in the activity of complex II/III compared to cells treated with 
serotonin or 5-HTP alone.  For serotonin or 5-HTP with NSD-1015 this effect was only 
significant when expressed as a proportion of cellular protein and not significant when 
expressed as a ratio to citrate synthase activity.  Citrate synthase activity is commonly 
used as a mitochondrial marker and as a measure of mitochondrial enrichment (Winder 
and Holloszy, 1977; Fatania and Dalziel, 1980; Hargreaves et al, 2007).  Citrate 
synthase activity was unaffected by any of the treatments used in the current 
experiments.  This suggests that the effect on complex II/III does not relate to changes 
in the amount of mitochondria.  Likewise total protein was unaffected by any of the 
treatments which indicates that the observed effects on complex II/III are not an artefact 
from a change in cell number.  Furthermore the % antimycin A inhibition during the 
assay of complex II/III was not altered between treatments, indicating that non-specific 
reduction of cytochrome c was not responsible for the observed differences in complex 
II/III activity.  The lack of significance in results expressed as a ratio to citrate synthase 
could be explained by a higher level of variation in these results compared to results 
expressed as a proportion of total protein.  Consequently the results could indicate that 
the combination of IFN-γ and 5-HTP or serotonin does lead to an increase in complex 
II/III activity.  Furthermore the effect of 5-HTP was not abolished by co-incubation 
with NSD-1015 suggesting that conversion of 5-HTP to serotonin was not required for 
this effect.   
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One possible explanation for this synergistic effect may relate to an increase in 
mitochondrial antioxidant status.  5-HTP or serotonin treatment led to a small increase 
in GSH, which may relate in part to the potential ability of indoles to act as free radical 
scavengers (Ng et al, 2000; Herraiz and Galisteo, 2004; Munoz-Castaneda et al, 2006).  
IFN-γ treatment has previously been demonstrated to increase MnSOD, which is 
responsible for the conversion of O2
•-
 to H2O2 within mitochondria (Okado-Matsumoto 
and Fridovich, 2001).  Potentially combined treatment with 5-HTP or serotonin and 
IFN-γ would increase both GSH and MnSOD, perhaps leading to an increased 
efficiency in O2
•-
 detoxification via SOD and subsequently H2O2 reduction via 
glutathione peroxidise.  Together this could lead to a lower level of ROS mediated 
damage to complexes II and III leading to enhanced activity. Furthermore the L-
tryptophan kynurenine metabolite kynurenic acid has been demonstrated to protect 
against toxicity of the MPP
+
 complex I inhibitor by reducing the level of the pro-
apoptotic Bax protein (Lee et al, 2008c).  Part of this protection was elicited by 
preventing depolarisation of the mitochondrial membrane.   
The increase in complex II/III activity in response to 5-HTP or serotonin and IFN-γ 
could indicate that this treatment affords some protection to neuronal-like cells leading 
to stimulation of oxidative phosphorylation.  However IFN-γ treatment has previously 
been demonstrated to lead to differentiation of SH-SY5Y cells (Ridge et al, 1996) and 
possibly the combined effect of indoles and IFN-γ altered the phenotype of these cells 
resulting in an increase in oxidative phosphorylation. IFN-γ can also activate iNOS 
leading to NO
•
 production (Bolanos et al, 1994; Bolanos et al, 1996; Minc-Golomb et 
al, 1996).  NO
•
 has been demonstrated to be an inhibitor of complex IV activity 
(Bolanos et al, 1994; Heales et al, 1994; Brown et al, 1995).  Both microglial cells and 
astrocytes have been demonstrated to produce NO
•
  in response to IFN-γ stimulation 
(Chao et al, 1992; Demerle-Pallardy et al, 1993; Corradin et al, 1993; Colasanti et al, 
1993).  Furthermore the increase in astrocyte produced NO
•
 has been shown to have a 
negative impact on neuronal respiration (Bolanos et al, 1996; Stewart et al, 2000).  
Consequently further work would need to be conducted to ascertain whether the 
combined effect of IFN-γ and 5-HTP or serotonin would increase neuronal complex 
II/III function in the presence of glial cells. 
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4.7 Conclusions 
AADC deficiency results in a deficit of serotonin and an accumulation of the precursor 
5-HTP in patient CNS.  The evidence presented in this chapter indicates that 5-HTP 
could be mildly toxic to neuronal-like cells.  The concentration range at which toxicity 
was observed was above that seen in patients, however it is possible that chronic 
exposure to 5-HTP could cause neuronal damage at lower concentrations.  5-HTP and 
serotonin were both found to increase intracellular GSH in neuronal-like cells.  This 
could indicate that indoles contribute to enhancing the antioxidant status of neurons, 
although 5-HTP has previously been shown to inhibit glutathione S-transferase, which 
could have a negative effect on detoxification of damaging compounds.  IFN-γ a known 
activator of the kynurenine pathway, was found to act synergistically with both 5-HTP 
and serotonin, leading to some neuronal toxicity at higher concentrations of indoles.  
However it is possible that in these investigations the kynurenine pathway was not 
activated and therefore the role of kynurenine metabolism in AADC deficiency requires 
further investigation.  At sub-toxic concentrations IFN-γ in combination with 5-HTP or 
serotonin appeared to increase the activity of complex II/III of the respiratory chain, this 
could represent a beneficial effect of indoles and IFN-γ in enhancing antioxidant 
protection, however this effect could also relate to differentiation of neuronal-like cells.  
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Chapter 5 
5 The effect of L-dopa and dopamine 
on cell viability, glutathione 
homeostasis and mitochondrial 
function 
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5.1 Introduction 
L-dopa has been demonstrated to accumulate in the CSF of patients with AADC 
deficiency (Brun et al, 2010).  Potentially the accumulation of this substrate may have 
damaging effects for patients.  L-dopa and dopamine have been shown to be toxic to 
isolated primary neuronal cultures and to neuronal cell lines including the SH-SY5Y 
neuroblastoma cell line (Mena et al, 1993; Basma et al, 1995; Lai and Yu, 1997; Nakao 
et al, 1997; Offen et al, 2001; Pedrosa and Soares-Da-Silva, 2002; Haque et al, 2003).  
This toxicity is primarily considered to be due to auto-oxidation of L-dopa and 
dopamine in cell culture medium inducing oxidative stress via ROS production.  In 
these studies the inhibition of AADC with benserazide or carbidopa did not prevent the 
toxicity of L-dopa indicating that it‟s conversion to dopamine was not required for 
toxicity (Basma et al, 1995; Pedrosa and Soares-Da-Silva, 2002; Haque et al, 2003).  
Much of the toxic effect of L-dopa and dopamine could be prevented by the 
extracellular addition of catalase, which converts H2O2 to 2H2O, demonstrating that 
extracellular generation of H2O2 was an important mechanism for toxicity (Lai and Yu, 
1997).  Additionally 3-OMD, a major L-dopa metabolite that accumulates to a greater 
extent than L-dopa in the CSF of AADC deficient patients, that does not auto-oxidise, 
has been shown not to be toxic in cell culture (Offen et al, 2001; Haque et al, 2003; 
Hyland et al, 1992; Maller et al, 1997; Brun et al, 2010). It has also been suggested that 
the in vitro toxicity of L-dopa may be an artefact of cell culture (Clement et al, 2002).  
Furthermore in vivo studies indicate that chronic L-dopa administration does not cause 
damage to the dopaminergic nigrostriatal pathway (Hefti et al, 1981; Perry et al, 1984; 
Quinn et al, 1986; Zeng et al, 2001; Mytilineou et al, 2003).  
The disparity between in vivo and in vitro toxicity of L-dopa and dopamine may in part 
relate to catalysis of auto-oxidation by some components of cell culture medium 
(Clement et al, 2002).  However it has also been demonstrated that glial-conditioned 
medium protects primary neuronal cultures from L-dopa induced toxicity (Mena et al, 
1996; Mena et al, 1997b).  In addition L-dopa was not toxic to neurons in a neuronal-
astrocyte co-culture system (Mena et al, 1997a).  This evidence indicates that glial cells, 
and particularly astrocytes may play a role in vivo in preventing the L-dopa or dopamine 
induced toxicity seen in isolated neuronal culture.  L-dopa may also have some 
neuroprotective effects.  The intracellular levels of GSH have been found to be 
increased in response to L-dopa treatment in both isolated neuronal culture and in 
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neuronal/astrocyte co-culture (Mytilineou et al, 1993; Mena et al, 1997a).  Dopamine 
has also been demonstrated to increase GSH levels in rat pheochromocytoma cells (Jia 
et al, 2008a).  However Han et al (1996) found that inhibition of AADC did not prevent 
the L-dopa induced rise in GSH in mouse neuroblastoma and pig kidney epithelial cells, 
indicating that conversion to dopamine was not required for the effect.  Furthermore 
pre-treatment with L-dopa or dopamine protected cells against cell death following 
subsequent treatment with inducers of oxidative stress (Han et al, 1996; Jia et al, 
2008a).  Conversely dopamine has been demonstrated to negatively affect GSH release 
from primary astrocytes, which may relate to dopamine auto-oxidation that in turn may 
have led to oxidation of GSH (Hirrlinger et al, 2002).   The effects of L-dopa upon GSH 
release from astrocytes were not investigated.  GSH release is considered to be the first 
stage in trafficking of GSH from astrocytes to neurons consequently alterations in GSH 
release can lead to decreased GSH synthesis within neurons (see section 1.7.6, Dringen 
et al, 1999; Stewart et al, 2002) 
Although L-dopa administration was not found to be toxic in wildtype animals recent 
studies indicate that alterations in the metabolism and/or storage of catecholamines may 
lead to neurodegeneration.  Mice expressing low levels of VMAT2 displayed reduced 
storage and increased turnover of striatal dopamine and this was accompanied by 
degeneration of dopaminergic striatal neurons at 18 and 24 months of age (Caudle et al, 
2007).  Furthermore expression of DAT in striatal neurons unable to store or metabolise 
dopamine also induced neurodegeneration in mice which was exacerbated by L-dopa 
administration (Chen et al, 2008a).  Conversely viral gene transfer of AADC into 
cultured striatal neurons, which were able to store dopamine, protected these cells from 
L-dopa toxicity (Doroudchi et al, 2005).  In this study the expression of AADC induced 
an increase in VMAT2 expression that potentially enhanced the ability of the neurons to 
store dopamine.  These studies imply that alterations in dopamine homeostasis and in 
particular increased cytosolic dopamine or reduced dopamine storage can lead to 
neurodegeneration.  In AADC deficiency conversion of L-dopa to dopamine is severely 
reduced. L-dopa accumulates in the CSF of AADC deficient patients and potentially 
therefore L-dopa may also be increased in the cytosol of dopaminergic neurons.  The 
consequences of increased cytosolic L-dopa are unknown; however it could be similarly 
toxic to increased cytosolic dopamine.  Furthermore dopamine has been demonstrated 
in vitro and in SH-SY5Y cells to reduce mitochondrial O2 consumption and lead to 
mitochondrial membrane depolarisation (Cohen et al, 1997; Berman and Hastings, 
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1999; Gluck et al, 2002; Gluck and Zeevalk, 2004; Brenner-Lavie et al, 2008; Brenner-
Lavie et al, 2009).  These effects were related in part to ROS generation as well as 
effects of dopamine-quinone.  It is possible that L-dopa accumulation could lead to 
similar changes in respiration which could impact upon the pathogenesis of AADC 
deficiency. 
5.2 Aims 
1) To determine the toxicity of L-dopa, 3-OMD and dopamine in a human neuronal 
cell line. 
2) To investigate the effect of increased levels of L-dopa and dopamine on 
intracellular GSH and GSH release in human neuronal and astrocyte cell lines 
3) To investigate the effect of L-dopa and dopamine on the mitochondrial 
respiratory chain 
5.3 Methods 
5.3.1 Treatment solutions 
20mM NSD-1015, 10mM L-dopa, 10mM dopamine, 10mM 3-OMD, 10mM 
noradrenaline, 15KU/mL SOD, 3KU/mL catalase, 300µM tranylcypromine, 300µM Ro-
41-0960, 300µM SCH-23390 and 300µM sulpiride were made up as stock solutions in 
HPLC grade H2O, 0.2µM sterile filtered and stored at -20˚C. 
5.3.2 Cell culture 
Routine cell culture was performed as described in section 2.2.6 for SH-SY5Y cells and 
in section 2.2.7 for 1321N1 cells 
5.3.3 Measurement of catecholamines 
Cells and medium were prepared as described in section 2.2.8.1 and catecholamines 
measured as described in section 2.2.1 
5.3.4 Measurement of GSH 
Cells and minimal medium were prepared as described in section 2.2.8.2 and section 
2.2.8.3 and GSH measured as described in section 2.2.4 
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5.3.5 SRB cell proliferation assay 
The SRB cell proliferation assay was performed as described in section 2.3 
5.3.6 LDH Release assay 
The LDH release assay was performed as described in section 2.4 
5.3.7 Mitochondrial respiratory chain complex assays and citrate synthase 
The activity of complex I, II/III, IV and citrate synthase were determined by the 
methods described in section 2.7  
5.4 Experimental Protocol 
5.4.1 Catecholamine measurement 
SH-SY5Y cells were seeded in 12.5mL DMEM/F-12 + 100mL/L FBS at a density of 
5.00 x 10
4
 cells/cm
2
 in 56.7cm
2
 cell culture dishes.  6.25µL 20mM NSD-1015 (final 
conc. 10µM), 12.5µL 10mM tranylcypromine (final conc. 10µM) or 12.5µL 10mM Ro-
41-0960 (final conc. 10µM) were added to appropriate dishes and 12.5µL sterile HPLC 
grade H2O was added to untreated dishes.  The concentration of NSD-1015 used was 
chosen based on investigations of indoleamines (see section 4.5.2).  The concentration 
of tranylcypromine and Ro-41-0960 were chosen based on previous investigations 
(Blessing et al, 2003; Fitzgerald et al, 2007).  Cells were incubated for 24hr at +37˚C in 
5.0% CO2 to allow cells to adhere.  62.5µL 10mM L-dopa (final conc. 50µM) or 10mM 
dopamine (final conc. 50µM) were added to appropriate dishes and cells incubated for 
48hr at +37˚C in 5.0% CO2.  These concentrations of L-dopa and dopamine were 
chosen to minimise cellular toxicity whilst also maximising the availability of substrate 
for metabolism over the incubation period (see section 5.5.2). Cells and cell culture 
medium were then processed as indicated for catecholamine measurement (see section 
5.3.3). 
5.4.2 Toxicity testing 
For SRB and LDH release assays SH-SY5Y cells were seeded in 96-well plates at a 
density of 1.80 x 10
4
 cells/well in 180µL/well DMEM/F-12 + 100mL/L FBS.  10µL 
NSD-1015 (200µM: final conc. 10µM or 20µM: final conc. 1µM) was added to treated 
wells, 10µL sterile HPLC grade H2O was added to untreated wells.  Plates were 
incubated for 24hr to allow cells to adhere at +37˚C in 5.0% CO2.  10µL L-dopa, 
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dopamine or 3-OMD (concentration range: 10mM to 10µM: final conc. 500µM to 
0.5µM) were added to appropriate treated wells.  10µL sterile HPLC grade H2O was 
added to control wells.  Cells were then incubated for 48hr at +37˚C in 5.0% CO2.  Cells 
were then processed as indicated for the appropriate assay (see section 5.3.5 for the SRB 
assay and section 5.3.6 for LDH release assay).   
For LDH release into minimal medium SH-SY5Y cells or 1321N1 cells were seeded at 
a density of 1.80 x 10
4
 cells/well in 180µL DMEM/F-12 +100mL/L FBS or DMEM + 
100mL/L FBS respectively.  10µL 200µM NSD-1015 (final conc. 10µM) was added to 
appropriate wells, 10µL sterile HPLC grade H2O was added to all other wells.  Plates 
were incubated at +37˚C in 5.0% CO2 for 24hr to allow cells to adhere.  10µL 1mM L-
dopa (final conc. 50µM) or dopamine (1mM: final conc. 50µM or 0.2mM: final conc. 
10µM) were added to treated wells. 10µL sterile HPLC grade H2O was added to control 
wells.  Plates were incubated for the indicated length of time at +37˚C in 5.0% CO2.  
Cell culture medium was removed, cells were washed once with 200µL/well HBSS and 
subsequently incubated at +37˚C in 5.0% CO2 for 4hr.  The LDH release assay was then 
performed as indicated (see section 5.3.6).  
5.4.3 GSH measurement 
SH-SY5Y cells were seeded in 3mL DMEM/F-12 + 100mL/L FBS at a density of 5.00 
x 10
4
 cells/cm
2
 in 6-well cell culture dishes, the surface area of each well was 9.6cm
2
. 
1321N1 cells were seeded at a density of 6.25 x 10
4
 cells/cm
2
 in 3mL DMEM + 
100mL/L FBS in 6-well cell culture dishes. 150µL NSD-1015 (1mM: final conc. 50µM 
or 0.2mM: final conc. 10µM), 100µL 15KU/mL SOD (final. 500U/mL), 100µL 
3KU/mL catalase (final. 100U/mL), 100µL 300µM tranylcypromine (final conc. 10µM) 
or 100µL 300µM Ro-41-0960 (final conc. 10µM) were added to appropriate treated 
wells.  The concentration of SOD, catalase, tranylcypromine and Ro-41-0960 used were 
based on previous studies (Lai and Yu et al, 1997; Stewart et al, 2002; Blessing et al, 
2003; Fitzgerald et al, 2007). 150µL sterile HPLC grade H2O was added to untreated 
wells.  Plates were incubated at +37˚C in 5.0% CO2 for 24hr to allow cells to adhere. 
Where indicated 100µL 300µM SCH-23390 or sulpiride (final conc. 10µM) were added 
to appropriate wells and incubated for 1hr.  The concentrations of SCH-23390 and 
sulpiride were chosen based on previous investigations (Bryson et al, 1992; Hall et al, 
1993; Koshimura et al, 2000). 15µL L-dopa or dopamine (10mM: final conc. 50µM; 
2mM: final conc. 10µM or 0.2mM: final conc. 1µM) were added to appropriate treated 
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wells. 15µL sterile HPLC grade H2O was added to untreated wells.  Plates were then 
incubated at +37˚C in 5.0% CO2 for the indicated length of time.  For determination of 
intracellular GSH cells were processed as indicated (see section 5.3.4).  For 
determination of GSH release cell culture medium was removed, cells were washed 
once with 2mL/well HBSS and subsequently incubated for 4hr in 1mL/well minimal 
medium at +37˚C in 5.0% CO2.  Minimal medium was then removed and processed as 
indicated (see section 5.3.4). 
5.4.4 Mitochondrial respiratory chain 
SH-SY5Y cells were seeded in 30mL DMEM/F-12 + 100mL/L FBS at a density of 5.00 
x 10
4
 cells/cm
2
 in 145cm
2
 cell culture dishes.  15µL 20mM NSD-1015 (final conc. 
10µM) was added to treated dishes and 15µL sterile HPLC grade H2O was added to 
untreated dishes.  Cells were incubated for 24hr at +37˚C in 5.0% CO2 to allow cells to 
adhere.  150µL L-dopa (10mM: final conc. 50µM) or dopamine (10mM: final conc. 
50µM) were added to appropriate dishes, 150µL sterile HPLC grade H2O was added to 
control dishes.  Cells were incubated for 48hr at +37˚C in 5.0% CO2.  Cells were then 
processed as indicated for respiratory chain complex assays and citrate synthase (see 
section 5.3.7). 
5.5 Results 
5.5.1 Effect of NSD-1015 on catecholamine metabolism in human neuroblastoma 
cells 
SH-SY5Y cells were treated with 10µM NSD-1015 for 24hr at which point 50µM L-
dopa was added and incubated for 24hr and 48hr.  After these incubations the levels of 
L-dopa, dopamine and metabolites were measured in cell homogenates and in the cell 
culture medium. Consistent with inhibition of AADC the intra- and extracellular 
concentrations of L-dopa and 3-OMD were significantly increased, whilst the 
concentrations of dopamine, DOPAC and HVA were significantly decreased at both 
24hr and 48hr in comparison to cells treated with L-dopa alone (see table 5.1).  When 
NSD-1015 treated cells were incubated with 50µM dopamine in place of L-dopa there 
were significant reductions in the extracellular levels of DOPAC and HVA at both 24hr 
and 48hr, whilst extracellular dopamine was increased at 24hr in comparison to cells 
treated with dopamine only (see table 5.1).  Similarly the intracellular level of DOPAC 
and HVA were significantly decreased at 24hr (p <0.001, p <0.01 respectively) and 
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HVA was also decreased at 48hr (p <0.05).  This could be indicative of reductions in 
MAO activity.  Furthermore the extracellular concentration of 3-OMD was also 
significantly reduced at 48hr (p <0.01) indicating that COMT may also be affected. 
5.5.2 Effect of L-dopa and dopamine on neuroblastoma cell survival 
The SRB assay was used to determine the effect on cell growth of a 48hr treatment of 
SH-SY5Y neuroblastoma cells with varying concentrations of L-dopa and dopamine. At 
a concentration of 50µM both L-dopa and dopamine were found to reduce cell growth 
by approximately 29% compared to untreated control (p <0.001, p <0.05 respectively; 
see figure 5.1a).  L-dopa and dopamine treatment at concentrations >250µM led to a 
loss of cells relative to the amount of cells present before treatment.  The overall effect 
of L-dopa and dopamine upon SH-SY5Y cells was found to be significantly different (p 
<0.001).  From individual comparisons this difference was significant only at lower 
concentrations from 0.5µM to 25µM, with no difference observed at ≥50µM (see figure 
5.1a). At these concentrations L-dopa had less effect on cell proliferation in comparison 
to dopamine.  3-OMD had no effect on neuroblastoma cell proliferation at 
concentrations up to 500µM (p = 0.989). The effect of L-dopa on cell proliferation was 
also investigated in cells that had been treated with NSD-1015.  NSD-1015 alone did 
not influence SH-SY5Y cell proliferation at either 1µM or 10µM (p = 0.760, p = 0.263 
respectively).  Overall 10µM NSD-1015 had a significant effect on the response of SH-
SY5Y cells to L-dopa in comparison to cells treated with L-dopa alone (p <0.05), 
however when each L-dopa concentration was compared individually 10µM NSD-1015 
had no significant effect at any L-dopa concentration tested in comparison to cells 
treated with L-dopa alone.  Treatment with 1µM NSD-1015 did not alter the effect of L-
dopa treatment on SH-SY5Y cell proliferation (p = 0.705; see figure 5.1b). 
In addition to cell proliferation the effect of L-dopa and dopamine on membrane 
integrity was investigated using the LDH release assay.  Treatment of SH-SY5Y cells 
with 250µM L-dopa or dopamine for 48hr led to significant increases in LDH release to 
83 ± 7% and 90 ± 10% of control respectively (p < 0.001 for both, see figure 5.2a). At 
concentrations of 100µM or below, L-dopa treatment had no effect on LDH release.  
Conversely dopamine treatment produced increases in LDH release at both 50µM and 
100µM compared to control (p <0.05, p <0.01 respectively) and in comparison to L-
dopa treatment (p <0.05, p <0.001 respectively).  3-OMD did not affect LDH release 
from SH-SY5Y cells up to a concentration of 250µM (p = 0.903; see figure 5.2a). The 
 1
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Treatment Incubation 
time (hr) 
L-dopa 3-OMD dopamine DOPAC HVA 
INTRACELLULAR 
L-dopa 
control 
24 27 ± 8 0 ± 0 919 ± 126 1020 ± 76 145 ± 33 
48 21 ± 6 2 ± 2 289 ± 46 255 ± 55 171 ± 31 
L-dopa + 
NSD-1015 
24 139 ± 19### 31 ± 7## 109 ± 12### 9 ± 2### 7 ± 2## 
48 105 ± 13### 30 ± 7## 107 ± 14## 11 ± 3## 13 ± 5### 
dopamine 
control 
24 33 ±9 0 ± 0 402 ± 39 850 ± 89 165 ± 18 
48 28 ± 7 2 ± 2 223 ± 51 103 ± 33 103 ± 22 
dopamine + 
NSD-1015 
24 38 ± 10 1 ± 1 518 ± 51 146 ± 18### 75 ± 11## 
48 28 ± 10 1 ± 1 223 ± 29 32 ± 6 46 ± 10# 
EXTRACELLULAR 
L-dopa 
control 
24 14768 ± 1072 0 ± 0 3854 ± 425 4160 ± 474 1419 ± 198 
48 4689 ± 602 26 ± 26 1963 ± 200 3761 ± 311 4436 ± 542 
L-dopa + 
NSD-1015 
24 23351 ± 713### 416 ±  115## 145 ± 99### 0 ± 0### 0 ± 0### 
48 16223 ±  1080### 1266 ± 158### 35 ± 35### 180 ± 128### 263 ± 105### 
dopamine 
control 
24 960 ± 23 181 ± 57 19663 ± 1186 7100 ± 554 2120 ± 200 
48 945 ±  22 287 ± 35 2458 ± 380 4023 ± 428 4458 ± 538 
dopamine + 
NSD-1015 
24 958 ±  22 104 ± 44 28304 ± 739### 1211 ± 142### 447 ± 79### 
48 947 ± 28 73 ± 44## 1447 ± 389 452 ± 77### 1350 ± 257### 
 
Table 5.1 Catecholamine levels following treatment with L-dopa or dopamine and NSD-1015.  Cells treated with 10µM NSD-1015 for 24hr before 
the addition of 50µM L-dopa or dopamine.  Intracellular values expressed as pmol/mg of protein and extracellular values expressed as nM. All values 
are mean ± SEM of 5 independent experiments. 
#
 p <0.05, 
## 
p <0.01, 
### p <0.001 determined by Student‟s t-test comparing NSD-1015 treatment to 
control. 
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Figure 5.1 SH-SY5Y cell proliferation following L-dopa, dopamine, 3-OMD and 
NSD-1015 treatment.  a. The effect of L-dopa, dopamine and 3-OMD treatment on cell 
proliferation as measured by SRB assay. b. The effect of NSD-1015 on L-dopa induced 
changes in cell proliferation measured by SRB assay.  ΔA490: Change in absorbance at 
490nm compared to cells prior to treatment.  Results are mean ± SEM of 6 independent 
experiments. * p <0.05, ** p <0.01, ***p <0.001 difference in comparison to 0 by 
ANOVA followed by least significant difference test. 
#
 p <0.05, 
# #
 p <0.01 determined 
by Student‟s t-test. 
159 
 
 
Figure 5.2 SH-SY5Y LDH release following L-dopa, dopamine, 3-OMD and NSD-
1015 treatment.   a. The effect of L-dopa, dopamine and 3-OMD on membrane integrity 
measured by the LDH release assay. b. LDH release in response to L-dopa following 
treatment with NSD-1015.  % LDH release: LDH activity in cell culture medium as a 
percentage of total LDH activity following complete cell lysis.  Results are mean ± 
SEM of 5 independent experiments.  ***p <0.001 difference in comparison to 0 by 
ANOVA followed by least significant difference test. 
#
 p <0.05, 
# #
 p <0.01 determined 
by Student‟s t-test. 
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level of LDH release in response to 250µM L-dopa appeared to be reduced by NSD-
1015 at 1µM and 10µM, however this effect was not statistically significant (p = 0.391, 
p = 0.060; see figure 5.2b).   
5.5.3 Intracellular GSH neuroblastoma cells 
Treatment of SH-SY5Y cells with 50µM L-dopa for 48hr led to an approximately 2-fold 
increase in intracellular levels of GSH compared to untreated control (p <0.01; see 
figure 5.3a).  No effect on intracellular GSH was seen at earlier time points after 
treatment with 50µM L-dopa.  Likewise intracellular GSH was unaltered by treatment 
with 10µM L-dopa across all tested time points. In comparison to untreated control 
intracellular GSH was increased by approximately 3-fold after both 24hr and 48hr 
treatment with 50µM dopamine (p <0.05 for both; see figure 5.3b).  No increase in 
intracellular GSH was seen after 50µM dopamine at earlier time points.  Furthermore 
10µM dopamine treatment did not alter intracellular GSH across all tested time points.  
SH-SY5Y cells have been reported to express dopamine β-hydroxylase (Biedler et al, 
1978) therefore it was considered possible that the effect of dopamine was due to 
conversion to noradrenaline.  Consequently the effect of 50µM noradrenaline on 
intracellular GSH was also tested.  This concentration of noradrenaline had no effect on 
intracellular GSH in SH-SY5Y cells after 48hr treatment (p = 0.968), indicating that the 
effect of dopamine was not related to conversion to noradrenaline (see figure 5.4a).   
To examine whether the response of intracellular GSH to L-dopa was dependent on 
conversion to dopamine SH-SY5Y cells were treated with NSD-1015.  Treatment with 
10µM and 50µM NSD-1015 significantly inhibited the increase in intracellular GSH 
seen after 48hr treatment with 50µM L-dopa (p <0.01, p <0.001 respectively; see figure 
5.4b).  As inhibition of AADC was associated with an increase in 3-OMD 
concentrations (see table 5.1) the effect of 3-OMD upon the response of intracellular 
GSH to L-dopa treatment was therefore also examined. Treatment with 50µM 3-OMD 
alone for 48hr produced no change in intracellular GSH in SH-SY5Y cells (p = 0.269; 
see figure 5.4a).  Treatment of SH-SY5Y cells with 50µM L-dopa and 50µM 3-OMD 
combined for 48hr led to significant increases in intracellular GSH (p <0.001) and this 
increase was not significantly different from treatment with 50µM L-dopa alone (p = 
0.229). 
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Figure 5.3 Intracellular GSH in SH-SY5Y cells following treatment with L-dopa or 
dopamine. L-dopa or b. dopamine. Results are mean ± SEM of 3-4 independent 
experiments. *p <0.05, **p <0.01 determined by ANOVA followed by least significant 
difference test. 
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To investigate the involvement of extracellular auto-oxidation in the increase in 
intracellular GSH in response to dopamine and L-dopa the antioxidant enzymes catalase 
and superoxide dismutase were added to SH-SY5Y cells 24hr before and during 
dopamine or L-dopa treatment.  Catalase converts H2O2 to 2H2O and superoxide 
dismutase converts O2
•-
 to H2O2.  The addition of 100U/mL catalase had no effect on 
the increase in GSH seen in SH-SY5Y cells treated with 50µM dopamine for 48hr (p = 
0.428) or on the level of GSH measured in control cells (p = 0.113; see figure 5.5).  
However combined treatment of 100U/mL catalase with 50µM L-dopa resulted in an 
approximately 1.4-fold increase in intracellular GSH in comparison to cells treated with 
50µM L-dopa alone (p <0.05; see figure 5.5).  The extracellular addition of 500U/mL 
superoxide dismutase also had no significant effect on the increase in intracellular GSH 
seen in response to 50µM dopamine or L-dopa (p = 0.770, p = 0.160 respectively), nor 
on the level of GSH in untreated control cells (p = 0.737; see figure 5.5).  
The response of intracellular GSH in SH-SY5Y cells to dopamine was further 
characterised by inhibiting different components of the dopamine system.  SH-SY5Y 
cells were treated with 10µM tranylcypromine, a non-selective MAO inhibitor, for 24hr 
before and during dopamine or L-dopa treatment.  This treatment had no effect on the 
intracellular concentration of GSH in control cells (p = 0.885) or on the increased levels 
of GSH seen after treatment for 48hr with 50µM dopamine or L-dopa (p = 0.395, p = 
0.132, respectively; see figure 5.5).  To ensure that 10µM tranylcypromine treatment 
was inhibiting MAO the levels of catecholamines were measured after incubation with 
50µM L-dopa for 48hr in SH-SY5Y cells.  This treatment produced significant 
decreases in intracellular DOPAC and HVA (p <0.05, p <0.01 respectively), 
extracellular DOPAC and HVA (p <0.001, p <0.01 respectively) and a significant 
increase in extracellular dopamine (p <0.001; see table 5.2).  Intracellular DOPAC was 
decreased by approximately 80%, suggesting a relatively high level of MAO inhibition.   
SH-SY5Y cells were also treated with the COMT inhibitor Ro-41-0960.  At 10µM this 
treatment led to a decrease in the intracellular concentration of HVA by approximately 
85% after 48hr treatment with 50µM L-dopa compared to control cells treated with L-
dopa alone (p <0.001; see table 5.2).  Likewise extracellular HVA was undetectable 
after Ro-41-0960 treatment compared to a control value of 4436.34 ± 541.62nM.  
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Figure 5.4 Intracellular GSH in SH-SY5Y following noradrenaline, 3-OMD and 
NSD-1015 treatment. a. Intracellular GSH in SH-SY5Y cells following 48hr treatment 
as indicated, mean ± SEM of 3-4 independent experiments b. Intracellular GSH in SH-
SY5Y cells treated with NSD-1015 for 24hr and subsequently for 48hr with L-dopa, 
mean ± SEM of 10 independent experiments. **p <0.01, ***p <0.001 determined by 
ANOVA followed by least significant difference test. 
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Figure 5.5 Intracellular GSH in SH-SY5Y cells following treatment with L-dopa and dopamine influence of receptors, degradation and auto-
oxidation.  Cells were treated with 500U/mL SOD, 100U/mL catalase, 10µM tranylcypromine or 10µM Ro-41-0960 for 24hr or with 10µM SCH-
23390 or 10µM sulpiride for 1hr followed by a 48hr incubation with 50µM L-dopa or dopamine or vehicle (control).  Results are mean ± SEM of 3-10 
independent experiments. 
#
 p <0.05 determined by Student‟s t-test. 
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Upstream of COMT, DOPAC and dopamine were significantly increased intracellularly 
and dopamine increased extracellularly in Ro-41-0960 treated cells in comparison to 
control (see table 5.2).  Together this indicates a high level of COMT inhibition by Ro-
41-0960.   However treatment with Ro-41-0960 did not alter the increased levels of 
GSH seen in cells treated with 50µM L-dopa or dopamine (p = 0.468, p = 0.398 
respectively) or the GSH concentration in control cells (p = 0.857; see figure 5.5). 
The involvement of dopamine receptors in the GSH response to dopamine and L-dopa 
was also investigated.  Dopamine receptor antagonists were added to SH-SY5Y cultures 
1hr prior to the addition of L-dopa or dopamine and then incubated for 48hr.  The D1-
like (D1 and D5) receptor antagonist SCH 23390 at 10µM had no effect on intracellular 
GSH concentrations in control cells (p = 0.887) or on the increase in GSH seen after 
dopamine or L-dopa treatment (p = 0.505, p = 0.843 respectively; see figure 5.5).  
Similarly the D2-like (D2, D3 and D4) antagonist sulpiride at 10µM also had no effect 
upon intracellular GSH concentrations in control cells (p = 0.179), or after dopamine or 
L-dopa treatment (p = 0.140, p = 0.495 respectively).  
 
 
Treatment L-dopa 3-OMD dopamine DOPAC HVA 
INTRACELLULAR 
L-dopa control 21 ± 6 2 ± 2 289 ± 46 255 ± 55 171 ± 31 
L-dopa + MAOI 22 ± 9 1 ± 1 294 ± 81 51 ± 13* 54 ± 24** 
L-dopa +COMTI 25 ± 7 0 ± 0 476 ± 62** 966 ± 99*** 25 ± 24*** 
EXTRACELLULAR 
L-dopa control 4689 ± 602 26 ± 26 1963 ± 200 3761 ± 311 4436 ± 542 
L-dopa + MAOI 4535 ± 391 31 ± 31 5716 ± 549*** 3203 ± 1535 1466 ± 441*** 
L-dopa +COMTI 5301 ± 640 92 ± 39 3787 ± 458** 6716 ± 1183 0 ± 0*** 
 
Table 5.2 Catecholamine levels following treatment with MAO and COMT inhibitors. 
10µM tranylcyromine (MAOI) or 10µM Ro-41-0960 (COMTI) added 24hr before the 
addition of 50µM L-dopa. Intracellular values expressed as pmol/mg of protein and 
extracellular values expressed as nM. All values are mean ± SEM of 4-5 independent 
experiments. *p <0.05, **p <0.01, ***p <0.001 difference from control determined by 
ANOVA followed by least significant difference test. 
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Figure 5.6 Intracellular GSH in 1321N1 cells following treatment with L-dopa and 
dopamine. a. L-dopa or b. dopamine. Results are mean ± SEM of 3-4 independent 
experiments.  
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Figure 5.7 GSH release from 1321N1 cells following L-dopa or dopamine treatment.  
GSH release measured over 4hr following incubation with a. L-dopa or b. dopamine. 
All results are mean ± SEM from 7-8 independent experiments. **p <0.01 determined 
by ANOVA followed by least significant difference test. 
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Figure 5.8 LDH and GSH release from 1321N1 cells following dopamine treatment 
influence of receptors, degradation and auto-oxidation. a. LDH release from 1321N1 
cells over 4hr in minimal medium following pre-treatment with dopamine for 24hr, 
mean ± SEM from 3-4 independent experiments. b. GSH release from 1321N1 cells. 
Cells were treated with 500U/mL SOD, 100U/mL catalase, 10µM tranylcypromine or 
10µM Ro-41-0960 for 24hr or with 10µM SCH-23390 or 10µM sulpiride followed by a 
24hr incubation with 50µM dopamine or vehicle (control).  Results are mean ± SEM 
from 3-4 independent experiments. 
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5.5.4 Intracellular GSH astrocytoma cells 
The effect of L-dopa and dopamine on intracellular GSH concentration was also 
investigated in the human astrocytoma cell line 1321N1.  L-dopa treatment at either 
10µM or 50µM for up to 48hr had no effect on intracellular GSH concentrations (see 
figure 5.6a). Similarly 10µM or 50µM dopamine also had no effect on intracellular 
GSH levels for up to 48hr of treatment (see figure 5.6b).  One important difference 
between astrocytes and neurons is that astrocytes have an approximately 2-fold higher 
GSH content and consequently a higher antioxidant capacity (Makar et al, 1994; 
Bolanos et al, 1995).  Untreated 1321N1 astrocytoma cells also had an approximately 
1.8-fold higher level of intracellular GSH in comparison to untreated SH-SY5Y cells in 
the current study at 72hr in culture (p = 0.01, n = 4).  
5.5.5 GSH Release from human astrocytoma cells 
The trafficking of GSH from astrocytes to neurons is considered to be an important 
mechanism for maintaining neuronal GSH levels (see section 1.7.6).  The first stage in 
the trafficking process is the release of GSH from astocytes.  The effect of L-dopa and 
dopamine on the release of GSH from astrocytomas was consequently investigated.  
Cells were treated with L-dopa or dopamine and subsequently washed and incubated for 
4hr in minimal medium.  The amount of GSH released was defined as the concentration 
of GSH in the minimal medium after this 4hr period.  L-dopa treatment for up to 24hr 
had no effect on GSH release from astrocytoma cells at either 10µM or 50µM (p = 
0.609; see figure 5.7a).  Conversely treatment of astrocytoma cells with dopamine for 
24hr led to significant increases in GSH release with 50µM dopamine (p <0.05, p <0.01 
respectively; see figure 5.7b).  It is important to note that the 1321N1 astrocytoma cells 
were not found to express detectable AADC activity with L-dopa as substrate (see 
section 4.5.1), consequently added L-dopa would not be converted to dopamine in this 
cell line.  To determine whether the release of GSH was specific or whether it was 
related to disruption of membrane integrity LDH release into the minimal media over 
the 4hr incubation was measured after 24hr treatment with dopamine in the same 
manner as GSH release measurement.  No significant change in LDH release was found 
for dopamine treatment at 10µM or 50µM in comparison to untreated control (p = 
0.693, p = 0.797 respectively; see figure 5.8a).  This indicates that dopamine treatment 
induced a specific increase in GSH release from astrocytoma cells, rather than a non-
specific effect on cell lysis. 
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Treatment with 100U/mL catalase for 24hr prior and during the 24hr incubation with 
50µM dopamine produced no change in the increased level of GSH release from 
astrocytoma cells (p = 0.430; see figure 5.8b).  This treatment also did not change the 
level of GSH release from untreated control cells (p = 0.350).  Likewise 500U/mL 
superoxide dismutase had no effect on GSH release in control cells (p = 0.130) or on the 
increased release from dopamine treated cells (p = 0.591; see figure 5.8b).  Treatment 
with 10µM tranylcypromine or Ro-41-0960 for 24hr prior to and during the incubation 
with 50µM dopamine had no effect on the increased amount of GSH release (p = 0.492, 
p = 0.916 respectively; see figure 5.8b).  The level of GSH release from untreated 
control cells was also unchanged by treatment with 10µM tranylcypromine or Ro-41-
0960 (p = 0.505, p = 0.128 respectively). Treatment with 10µM of the dopamine 
receptor antagonists SCH-23390 or sulpiride for 1hr before and during incubation with 
50µM dopamine did not alter the increased GSH release from astrocytoma cells (p = 
0.874, p = 0.627, respectively; see figure 5.8b).  10µM SCH 23390 or sulpiride also did 
not change GSH release from untreated control astrocytoma cells (p = 0.420, p = 0.489 
respectively). 
5.5.6 GSH Release from human neuroblastoma cells 
GSH release was measured in the same way as for 1321N1 cells (see section 5.5.5).  
Treatment of SH-SY5Y cells with 50µM dopamine for 48hr produced an approximately 
5-fold increase in GSH release (p <0.01, see figure 5.9a).  However this treatment also 
resulted in an approximately 2.5-fold increase in LDH release (p <0.01, figure 5.9b), 
indicating that the effect of dopamine on GSH release was non-specific, and potentially 
as a result of increased cell lysis. 48hr treatment with 50µM L-dopa had no significant 
effect on either GSH release or LDH release over the 4hr incubation in minimal medium 
(p = 0.776, p = 0.064 respectively; see figure 5.9).  50µM L-dopa treatment for 48hr in 
the presence of 10µM NSD-1015 also had no significant effect on GSH release or LDH 
release over the 4hr incubation in minimal medium (p = 0.569, p = 0.244, respectively; 
see figure 5.9). 
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Figure 5.9 GSH and LDH release from SH-SY5Y cells following treatment with L-
dopa and dopamine. a. GSH release over 4hr from SH-SY5Y cells following 
incubation for 48hr with treatment as indicated, NSD-1015 was added 24hr before other 
treatments, mean ± SEM from 3 independent experiments. LDH release from SH-SY5Y 
cells over 4hr in minimal medium following pre-treatment as indicated for 48hr, NSD-
1015 was added 24hr before other treatments, mean ± SEM from 4 independent 
experiments.  **p <0.01 determined by ANOVA followed by least significant 
difference test. 
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5.5.7 Mitochondrial respiratory chain 
As 50µM dopamine and L-dopa have effects on cellular viability and 50µM dopamine 
was found to influence GSH concentrations in SH-SY5Y cells and therefore the effects 
of 48hr treatment with 50µM dopamine or L-dopa on the activity of the mitochondrial 
respiratory chain in SH-SY5Y cells was also investigated.  50µM L-dopa had no 
significant effect on complex I, II/III or IV either in the presence or absence of 10µM 
NSD-1015 (see figure 5.10).  10µM NSD-1015 alone also had no significant effect on 
any of the mitochondrial respiratory chain complexes.  50µM dopamine had no 
significant effect on the activity of complex II/III or IV, however this treatment led to an 
approximately 2-fold increase in the activity of complex I (see figure 5.10a, table 5.3).  
This effect was apparent both when complex I activity was expressed as a ratio to citrate 
synthase or as nmol/min/mg of protein.  Furthermore dopamine did not significantly 
change the % rotenone inhibition (p = 0.530), indicating that the increase in complex I 
activity was not related to changes in non-specific NADH oxidation. 
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Figure 5.10 SH-SY5Y cells activity of mitochondrial respiratory chain following 
treatment with L-dopa, dopamine and NSD-1015. Activity of a. complex I, b. complex 
II/III and c. complex IV expressed as a ratio to citrate synthase.  Cells were treated as 
indicated for 48hr, NSD-1015 was added 24hr before other treatments. Results are mean 
± SEM from 4 independent experiments. ** p <0.01 determined by ANOVA followed 
by least significant difference test. 
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 Complex I Complex II/III Complex IV Citrate 
synthase 
 Activity % inhibition Activity % inhibition   
Control 10.6 ± 1.8 71.3 ± 2.2 11.24 ± 2.3 96.5 ± 0.4 69.8 ± 7.0 103.0 ± 14.1 
Dopamine 20.4 ± 4.2** 68.1 ± 1.9 7.4 ± 1.7 94.5 ± 1.3 51.6 ± 9.6 109.1 ± 21.1 
L-dopa 15.1 ± 3.5 67.4 ± 1.4 8.2 ± 1.9 98.7 ± 1.7 54.0 ± 5.9 105.2 ± 16.3 
L-dopa + NSD-1015 12.0 ± 1.2 75.9 ± 5.6 10.0 ± 1.2 96.6 ± 1.2 70.1 ± 5.9 103.5 ± 9.1 
NSD-1015 7.2 ± 0.3 72.1 ± 2.6 7.9 ± 1.0 97.7 ± 1.2 63.3 ± 8.7 76.4 ± 2.4 
 
 
Table 5.3 SH-SY5Y cells activity of mitochondrial respiratory chain following treatment with L-dopa, dopamine and NSD-1015.  SH-SY5Y cells 
activity of mitochondrial respiratory chain complex I (nmol/min/mg of protein), complex II/III (nmol/min/mg of protein) and  complex IV (k/min/mg 
of protein) as well as citrate synthase activity (nmol/min/mg).  Complex I % inhibition following addition of rotenone and complex II/III % inhibition 
following addition of antimycin A.  Cells were treated as indicated for 48hr, 10µM NSD-1015 was added 24hr before other treatments. Dopamine and 
L-dopa were added at a concentration of 50µM. Results are mean ± SEM from 4 independent experiments. ** p <0.01 determined by ANOVA 
followed by least significant difference test. 
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5.6 Discussion 
5.6.1 The use of NSD-1015 to model AADC deficiency 
NSD-1015 was used in this study to inhibit AADC activity in SH-SY5Y neuroblastoma 
cells.  The pattern of metabolites in NSD-1015 treated cells after addition of L-dopa was 
similar to that seen in the CSF of AADC deficient patients (Hyland and Clayton, 1990; 
Brun et al, 2010).  Adding dopamine to the SH-SY5Y cells instead of L-dopa should 
bypass the NSD-1015 inhibition of AADC. It would therefore be expected that 
dopamine metabolites would be at similar levels in cells treated with NSD-1015 and 
dopamine in comparison to cells treated with dopamine alone.  However the results 
presented here demonstrated that this inhibitor led to decreased DOPAC, HVA and 3-
OMD following the addition of dopamine in comparison to cells treated only with 
dopamine.  The decreased levels of 3-OMD following dopamine and NSD-1015 
treatment could indicate direct inhibition of COMT, however this decrease in 3-OMD 
may also be explained by competition between L-dopa and dopamine for COMT. The 
dopamine NSD-1015 treated cells had higher levels of dopamine in comparison to cells 
treated only with dopamine.  This raised dopamine may have increased dopamine 
metabolism via COMT, increasing competition with L-dopa for COMT, consequently 
decreasing 3-OMD production. Furthermore the cells treated with L-dopa and NSD-
1015 had raised levels of 3-OMD as would be expected from AADC inhibition leading 
to increased degradation of L-dopa via COMT, but also indicating that NSD-1015 does 
not lead to direct inhibition of COMT.  The decrease in DOPAC and HVA levels in 
dopamine and NSD-1015 treated cells could indicate that NSD-1015 can directly inhibit 
MAO.  However it is also possible that inhibition or deficiency of AADC leads to 
cellular alterations which may decrease dopamine degradation via MAO.  For example 
AADC can produce not only dopamine and serotonin but also trace amines such as 2-
phenylethylamine and tyramine which are known to influence dopamine 
neurotransmission (reviewed by Burchett and Hicks, 2006).  It is possible therefore that 
the inhibition of AADC could lead to downregulation of MAO, potentially through 
decreased levels of trace amines, leading to the decreased levels of DOPAC and HVA 
observed following dopamine and NSD-1015 treatment.  Further work may be required 
using an AADC knockdown approach to determine whether AADC deficiency can 
influence MAO expression or activity. 
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5.6.2 Catecholamine toxicity in SH-SY5Y cells 
This study demonstrated both cell loss and increased LDH release in response to L-dopa 
or dopamine at concentrations greater than 250µM. This observation has been 
demonstrated before in SH-SY5Y cells and in a range of other cell types (Mena et al, 
1993; Basma et al, 1995; Lai and Yu, 1997; Nakao et al, 1997; Offen et al, 2001; 
Pedrosa and Soares-Da-Silva, 2002; Haque et al, 2003).  Cell death has been correlated 
with the formation of quinones and melanin indicating auto-oxidation of L-dopa and 
dopamine was involved in toxicity (Pardo et al, 1995; Basma et al, 1995; Lai and Yu, 
1997). The addition of antioxidants including ascorbic acid, GSH, sodium 
metabisulphite and N-acetyl-L-cysteine have all protected cells to some extent from L-
dopa and dopamine induced cell death (Pardo et al, 1995; Lai and Yu, 1997; Pedrosa 
and Soares-Da-Silva, 2002; Haque et al, 2003).  Furthermore extracellular addition of 
the enzymes catalase and superoxide dismutase also decreased L-dopa and dopamine 
induced cell death in most experiments demonstrating that O2
•-
 and H2O2 contribute to 
toxicity (Basma et al, 1995; Lai and Yu, 1997; Pedrosa and Soares-Da-Silva, 2002; 
Haque et al, 2003).  Induction of apoptosis was also found to be involved in the 
mechanism of L-dopa and dopamine induced cell death (Pedrosa and Soares-Da-Silva, 
2002; Haque et al, 2003).    
In the present study dopamine was demonstrated to increase LDH release at 50µM and 
100µM, whilst L-dopa had no effect at these concentrations.  This may suggest some 
difference in the mechanism of L-dopa and dopamine toxicity such that dopamine 
affects membrane integrity to a greater extent than L-dopa.  One potential explanation 
for this disparity could relate to an interaction between dopamine and lipids for example 
dopamine is known to form adducts with malondialdehyde, a product of lipid 
peroxidation (d‟Ischia et al, 1993; d‟Ischia et al, 1995).  Lai and Yu (1997) observed an 
increase in lipid peroxidation in SH-SY5Y cells after 10µM dopamine treatment but a 
decrease at >100µM.   The authors suggested that as the study measured thiobarbituric 
acid (TBA) reactivity with malondialdehyde the apparent decrease in lipid peroxidation 
may instead indicate formation of dopamine-malondialdehyde adducts which may not 
be reactive with TBA (d‟Ischia et al, 1993; d‟Ischia et al, 1995; Lai and Yu, 1997).  
Spencer et al (1996) using the same TBA reactivity method suggested that dopamine 
and L-dopa inhibit lipid peroxidation, and that dopamine was the more potent inhibitor.  
However as the TCA method may have been measuring malondialdehyde adduct 
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formation, rather than inhibition of lipid peroxidation, then this observation could 
instead be demonstrating that dopamine forms adducts with malondialdehyde more 
readily than L-dopa.  Whether dopamine-adduct formation with malondialdehyde 
effects membrane integrity has not been investigated, however Lai and Yu (1997) also 
demonstrated an increase in LDH release from SH-SY5Y cells at the same dopamine 
concentrations that were suggested to increase adduct formation. 
3-OMD had no effect on SH-SY5Y cell proliferation or on LDH release in the current 
study.  This indicates that 3-OMD is non-toxic, which has also been demonstrated in 
previous investigations (Offen et al, 2001).  The lack of toxicity most likely relates to 
the non-oxidisable nature of 3-OMD due to the presence of the methoxy group at 
position 4 of the phenyl ring (Offen et al, 2001; Haque et al, 2003).  This could suggest 
that the methylation of L-dopa to 3-OMD by COMT may be a protective mechanism 
against L-dopa auto-oxidation.  In support of this the extracellular addition of purified 
COMT was demonstrated to have a small protective effect on L-dopa induced toxicity 
in PC12 cells (Offen et al, 2001).  In the CSF of AADC deficient patients the level of 3-
OMD is generally higher than that of L-dopa (Brun et al, 2010).  This indicates that 
much of the L-dopa produced by AADC deficient patients is converted to 3-OMD.  This 
methylation may decrease the half-life of L-dopa in the brain and consequently may 
reduce the possibility of auto-oxidation occurring.   In AADC deficiency COMT 
inhibition could be considered as a treatment to prevent the breakdown of dopamine, 
however if COMT acts to protect against L-dopa toxicity then the use of COMT 
inhibitors may be detrimental to AADC deficient patients.  COMT inhibitors are 
currently used to treat Parkinson‟s disease to prevent peripheral methylation of 
administered L-dopa, but they may also inhibit central COMT (Ceravolo et al, 2002; 
Factor, 2008).  COMT inhibitors have also been used in the treatment of disorders of 
BH4 metabolism (Pearl et al, 2007).  However it has been reported that inhibition of 
COMT in mesencephalic cultures protects against L-dopa toxicity by a glial dependent 
mechanism (Storch et al, 2000; Blessing et al, 2003).  It may be important therefore to 
examine the effect of COMT inhibitors on L-dopa induced toxicity in an in vivo model 
of AADC deficiency. 
It is important to note that the concentration of L-dopa required to induce toxicity in 
SH-SY5Y cells (250µM) is much higher than that seen in the CSF of AADC deficient 
patients (Patient Range: <2-549 nM).  The concentration of L-dopa is likely to be higher 
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in the vicinity of tyrosine hydroxylase containing neurons than in the spinal cord, but 
may still not reach the high concentrations required for toxicity in vitro.  Due to the use 
of L-dopa in the treatment of Parkinson‟s disease the potential neurotoxicity of L-dopa 
has been widely debated.  The majority of in vivo studies have not found administration 
of L-dopa to be neurotoxic (Hefti et al, 1981; Perry et al, 1984; Quinn et al, 1986; 
Murer et al, 1998; Zeng et al, 2001; Mytilineou et al, 1993; Mytilineou et al, 2003; 
Fahn et al, 2005).  Conversely in one study where high dose L-dopa was administered 
intraperitoneally in rat there was damage to dopaminergic neurons (Jeon et al, 2007).  
Furthermore microdialysis of substantia nigra in rat with L-dopa was found to increase 
the production of OH
•-
 (Smith et al, 1994).   
There is potentially an important difference between L-dopa treatment of non-AADC 
deficient patients and the accumulation of L-dopa seen in AADC deficiency.  Namely in 
AADC deficiency L-dopa is produced within tyrosine hydroxylase positive neurons, 
however the majority cannot be converted to dopamine and so may not be sequestered 
into vesicles potentially leading to a cytosolic accumulation of L-dopa.  Certainly 
intracellular L-dopa was significantly increased in AADC inhibitor treated 
neuroblastoma cells in this study.  Conversely L-dopa exogenously administered to non-
AADC deficient individuals, taken up by dopaminergic neurons would then be 
converted into dopamine and stored in vesicles.  It has been demonstrated that increased 
cytosolic dopamine as a result of inadequate storage can lead to neurodegeneration in 
rodents (Caudle et al, 2007; Chen et al, 2008a).  If L-dopa is similarly toxic to 
dopamine, then increased cytosolic L-dopa may have a similar effect.  In the current 
study dopamine was found to affect membrane integrity at lower concentrations than L-
dopa. Similarly at concentrations <25µM dopamine had an inhibitory effect on SH-
SY5Y cells in comparison to L-dopa.  However at higher concentrations both affected 
cell proliferation to a similar extent suggesting a relatively equivalent neurotoxicity, 
which has also been suggested in previous studies (Lai and Yu, 1997; Pedrosa and 
Soares-Da-Silva, 2002).  Moreover the AADC inhibitor NSD-1015 had only a minor 
influence on the effect of L-dopa on cell proliferation demonstrating that conversion to 
dopamine was not required for toxicity.  The transduction of an AADC adeno-
associated virus vector into primary rat neuronal cultures has been shown to protect 
against L-dopa induced toxicity (Doroudchi et al, 2005).  The protection was linked to 
increased expression of AADC which in turn also led to increased VMAT2 expression, 
indicating that conversion of L-dopa to dopamine and its subsequent storage is a 
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protective mechanism.  This mechanism would be absent in AADC deficiency and 
therefore potentially increased neuronal cytosolic L-dopa could be a damaging factor in 
this disorder.  Further investigations in an in vivo model of AADC deficiency would be 
required to investigate this hypothesis. 
5.6.3 Dopamine and GSH 
Dopamine was demonstrated in this study to increase intracellular GSH in 
neuroblastoma cells and GSH release from astrocytoma cells.  L-dopa treatment also led 
to increased intracellular GSH in neuroblastoma cells however when AADC was 
inhibited with NSD-1015 this effect was attenuated, suggesting conversion of L-dopa to 
dopamine was required for this effect.  The MAO inhibitor tranylcypromine had no 
effect on the L-dopa induced GSH increase in neuroblastoma cells.  This demonstrates 
that the antagonism of the L-dopa effect on GSH by NSD-1015 was likely to be related 
to the inhibition of AADC rather than to potential changes in MAO activity or 
expression as a result of NSD-1015 treatment (see section 5.6.1).  L-dopa had no effect 
on the release of GSH from astrocytomas, in which AADC activity was undetectable 
and consequently L-dopa would not be converted to dopamine.  Previous studies have 
found that L-dopa treatment can increase intracellular GSH concentrations in primary 
mesencephalic cultures, Neuro-2A neuroblastoma cells and pig kidney epithelial (PKE) 
cells (Mytilineou et al, 1993; Han et al, 1996).  The inhibition of AADC by carbidopa 
or NSD-1055 did not alter this effect in Neuro-2A or PKE cells, moreover AADC 
inhibition further increased intracellular GSH levels above L-dopa treatment alone (Han 
et al, 1996).  The reason for the disparity between this and the current study may relate 
to differences between cell-type.  The increase in intracellular GSH in response to L-
dopa was much lower, <1.38-fold (Han et al, 1996) than the 2-fold increase observed in 
the current study.  Additionally the concentration of L-dopa used to evoke the response 
may also have influenced the dependence on conversion to dopamine, Han et al (1996) 
used 200µM L-dopa, 4-fold greater than that used in the current study.  Taken together 
this could indicate that the GSH response to L-dopa reported by Han et al (1996) was 
relatively non-specific and could relate to extracellular oxidation of L-dopa generating 
ROS and consequently leading to a cellular response increasing intracellular GSH 
concentrations. 
Dopamine has also been reported to induce increases in intracellular GSH in primary 
mesencephalic cultures and PC12 cells (Han et al, 1996; Jia et al, 2008a).  The 
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concentration range of dopamine that elicited this response in a dose-dependent manner 
was between 50µM and 150µM, comparable to the present study.  The increase in GSH 
in PC12 cells was accompanied by an increase in γ-glutamylcysteine ligase, the rate 
limiting enzyme in GSH synthesis (Jia et al, 2008a).  Furthermore the activity of 
glutathione peroxidase and glutathione reductase were unaltered, together these 
observations indicate that dopamine induces an increase in de novo synthesis of GSH 
rather than increased recycling.  Pre-treatment with L-dopa or dopamine, over the 
timescale required to induce increases in GSH, has also been demonstrated to protect 
cells from subsequent treatment with inducers of oxidative stress including 6-
hydroxydopamine and tert-butyl hydroperoxide (Han et al, 1996; Jia et al, 2008a).  Jia 
et al (2008a) demonstrated that dopamine treatment increased NAD(P)H: quinone 
oxidoreductase 1 (NQO1) activity and expression.  NQO1 catalyses the 2-electron 
reduction of quinones to hydroquinones including the reduction of cyclised dopamine-
o-quinone, a product of dopamine oxidation (Segura-Aguilar and Lind, 1989).  
Overexpression of NQO1 has been demonstrated to protect aganist dopamine-induced 
cellular toxicity (Zafar et al, 2006).  A range of other chemicals including tert-
butylhydroquinone, an inducer of oxidative stress, have been demonstrated to exhibit 
similar effects on GSH and NQO1 (Hara et al, 2003; Jia et al, 2008b; Jia et al, 2008c).  
Both γ-glutamylcysteine ligase and NQO1 have been demonstrated to be regulated by 
the transcription factor Nrf2 (Venugopal et al, 1996; Wild et al, 1999).  Nrf2 in turn is 
regulated in part by Keap1 that may act as a sensor for ROS and electrophiles (reviewed 
by Motohashi and Yamamoto, 2004).  Dopamine has previously been demonstrated to 
activate this pathway in a range of cell types (Shih et al, 2007; Wang et al, 2010b).  It is 
possible therefore that the increase in intracellular GSH observed in SH-SY5Y cells and 
previously in PC12 cells was related to the activation of this signalling pathway (Jia et 
al, 2008a). 
The effect of dopamine on release of glutathione from astrocytes has been previously 
investigated (Hirrlinger et al, 2002).  In this study the authors found that incubation of 
primary astrocytes with 50µM dopamine decreased total glutathione (GSH + 2 x GSSG) 
release.  This is in contrast to the present study where incubation with 10µM or 50µM 
dopamine increased GSH release from astrocytomas.  It is possible that this may relate 
to a difference between astrocytoma cells and primary astrocytes.  However a more 
likely explanation relates to the method by which the cells were treated with dopamine. 
In the current study astrocytoma cells were pre-treated with dopamine for 24hr, the cells 
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were then washed and subsequently incubated in minimal medium for 4hr and GSH was 
measured in the minimal medium after the 4hr.  Consequently no dopamine was present 
during the period in which GSH release was measured.  In contrast Hirrlinger et al 
(2002) incubated primary astocytes with dopamine for 6hr in minimal medium and 
subsequently measured total glutathione and GSSG in this medium.  The first disparity 
is the length of dopamine treatment.  In the present set of experiments 24hr was 
required to observe an increase in GSH release, after 4hr dopamine treatment there was 
no difference from control.  The second disparity relates to the presence of dopamine 
during the period of measured glutathione release.  Dopamine auto-oxidises readily in 
cell culture medium leading to the production of ROS (Clement et al, 2002).  Hirrlinger 
et al (2002) demonstrated that the decrease in total glutathione in the minimal medium 
was prevented by the addition of extracellular SOD indicating that this process was 
dependent on extracellular O2
•-
.  Consequently the decrease in total glutathione was 
likely to be related to extracellular oxidation of GSH, additionally whilst GSSG was not 
increased following 50µM dopamine treatment the proportion of GSSG to GSH was 
increased further suggesting GSH oxidation (Hirrlinger et al, 2002).  Therefore in the 
study of Hirrlinger and colleagues the loss of extracellular total glutathione may 
potentially relate to GSH-adduct formation rather than a decrease in release of GSH 
from astrocytes. 
The role of extracellular auto-oxidation in the dopamine induced increases in GSH 
within neuroblastomas and GSH release from astrocytomas was investigated by adding 
the antioxidant enzymes catalase and SOD to the cell culture medium.  As neither 
catalase nor SOD inhibited the rise in GSH in neuroblastomas or release from 
astrocytomas it is unlikely that the extracellular generation of H2O2 or O2
•-
 are involved 
in these responses.  However there may be other products of dopamine auto-oxidation 
which may elicit the GSH response.  In support of this hypothesis the rise in 
intracellular GSH in mesencephalic cultures in response to L-dopa was attenuated by 
the addition of the reducing agent ascorbate (Mytilineou et al, 1993).  In the current 
study inhibition of MAO with tranylcypromine or catechol-O-methyltransferase with 
Ro-41-0960 also had no effect on the GSH response to dopamine in neuroblastomas or 
astrocytomas.  This indicates that increased flux through MAO which generates H2O2 as 
a side product was not involved in this response.  Moreover this suggests that dopamine 
breakdown products including DOPAC, 3-methoxytryamine and HVA are unlikely to 
be involved in the alterations in GSH.  SCH-23390, an antagonist of D1 and D5 
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receptors and sulpiride, an antagonist of D2, D3 and D4 receptors also had no effect on 
the dopamine induced increase in GSH in neuroblastomas or increased release from 
astrocytomas.  This indicates that this response was not mediated through classical 
dopamine receptor signalling.  Comparable to dopamine the L-dopa induced increase in 
intracellular GSH in SH-SY5Y cells was also not inhibited by catalase, SOD, 
tranylcypromine, Ro-41-0960, SCH-23390 or sulpiride.  Mytilineou et al (1993) also 
found that catalase, SOD and the MAO inhibitor pargyline had no effect on the L-dopa 
induced rise in intracellular GSH in mesencephalic cultures. However in the current 
study combined treatment of SH-SY5Y cells with L-dopa and catalase did lead to a 
small increase in intracellular GSH in comparison to cells treated with L-dopa alone.  
This increase could relate to lowered H2O2 due to the presence of extracellular catalase, 
in turn reducing intracellular oxidation of GSH by glutathione peroxidase. 
The Nrf2-keap1 signalling pathway may potentially provide a mechanistic explanation 
not only for the increase in intracellular GSH seen in neuroblastoma cells but also for 
the increased release of GSH from astrocytoma cells.  The molecular association 
between Nrf2 and Keap1 prevents Nrf2 from entering the nucleus and additionally 
increases degradation of Nrf2 via the ubiquitin-proteasome (Itoh et al, 1999; Zipper and 
Mulcahy, 2002; Itoh et al, 2003).  Modification of keap1 at cysteine residues for 
example by ROS in combination with phosphorylation of Nrf2 leads to dissociation of 
Nrf2 from keap1 (reviewed by Kaspar et al, 2009).  Nrf2 then translocates to the 
nucleus where it binds to AREs (antioxidant response elements), consensus sequences 
found upstream of multiple genes involved in antioxidant defence, and increases gene 
transcription (Rushmore et al, 1991; Venugopal et al, 1996; Itoh et al, 1997).  Nrf2 in 
addition to up-regulating γ-glutamylcysteine ligase has also been demonstrated to 
induce expression of the multidrug resistance associated protein 1 (MRP1) a transporter 
protein involved in GSH release from astrocytes (Wild et al, 1999; Hayashi et al, 2003).  
The activation of this pathway can therefore increase both GSH synthesis and GSH 
release (Mulcahy and Gipp, 1995; Rahman et al, 1996; Hayashi et al, 2003; Minelli et 
al, 2009; reviewed by Peuchen et al, 1997).  Furthermore it has recently been 
demonstrated that dopamine can activate AREs and that this activation was dependent 
on dopamine oxidation (Wang et al, 2010b).  L-dopa was also found to activate AREs 
however this activation was much less potent than with dopamine, which perhaps could 
provide an explanation for the difference between the effects of L-dopa and dopamine 
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Figure 5.11 Proposed mechanism for the dopamine induced increase in GSH within neuronal-like cells and GSH release from astrocyte-like cells. 
γ-GCL: γ-glutamylcysteine ligase, GS: glutathione synthase, GSH: reduced glutathione, MRP1: multidrug resistance protein 1, γ-GT: γ-
glutamyltranspeptidase, ApN: aminopeptidase N, Nrf2: nuclear factor erythroid 2-related factor, keap1: kelch-like ECH associating protein 1, ARE: 
antioxidant responsive element, SOD: superoxide dismutase, GSSG: glutathione disulphide. 
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in the current study.  It will be of importance to further investigate whether the 
activation of AREs is involved in the observed GSH responses in neuroblastomas and 
astrocytomas.  Furthermore investigation of the control mechanism by which the two 
cell types respond differentially to the same signal could be significant to an 
understanding of how the central nervous system responds to oxidative stress. 
In the current set of experiments L-dopa was unable to induce an increase in GSH in 
neuroblastoma cells unless it was first converted to dopamine by AADC.  Similarly 
astrocytoma cells were unresponsive to L-dopa and do not express AADC activity.  
This suggests that dopamine or a product of dopamine auto-oxidation could be a 
specific signal for up-regulation of GSH within the brain. Accordingly in AADC 
deficiency, where there is a severe deficit of dopamine, this signal may be absent.  In 
consequence the brains of AADC deficient patients may have decreased levels of GSH 
or decreased control over GSH.  The result of this could be decreased antioxidant 
defences and therefore an increased vulnerability to ROS.  Further work will be required 
in both primary neuronal cultures and in vivo in order to further understand the 
physiological and pathophysiological relevance of these observations.  Measuring GSH 
in the CSF of patients with AADC deficiency could be a potentially important 
experiment to ascertain whether GSH is decreased and therefore whether antioxidant 
therapy could be of benefit for these patients. 
5.6.4 Complex I and dopamine 
GSH redox cycling forms one of the major antioxidant defence systems within the 
mitochondrial matrix (Jocelyn and Dickson, 1980; Martensson et al, 1990; Heales et al, 
1995).  Furthermore activity of the respiratory chain is sensitive to changes in GSH 
status (Heales et al, 1995; Bolanos et al, 1996; Merad-Boudia et al, 1998; Merad-
Saidoune et al, 1999; Chinta and Andersen, 2006).  Alterations in GSH levels such as 
observed within SH-SY5Y cells suggested that there may be other mitochondrial 
changes and consequently the activity of the mitochondrial respiratory chain was 
investigated.  The activity of complex I of the mitochondrial respiratory chain was 
increased in response to dopamine treatment in SH-SY5Y cells.   However previous 
studies have found that dopamine negatively effects respiration (Ben Shachar et al, 
1995; Cohen et al, 1997; Berman and Hastings; 1999; Gluck et al, 2002; Gluck and 
Zeevalk, 2004; Brenner-Lavie et al, 2008; Brenner-Lavie et al, 2009).  In vitro 10µM 
dopamine treatment has been demonstrated to act as an inhibitor of complex I activity 
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possibly via dopamine auto-oxidation (Ben Shachar et al, 1995).  In isolated intact 
mitochondria dopamine has also been shown to reversibly reduce respiration, measured 
as O2 consumption (Cohen et al, 1997; Berman and Hastings; 1999; Gluck et al, 2002; 
Gluck and Zeevalk, 2004).  This effect was found to be dependent on MAO and H2O2 
generation indicating that dopamine degradation via MAO producing H2O2 as a side 
product was responsible for this effect (Cohen et al, 1997; Berman and Hastings; 1999).  
Additionally in isolated mitochondria dopamine-quinone, a product of dopamine auto-
oxidation, was found to lead to uncoupling of electron transport from ATP synthesis, 
possibly indicating an increase in proton leakage across the mitochondrial inner 
membrane (Berman and Hastings, 1999).  Treatment of SH-SY5Y cells with 100µM 
dopamine was shown to depolarise the mitochondrial membrane potential by ~30%, 
which may have been related to inhibition of complex I (Brenner-Lavie et al, 2008).  
Furthermore dopamine treatment of SH-SY5Y cells over 10min led to a 20% reduction 
in respiration measured as O2 consumption (Brenner-Lavie et al, 2009).  However this 
decrease was not sustained in 24hr and 48hr treatments, unless cells were treated 
concomitantly with tranylcypromine.  The above studies indicate that dopamine either 
directly or via ROS production can decrease mitochondrial respiration possibly through 
an effect on complex I.  However none of these studies directly measured complex I 
activity in cells following treatment with dopamine.   
The increase in complex I activity after dopamine treatment in the current study could 
suggest a compensatory up-regulation as a result of decreased respiration or increased 
ROS following dopamine treatment.  In support of this L-dopa administration to rats 
was found to lead to an increase in mitochondrial complex I activity and protein in the 
substantia nigra and was associated with increased dopamine concentrations (Calabrese 
et al, 2007).  This up-regulation was related to an induction of heat shock proteins 
which are potentially involved in the cellular response to oxidative stress (Omar and 
Pappolla, 1993; Calabrese et al, 2003).  Alternatively the increase in intracellular GSH 
observed in response to dopamine treatment in the present study could be responsible 
for the increase in complex I activity.  The activity of complex I has been demonstrated 
to be sensitive to GSH concentrations such that decreased GSH increases the 
vulnerability of complex I to oxidative damage (Heales et al, 1995; Bolanos et al, 1996; 
Merad-Boudia et al, 1998; Merad-Saidoune et al, 1999; Chinta and Andersen, 2006).  
Potentially the heightened level of GSH may surmount a basal level of ROS mediated 
damage allowing complex I to function with a higher activity. Conceivably if dopamine 
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increases complex I activity at physiological levels then a consequence of dopamine 
deficiency, such as in AADC deficiency, would be a reduction in complex I activity. 
Notably L-dopa did not have the same effect on complex I indicating that this is a 
specific effect of dopamine.  In isolated Guinea pig liver mitochondria approximately 
50-60% of ubiqunione exists as reduced ubiquinol during respiration (Takada et al, 
1984).  Increased complex I activity in response to dopamine may increase the 
proportion of ubiquinol in the mitochondrial inner membrane.  In addition to its role in 
oxidative phosphorylation ubiquinol can also act as an antioxidant and may be 
particularly effective at terminating lipid peroxidation (Frei et al, 1990; reviewed by 
James et al, 2004).  Conversely the ubisemiquinone radical formed from one electron 
oxidation of ubiquinol can react with O2 to produce O2
•-
 and subsequently H2O2 which 
potentially may propagate further ROS generation (Frei et al, 1990; Schultz et al, 1996).  
Consequently increased complex I activity could have both antioxidant and pro-oxidant 
effects.  However further work is required in an in vivo model of AADC deficiency to 
ascertain if there are alterations of mitochondrial function in the brains of AADC 
deficient patients and to ascertain the pathophysiological relevance of this observation. 
5.7  Conclusions 
The state of AADC deficiency leads to an accumulation of L-dopa and a deficiency of 
dopamine.  Evidence presented in this chapter indicates that L-dopa accumulation may 
potentially lead to damage to dopaminergic neurons.  Furthermore dopamine has been 
shown to potentially increase GSH concentrations in the brain by increasing GSH levels 
in neuronal-like cells and GSH release from astrocyte-like cells.  Consequently the 
dopamine deficit in AADC deficiency could lead to an impairment of antioxidant 
responses within the brain.  This could provide an indication that the catecholaminergic 
neurons of AADC deficient patients could have a heightened susceptibility to oxidative 
stress that could possibly lead to cell death.  Additionally as dopamine treatment 
increased complex I activity in neuroblastoma cells it is also possible that dopamine 
deficiency may lead to a reduction in complex I in catecholaminergic neurons.  
However further work will be required in an animal model of AADC deficiency, in 
patient samples and in post mortem tissue to ascertain the relevance of these 
observations for patients with AADC deficiency. 
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Chapter 6 
6 The influence of pyridoxal 5‟-
phosphate availability on aromatic 
L-amino acid decarboxylase 
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6.1 Introduction 
Pyridoxal 5‟-phosphate (PLP) the active form of vitamin B6 acts as a coenzyme for the 
decarboxylation of aromatic amino acids by AADC.  Vitamin B6 usually in the form of 
pyridoxine is a common although not universal treatment of AADC deficiency (Brun et 
al, 2010).   This treatment was administered in the first two AADC deficiency cases in 
an attempt to bolster residual AADC enzyme activity (Hyland et al, 1992).  In response 
to this treatment CSF levels of L-dopa and 3-O-methyldopa were reduced and 
homovanillic acid concentrations were increased, suggestive of an improvement in 
dopamine metabolism.  In another patient vitamin B6 treatment was associated with 
increased plasma serotonin and decreased 3-O-methyldopa and L-dopa (Maller et al, 
1997). However in this case there was no concomitant improvement in clinical 
symptoms.  Furthermore vitamin B6 treatment in the majority of reported cases has not 
led to any substantial improvement in clinical picture (Swoboda et al, 1999; Pons et al, 
2004).  
The majority of ingested pyridoxine is converted to PLP in the liver by sequential 
phosphorylation and oxidation steps catalysed by pyridoxal kinase and pyridox(am)ine 
5‟-phosphate oxidase (PNPO), respectively (McCormick and Snell, 1959; McCormick 
et al, 1961; Wada and Snell, 1961).  PLP is then released into circulation but must be 
dephosphorylated by tissue non-specific alkaline phosphatase prior to crossing the 
blood-brain barrier and/or being transported into cells (Lumeng et al, 1974; Lumeng et 
al, 1980; Whyte et al, 1985). Within cells pyridoxal is re-phosphorylated by pyridoxal 
kinase to produce the active coenzyme.  Intracellular AADC is then able to bind PLP 
and consequently exert its catalytic activity.  However, PLP also acts as a coenzyme for 
a wide array of enzymatic reactions and can interact with a range of other proteins 
including hormone receptors and transcription factors (Allgood et al, 1990; Allgood et 
al, 1993; Huq et al, 2007).  The relative complexity of PLP metabolism and 
pharmacokinetics, and the multitude of potential sites of action perhaps suggest that the 
efficacy of vitamin B6 treatment in AADC deficiency may depend on multiple factors. 
One potential efficacious effect of vitamin B6 treatment could be to influence the 
availability of active AADC.  It has previously been demonstrated that PLP can act to 
stabilise some enzymes and prevent their degradation.  For example the activity of the 
PLP-dependent enzyme tyrosine aminotransferase (TAT) in rat liver has been shown to 
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increase in a dose-dependent and protein synthesis dependent manner in response to 
vitamin B6 treatment (Greengard and Gordon, 1963).  In addition it has been 
demonstrated that the half-life of TAT is increased in rat liver after pyridoxine 
administration (Snape et al, 1980).  Later PLP was found to protect TAT from 
degradation by the ubiquitin-proteasome in vitro (Gross-Mesilaty et al, 1997).  Taken 
together these findings indicate that PLP may act as a chaperone, preventing the 
degradation of newly synthesised TAT via the proteasome.  PLP is also known to 
influence expression of other proteins through interaction with transcription factors.  
Treatment with a vitamin B6 antagonist or pyridoxine respectively increased or reduced 
glucocorticoid receptor mediated gene expression through a mechanism involving the 
transcription factor nuclear factor 1 (Allgood et al, 1990; Allgood et al, 1993). 
Furthermore PLP has been found to bind to a specific lysine residue of the nuclear 
receptor interacting protein 140 (RIP140; Huq et al, 2007).  This interaction of PLP 
with RIP140 prevented RIP140 export from the nucleus and increased its transcriptional 
repressor activity. 
Vitamin B6 deficiency in rodents has been found to reduce AADC activity in a range of 
tissues including brain (Rahman et al, 1982; Siow and Dakshinamurti, 1985; Guilarte et 
al, 1987).  In each study AADC activity was measured both with and without the 
addition of PLP to the reaction mixture.  Adding PLP to the reaction did not return 
AADC activity to control levels indicating that the amount of active AADC may have 
been reduced.  In rat pheochromocytoma cells cultured in vitamin B6 deficient medium 
together with 4-deoxypyridoxine, a vitamin B6 antagonist, both AADC activity and 
AADC protein were reduced (Matsuda et al, 2004).  Together these findings indicate 
that as well as acting as a co-enzyme PLP could play an additional role in maintaining 
the availability of active AADC.  In addition to AADC deficiency vitamin B6 has been 
suggested to be a beneficial treatment for drug-induced Parkinsonism, tardive 
dyskinesia and some Parkinson‟s disease patients treated with L-dopa and a peripheral 
decarboxylase inhibitor (Sandyk and Pardeshi, 1990; Tan et al, 2005; Lerner et al, 
2007).  The benefits of vitamin B6 treatment in these conditions could relate to 
increased AADC activity, due to increased availability of PLP, in turn leading to 
improvements in monoamine metabolism.  An improved understanding of the effect of 
PLP on AADC availability may potentially explain the efficacy of vitamin B6 treatment 
in these conditions and could indicate previously unknown benefits of vitamin B6 
treatment for AADC deficiency.  
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6.2 Aims 
1. To determine the effect of altered PLP availability on AADC in patients with 
PNPO deficiency and in cell culture 
2. To determine the mechanism by which PLP influences AADC availability 
6.3 Acknowledgement 
Pat of this work has been published (Allen et al, 2010).  All experimental work was my 
own with the exception of PLP measurement, which was performed by Viruna 
Neergheen and Marcus Oppenheim (Neurometabolic Unit, National Hospital) and 
measurement of the AADC kinetics of one patient with PNPO deficiency which was 
undertaken by Keith Hyland (Horizon Molecular Medicine LLC, Atlanta, GA, USA). 
6.4 Methods 
6.4.1 Patient Samples 
Patient samples were lithium heparin plasma.  Plasma AADC activity was measured in 
5 control patients (3 male, 2 female; age range: 2 months to 3 years), 6 patients with 
AADC deficiency (3 male, 3 female; age range: 7 months to 6 years) and two patients 
with PNPO deficiency (2 male; age range: 2 weeks to 6 weeks).  All patient samples 
were tested as part of diagnostic investigations requested by the patient‟s clinician and 
after informed consent.  Anonymised control samples were from patients found not to 
have conditions relating to vitamin B6 or monoamine metabolism used in accordance 
with accredited Neurometabolic Unit (National Hospital for Neurology and 
Neurosurgery) procedures.   
6.4.2 Treatment solutions 
200mM 4-deoxypyridoxine, 10mM PLP and 10mM pyridoxal were made up as stock 
solutions in HPLC grade H2O, 0.2µM sterile filtered and stored at -20˚C.  The PLP 
stock solution was protected from light. 3mg/mL cycloheximide was made up in HPLC 
grade H2O, 0.2µM sterile filtered and stored at +4˚C. 
6.4.3 Cell culture 
Routine cell culture of SH-SY5Y cells was performed as described in section 2.2.6. 
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6.4.4 AADC Activity 
AADC activity with either L-dopa or 5-HTP as substrate was measured as described in 
section 3.3.3 and section 3.3.4. 
6.4.5 Measurement of PLP 
Cells were prepared as described in section 3.3.2 and PLP was measured as described in 
section 2.2.5. 
6.4.6 Measurement of catecholamines 
Cells and medium were prepared as described in section 2.2.8.1 and catecholamines 
measured as described in section 2.2.1. 
6.4.7 Western Blotting 
Cells were prepared as described in section 2.2.8.4 Western blotting was performed as 
described in section 2.5. 
6.4.8 Quantitative PCR 
RNA was isolated as decribed in section 2.6.2.  RT-PCR was performed as described in 
section 2.6.3 and quantitative PCR was performed as described in section 2.6.5 
 
6.5 Experimental Protocol 
6.5.1 AADC activity and PLP measurement 
SH-SY5Y cells in DMEM/F-12 + 100mL/L FBS were counted using a Neubauer 
improved hemocytometer and the appropriate quantity was centrifuged at 500xg for 
5min at room temperature.  Cells were then resuspended either in DMEM/F-12 + 
100mL/L FBS or in pyridoxine deficient DMEM/F-12 + 100mL/L FBS. Cells were 
seeded at a density of 5.00 x 10
4
 cells/cm
2
 in 6-well cell culture dishes, the surface area 
of each well was 9.6cm
2
. 75µL 200mM 4-deoxypyridoxine (final conc. 5mM), 75µL 
PLP (400µM: final conc. 10µM or 4mM: final conc. 100µM) or 75µL 4mM pyridoxal 
(final conc. 100µM) was added to appropriate treated wells.  75µL sterile HPLC grade 
H2O was added to untreated wells.  Plates were incubated at +37˚C in 5.0% CO2 for 
72hr.  For determination of AADC activity cells were processed as indicated in section 
6.4.4 and for PLP determination as indicated in section 6.4.5. 
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Figure 6.1 Pyridoxal 5’-phosphate metabolic pathway in humans. ATP: adenosine 
triphosphate, ADP: adenosine diphosphate. PNPO: pyridoxamine 5‟-phosphate oxidase. 
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6.5.2 AADC enzyme kinetics, mRNA expression and western blotting 
SH-SY5Y cells in DMEM/F-12 + 100mL/L FBS were counted using a Neubauer 
improved hemocytometer and the appropriate quantity was centrifuged at 500xg for 
5min at room temperature.  Cells were then resuspended either in DMEM/F-12 + 
100mL/L FBS or in pyridoxine deficient DMEM/F-12 + 100mL/L FBS. Cells were 
seeded at a density of 5.00 x 10
4
 cells/cm
2
 in 56.7cm
2
 cell culture dishes. 312.5µL 
200mM 4-deoxypyridoxine (final conc. 5mM) or 312.5µL 400µM PLP (final conc. 
10µM) were added to appropriate dishes. 312.5µL sterile HPLC grade H2O was added 
to untreated dishes.  Plates were incubated at +37˚C in 5.0% CO2 for 24hr or 72hr.  For 
determination of AADC enzyme kinetics cells were processed as indicated for AADC 
activity in section 6.4.4, for mRNA analysis cells were processed as indicated in section 
6.4.8 and for western blotting cells were processed as indicated in section 6.4.7. 
6.5.3 AADC stability 
The stability of AADC was determined by a previously described method (Moore et al, 
2003), where AADC activity was monitored in the absence of protein synthesis to 
determine whether the degradation rate had increased in response to treatment. 
Cycloheximide was added at a concentration previously used to inhibit protein synthesis 
(Iredale et al, 1996; Kalfon et al, 2006).  Cells were cultured and treated as described in 
section 6.5.1.  After the 72hr incubation 100µL 3mg/mL cycloheximide was added to 
each well.  Cells were either harvested immediately or incubated for 4hr or 8hr at 37˚C 
in 5.0% CO2.  Cells were harvested and processed as indicated for AADC activity (see 
section 6.4.4). 
6.5.4 Catecholamines measurement 
 For catecholamine measurement cells were cultured and treated as described in section 
6.5.1.  After the 72hr incubation 62.5µL 10mM L-dopa (final conc. 50µM) was added 
to all dishes and incubated for 1hr at +37˚C in 5.0% CO2. Cells and cell culture medium 
were then processed as indicated for catecholamine measurement (see section 6.4.6). 
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6.6 Results 
6.6.1 Plasma AADC activity in PNPO deficient patients 
For all AADC assays, with either L-dopa or 5-HTP as substrate using patient or cell 
culture samples, PLP at a saturating level of 70µM was incubated at +37°C for 120 
minutes prior to the addition of substrate.  Therefore it is unlikely that AADC activity 
was dependent on the concentration of PLP coenzyme present during the assay.  Plasma 
AADC activity with L-dopa as substrate was determined in two patients with PNPO 
deficiency (see section 1.4.4). L-dopa decarboxylation was below the paediatric 
reference range in both cases (reference range: 36-129 pmol/min/mL) and additionally 
was reduced in comparison to controls of a similar age (see figure 6.2).  Plasma AADC 
activity was also determined in six paediatric patients with AADC deficiency.  The 
activity of the majority of these patients was almost undetectable and in all cases below 
that observed for the PNPO deficient patients (see figure 6.2). The enzyme kinetics of 
AADC for PLP was also determined for one patient with PNPO deficiency by 
measuring L-dopa decarboxylation in plasma at different concentrations of PLP (0.5 to 
70.0µM).  The coenzyme Km apparent of this patient was found to be increased to 
15.0µM in comparison to control (3.1 ± 0.4µM; see section 3.4.3; the Km apparent for 
the PNPO patient was measured by Keith Hyland (Horizon Molecular Medicine LLC, 
Atlanta, GA, USA).   
6.6.2 AADC activity in SH-SY5Y cells 
SH-SY5Y cells were exposed to four different treatments aimed at altering PLP 
availability or metabolism.  In order to increase PLP availability cells were cultured 
with 10μM PLP in DMEM/F-12, which contains 9.71µM pyridoxine (Invitrogen).  
Cells were also cultured in pyridoxine deficient (-B6) medium in order to deplete cells 
of PLP.  Additionally cells were cultured with the vitamin B6 antagonist 4-
deoxypyridoxine (4-DP) at a 5mM concentration in either -B6 culture medium or 
control culture medium. AADC activity with L-dopa as substrate was measured in cells 
exposed to the different vitamin B6 conditions for 72hr.  Cells cultured in -B6 medium 
were found to have significantly reduced L-dopa decarboxylation activity to
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Figure 6.2 Plasma AADC L-dopa decarboxylase activity in paediatric disease control, 
PNPO deficient and AADC deficient patients. ------ Indicates lower limit of paediatric 
reference range (36 to 129 pmol/min/mL). 
approximately 70% of control (p <0.05; see figure 6.3a). 4-DP treatment of cells 
cultured in -B6 medium led to further decreases in L-dopa decarboxylation to 
approximately 30% of control (p <0.001).  L-dopa decarboxylation was decreased to a 
similar extent when cells cultured in control medium were treated with 4-DP.  L-dopa 
decarboxylation was not significantly different between 4-DP treated cells in control or 
-B6 medium (p = 0.526; see figure 6.3a). Due to the similarity between the two 4-DP 
conditions only 4-DP treated cells grown in -B6 medium were investigated in further 
experiments.  This treatment was chosen to allow a direct comparison to be made to the 
work of Matsuda et al (2004) who also used this treatment.   
AADC activity with 5-HTP as substrate was altered to a similar extent to that of L-dopa 
decarboxylation following the same treatments.  SH-SY5Y cells cultured for 72hr in -B6 
medium had reduced AADC activity with 5-HTP to approximately 70% of control (p 
<0.001) and activity was further reduced to approximately 30% of control with 4-DP 
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Figure 6.3 AADC activity in SH-SY5Y homogenates following vitamin B6 treatments. 
AADC activity with a. L-dopa and b. 5-HTP as substrate.  Cells were cultured for 72hr 
under the following conditions: -B6, vitamin B6 deficient medium; -B6 4-DP, vitamin 
B6 deficient medium + 5mM 4-deoxypyrdioxine; 4-DP: control medium + 5mM 4-
deoxypyridoxine; PLP, control medium + 10µM PLP.  Results are mean ± SEM of 5-11 
independent experiments. *p <0.05, ***p <0.001, difference in comparison to control 
by ANOVA followed by least significant difference test. 
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treatment coupled with -B6 medium (p <0.001; see figure 6.3b).  In cells treated with 
10µM PLP there was no statistically significant change in AADC activity with either L-
dopa or 5-HTP as substrate compared to control (p = 0.283; p = 0.482, respectively).  
To ascertain whether 4-DP had a direct inhibitory effect on AADC it was added in vitro 
to SH-SY5Y homogenates at the same time point as PLP during the AADC assay with 
L-dopa as substrate.  4-DP was not found to have any direct effect on AADC activity 
(see figure 6.4)   
6.6.3 PLP in SH-SY5Y cells 
PLP was measured by Viruna Neergheen and Marcus Oppenheim (Neurometabolic 
Unit, National Hospital).  The intracellular levels of PLP were determined after the cells 
had been treated for 72hr with the different vitamin B6 conditions.  72hr culturing in -B6 
medium or in -B6 medium with 4-DP led to significant reductions in intracellular PLP 
concentrations to 66% and 67% of control respectively (p <0.01 and p <0.05, 
respectively; see figure 6.5). This indicates that 4-DP treatment does not directly affect 
the intracellular availability of PLP.  Treatment of SH-SY5Y cells with 10µM PLP for 
72hr did not increase intracellular PLP concentrations.  Cells were also treated with 
100μM PLP which also did not lead to increases in intracellular PLP at the 72hr time 
point (see figure 6.5).  As PLP must be dephosphorylated prior to cellular uptake the 
ability of pyridoxal to increase intracellular PLP concentrations was also investigated.  
Treatment with 100µM pyridoxal also did not increase intracellular PLP concentrations 
after 72hr (see figure 6.5). 
6.6.4 Substrate Kinetics 
The coenzyme Km of AADC for PLP could not be determined in SH-SY5Y cell culture 
samples due to the high proportion of AADC that was already bound to PLP (see 
section 3.5.3).  Consequently the altered coenzyme Km found in the PNPO deficient 
patient could not be further investigated in this cell culture model.  In order to 
characterise the alterations found in AADC activity in cells exposed to the different 
vitamin B6 treatments the substrate kinetics of AADC was determined in culture extracts 
following 72hr of treatment.  Substrate kinetics were determined by varying the 
concentration of L-dopa (25 to 2000µM) or 5-HTP (5 to 500µM) present during the 
reaction.   L-dopa decarboxylation appeared to follow classical Michaelis-Menten 
kinetics in samples from all four conditions with the reaction saturated by 1000µM of
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Figure 6.4 AADC activity with L-dopa as substrate in SH-SY5Y cell homogenates in 
the presence of 4-deoxypyridoxine. 4-DP: 5mM 4-deoxypyridoxine (was added to 
homogenate at the start of the assay, the final concentration of 4-deoxypyridoxine 
during the assay was 500μM. Results are mean ± SEM of 5 to 11 independent 
experiments  
 
Figure 6.5 Intracellular concentration of PLP in SH-SY5Y cells after vitamin B6 
treatments.  Cells treated for 72hr with -B6, vitamin B6 deficient medium; -B6 4-DP, 
vitamin B6 deficient medium + 5mM 4-deoxypyrdioxine; or with PLP or pyridoxine at 
the indicated concentration. Results are mean ± SEM of 3-5 independent experiments.  
*p <0.05, **p <0.01, difference in comparison to control by ANOVA followed by least 
significant difference test. 
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L-dopa in each treatment.  However the rate of reaction achieved by the point of 
saturation was reduced compared to control in cells cultured in -B6 medium and further 
reduced in 4-DP treated cells also cultured in -B6 medium (see figure 6.6a).  The same 
was found with 5-HTP as substrate where the reaction for each vitamin B6 condition 
was saturated by 250µM of 5-HTP.  The rate of reaction achieved at saturation was 
lower in cells cultured in -B6 medium and lower still in cells treated with 4-DP and 
cultured in -B6 medium (see figure 6.6b).  In cells treated with 10µM PLP small 
increases in the reaction rate at saturation were found with either 5-HTP or L-dopa as 
substrate.   Vmax and substrate Km for each condition were determined by Lineweaver-
Burk plots (see figure 6.7a and 6.7b).  The Km apparent for the substrate with either L-
dopa or 5-HTP was not significantly different for any of the vitamin B6 conditions in 
comparison to control (see table 6.1). Note that this is the substrate Km that was 
unchanged in this experiment not the coenzyme Km, which was found to be altered in 
one PNPO deficient patient.  However the Vmax with L-dopa as substrate was decreased 
by approximately 30% (p < 0.05) and 75% (p < 0.001) in cells grown in -B6 medium 
and in 4-DP treated cells grown in -B6 medium respectively (see table 6.1).  With 5-
HTP as substrate Vmax was reduced compared to control by approximately 36% (p < 
0.05) and 74% (p < 0.001) in cells grown in -B6 medium and in 4-DP treated cells 
grown in -B6 medium respectively.  Cells treated with 10µM PLP showed no 
statistically significant change in Vmax. 
6.6.5 AADC Protein, Stability and Expression   
Western blotting was performed using an antibody raised against a C-terminal peptide 
of amino acids 464-475 of human AADC (Abcam).  This antibody detected two bands 
at approximately 50kDa (see figure 6.8).  These two bands are most likely two isoforms 
of AADC termed AADC480 and AADC442 which have predicted molecular masses of 
54kDa and 50kDa respectively (O‟Malley et al, 1995; Chang et al, 1996).  AADC442 is 
missing exon 3 and so consequently would still possess the recognition site for the 
antibody used in the current study.  AADC protein was reduced in cells cultured in -B6 
medium as well as those cells also treated with 4-DP (see figure 6.8).  Using 
quantification software (Bio-Rad), 4-DP treated cells cultured in -B6 medium had the 
lowest level of AADC protein, 70 ± 5% of control (n = 3).  AADC protein was reduced 
to a lesser extent in the cells cultured in -B6 medium at 78 ± 13% of control (n = 4), 
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while control cells and cells treated with 10µM PLP had approximately equivalent 
levels of AADC protein. 
The stability of AADC was monitored by measuring the change in AADC activity with 
L-dopa as substrate after inhibition of protein synthesis with 100µg/mL cycloheximide.  
This protocol has been used previously in SH-SY5Y cells to investigate the stability of 
other proteins (Moore et al, 2003).  Consistent with observations described above cells 
cultured for 72hr in -B6 medium and those cultured in -B6 medium with 4-DP had 
decreased levels of L-dopa decarboxylation, with greater reductions seen in  4-DP 
treated cells, in comparison to control (see figure 6.9a). Subsequent to this 72hr 
treatment AADC activity was measured at 4hr and 8hr after the addition of 
cycloheximide.  No change in AADC activity with L-dopa was observed in control 
cells, cells cultured in -B6 medium or 4-DP treated cells cultured in -B6 medium across 
the 8hr incubation with cycloheximide (see figure 6.9a).  This indicates that AADC 
stability is unaffected by these treatments over the tested time period. To establish 
whether the observed changes in the levels of AADC protein and activity in response to 
the vitamin B6 treatments were related to changes in expression AADC mRNA levels 
were measured by quantitative PCR.  AADC mRNA levels were normalised against 
GAPDH mRNA, GAPDH mRNA was not significantly different from control in any of 
the vitamin B6 treatments tested at either 24hr or 72hr (p = 0.206; p = 0.747 
respectively). There were no statistically significant changes in AADC mRNA 
expression across the treatment groups in comparison to control after 24hr.  Likewise 
there were no statistically significant changes in AADC mRNA at 72hr in cells cultured 
in -B6 medium or in cells treated with 10µM in comparison to control cells.   However 
at 72hr of treatment AADC mRNA expression was significantly reduced in cells 
cultured in -B6 medium treated with 4-DP in comparison to control cells (p < 0.01; see 
figure 6.9b). 
6.6.6 Catecholamine metabolism following vitamin B6 treatment 
As AADC activity was reduced following treatment with -B6 medium or -B6 medium 
with 4-DP the effect of these treatments upon monoamine metabolism in intact SH-
SY5Y cells was also investigated.  AADC activity was found to be decreased by a 
similar level with either L-dopa or 5-HTP as substrate (see section 6.6.2) therefore only 
catecholamine metabolism was investigated as it was considered that this would also be 
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representative of indoleamine metabolism.  Cells were cultured under the different 
vitamin B6 treatment conditions for 72hr, after which a saturating concentration of L-
dopa (50µM) was added for 1hr to allow a maximum level of catecholamine 
metabolism to be observed.  Following this incubation cells were harvested and 
intracellular and extracellular levels of catecholamines determined.  Intracellular and 
extracellular levels of dopamine and DOPAC were decreased and intracellular L-dopa 
increased in cells cultured in –B6 medium with 4-DP in comparison to control (see table 
6.2).  Extracellular dopamine was also decreased in cells cultured in –B6 medium alone 
compared to control, however intracellular dopamine and intra- and extracellular 
DOPAC were unaffected.  HVA levels were not altered after any of the vitamin B6 
treatments. Treatment with 10µM PLP had no effect on L-dopa, dopamine or 
metabolites in comparison to control.  
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Figure 6.6 AADC enzyme kinetics in SH-SY5Y cell homogenates following vitamin 
B6 treatments. Cells were treated for 72hr with -B6: vitamin B6 deficient medium, -B6 
4-DP: vitamin B6 deficient medium + 5mM 4-deoxypyridoxine, control and PLP: 10μM 
PLP. a. L-dopa decarboxylase activity at varying concentrations of L-dopa (25 to 
2000µmol/L). b. 5-HTP decarboxylase activity at varying concentrations of 5-HTP (5 to 
500µmol/L).  Results are mean ± SEM of 5-6 independent experiments. 
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Figure 6.7 Lineweaver-Burk double reciprocal plot of SH-SY5Y cell homogenates 
following vitamin B6 treatments.  a. 1/S [1/L-dopa (μM)] against 1/V [1/L-dopa 
decarboxylase activity (pmol/min/mg)] b. 1/S [1/5-HTP (μM)] against 1/V [1/5-HTP 
decarboxylase activity (pmol/min/mg)]. ).  Results are mean ± SEM of 5-6 independent 
experiments.
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 Control -B6 -B6 4-DP PLP 
L-dopa     
Km 333 ± 62 307 ± 44 284 ± 57 302 ± 31 
Vmax 4453 ± 588 3199 ± 264* 1071 ± 150*** 4705 ± 309 
5-HTP     
Km 47 ± 5 53 ± 6 45 ± 8 50 ± 2 
Vmax 426 ± 23 314 ± 10* 152 ± 11*** 515 ± 46 
 
Table 6.1 Km and Vmax of SH-SY5Y cell homogenate following vitamin B6 treatments.  
Km (μM) and Vmax (pmol/min/mg) values for AADC with L-dopa and 5-HTP as 
substrates. SH-SY5Y cells were cultured for 72hr under the following conditions. -B6: 
vitamin B6 deficient medium, -B6 4-DP: vitamin B6 deficient medium + 5mM 4-
deoxypyridoxine, control and PLP: 10μM PLP. Results are mean ± SEM of 5-6 
independent experiments.  * p < 0.05, *** p < 0.001, difference in comparison to 
control by ANOVA followed by least significant difference test. 
 
 
 
Figure 6.8 AADC protein in SH-SY5Y cells after vitamin B6 treatments. Western blot 
of SH-SY5Y cell homogenates probed for AADC and re-probed for β-actin as a loading 
control. Cell treatment in lanes: 1. vitamin B6 deficient medium, 2. vitamin B6 deficient 
medium + 5mM 4-deoxypyridoxine, 3. control, 4. 10μM pyridoxal 5‟-phosphate. 
Representative blot of 3-4 independent experiments.  
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Figure 6.9 AADC stability and mRNA after vitamin B6 treatments. a. AADC stability. 
100μg/mL cycloheximide was added after 72hr of vitamin B6 treatment and L-dopa 
decarboxylation was measured at 0, 4 and 8hr. Results are mean ± SEM of 5-6 
independent experiments. b. AADC mRNA expression levels measured by quantitative 
PCR expressed as arbitrary units/ molecules of GAPDH DNA.  Results are mean ± 
SEM of 3-5 independent experiments.  Treatments: -B6: vitamin B6 deficient medium, -
B6 4-DP: vitamin B6 deficient medium + 5mM 4-deoxypyridoxine, control and PLP: 
10μM PLP.  ** p < 0.01, difference in comparison to control by ANOVA followed by 
least significant difference test. 
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Treatment L-dopa dopamine DOPAC HVA 
INTRACELLULAR 
Control ND 1475 ± 666 823 ± 151 41 ± 4 
-B6 ND 1294 ± 578 730 ± 72 28 ± 10 
10µM PLP 1 ± 1 1789 ± 165 628 ± 74 34 ± 6 
-B6 + 4-DP 28 ± 13* 933 ± 157* 165 ± 53** 27 ± 12 
EXTRACELLULAR 
Control NM 913.04 ± 130 216.69 ± 56 ND 
-B6 NM 357.01 ± 144* 168.8 ± 89 ND 
10µM PLP NM 530.8 ± 196 187.68 ± 40 ND 
-B6 + 4-DP NM 125.07 ± 63** ND ND 
 
Table 6.2 Catecholamine levels in SH-SY5Y cells following vitamin B6 treatments. 
Cells treated for 72hr before the addition of 50µM L-dopa for 1hr prior to harvesting. 
Treatment conditions: -B6: vitamin B6 deficient medium, -B6 4-DP: vitamin B6 
deficient medium + 5mM 4-deoxypyridoxine, control and PLP: 10μM PLP.  NM: not 
measured, ND: not detectable. Results are mean ± SEM of 3 independent experiments. 
*p <0.05 , ** p <0.01, difference in comparison to control by ANOVA followed by 
least significant difference test. 
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6.7 Discussion 
6.7.1 AADC availability is reduced by PLP deficiency 
The activity of AADC was decreased in two patients with PNPO deficiency and in 
cultured neuroblastoma cells with reduced levels of PLP.  In cell culture the reduction in 
activity was associated with a decreased Vmax but not to changes in substrate Km.  This 
is suggestive of a reduction in active enzyme rather than a change in the interaction 
between enzyme and substrate, as would be indicated by a change in Km.  Furthermore 
in cells with reduced levels of PLP there was also a loss of AADC protein.  Taken 
together this evidence suggests that deficiency of PLP causes a reduction in active 
AADC protein.  PLP has previously been demonstrated to participate in mechanistic 
actions beyond its coenzyme function.  For example PLP can act to prevent the 
degradation of the PLP-dependent enzyme TAT (Greengard and Gordon, 1963; Snape 
et al, 1980; Gross-Mesilaty et al, 1997).  However in the current study there was no 
observed change in AADC stability for up to 8 hr in response to PLP deficiency.  
Consequently a similar mechanism to that observed for TAT is unlikely to account for 
the observed changes in AADC. The observed increase in the Km apparent of AADC for 
PLP in one PNPO deficient patient may perhaps indicate a reduced efficiency of the 
interaction between AADC and PLP.  This could indicate that PLP has a role in AADC 
folding or dimerisation and so consequently PLP deficiency could lead to an abundance 
of less mature forms of AADC which may have an altered Km for PLP.  Alternatively 
PNPO deficient patients are likely to accumulate PLP precursors, pyridoxine 5‟-
phosphate and pyridoxamine 5‟-phosphate, which at high concentrations may possibly 
compete with PLP for AADC binding.  This could also explain the altered Km apparent 
for PLP.   
The vitamin B6 antagonist 4-DP when added to the PLP deficient SH-SY5Y cells 
induced no further reduction in intracellular PLP concentrations. However there were 
further losses in AADC activity and protein.  It has previously been demonstrated that 
administration of 4-DP to rats does not alter PLP availability (Bayoumi et al, 1972; 
Coburn et al, 1981).  However 4-DP did reduce the availability of the PLP-dependent 
enzyme glutamic acid decarboxylase, whilst a vitamin B6 deficient diet had no effect 
(Bayoumi et al, 1972).  This indicates that the effects of PLP deficiency and those of 4-
DP may act via different mechanisms.  In the current study PLP-deficient 4-DP treated 
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cells were found to have reduced AADC mRNA expression at 72 hours which was not 
observed in PLP deficient cells that were not treated with 4-DP.  This demonstrates that 
the difference between 4-DP treatment and PLP deficiency cells may relate to effects of 
4-DP on AADC expression.  Matsuda et al (2004) reported a loss of AADC activity and 
protein in response to 4-DP in combination with vitamin B6 deficient medium in rat 
pheochromocytoma cells.  The authors suggested that this loss was related to an 
increase in AADC degradation.  However in the current study treatment of PLP 
deficient cells with 4-DP did not alter the stability of AADC over 8hr demonstrating 
that increased degradation may not be involved in this response.  Furthermore the 
reduction in AADC expression observed here indicates that downregulation rather than 
increased degradation may, at least in part, be responsible for the effect of this 
treatment.  In the current experiments 4-DP alone led to a loss of AADC activity with 
L-dopa as substrate similar to that seen with the 4-DP cells cultured in vitamin B6 
deficient media, however the effect of 4-DP alone on PLP availability, AADC protein 
or mRNA expression was not investigated.  It could be important for future 
investigations to examine the effect of 4-DP treatment in cells that are not cultured in 
vitamin B6 deficient media to provide an improved understanding of the effect of this 
chemical upon AADC and PLP availability.   
4-DP can be phosphorylated by pyridoxal kinase to 4-deoxypyridoxine 5‟-phosphate 
(Hurwitz, 1955).  4-deoxypyridoxine 5‟-phosphate has been shown to compete with 
PLP binding in the active site of some PLP-dependent enzymes, thereby acting as a 
competitive inhibitor for PLP but a non-competitive inhibitor for the substrate (Meister 
et al, 1953; Hurwitz, 1955; Amer et al, 1967).  A reduced Vmax but unaltered Km such as 
that observed here in 4-DP treated PLP deficient cells could indicate a kinetic change 
resulting from inhibitor that is non-competitive for the substrate.  However a decrease in 
active enzyme would also result in a reduced Vmax and unaltered Km which would also 
be consistent with the observed reduction of AADC protein and expression. 
Consequently it seems unlikely that inhibition alone can account for the loss in AADC 
activity.  It has previously been observed that PLP can interact with transcription factors 
leading to alterations in expression (Allgood et al, 1993; Huq et al, 2007). Potentially 4-
DP or its phosphorylated derivative could act as an inhibitor for the interaction of PLP 
with a transcription factor and that the inhibition of this interaction led to the observed 
decrease in AADC expression.  The ability of a PLP antagonist to reduce AADC 
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expression may potentially indicate that PLP is involved in the control of AADC 
expression.  This effect may not have been apparent in the PLP deficient cells as 
intracellular PLP concentrations were only reduced by one-third.  Conversely it is also 
possible that the observed alteration in AADC expression relates to a nonspecific action 
of 4-DP rather than an effect of PLP antagonism. 
The proportion of AADC activity lost with either L-dopa or 5-HTP as substrate was 
almost equal in the current study in response to PLP deficiency or 4-DP treatment.  
However in vitamin B6 deficient rodents it has been shown that in some tissues the loss 
of L-dopa decarboxylase and 5-HTP decarboxylase activities were not equivalent 
(Rahman et al, 1982; Siow and Dakshinamurti, 1985).  One potential explanation for 
this previously observed difference could relate to post-translational modification of 
AADC.  AADC has been demonstrated to be phosphorylated by both cAMP and cyclic 
guanosine monophosphate (cGMP) -dependent protein kinases in a manner that 
increases AADC L-dopa decarboxylase activity (Duchemin et al, 2000; Duchemin et al, 
2010).  It is possible that the phosphorylation of AADC could induce alterations in its 
structure allowing one substrate to be favoured over another.  This could explain 
possible differences in AADC substrate preference between individual tissues.  
However despite this hypothetical difference the expected overall effect of a loss of 
AADC, either due to PLP deficiency or AADC deficiency, would be to decrease both 
dopamine and serotonin metabolism by a relatively equivalent level. 
6.7.2 Clinical consequences of the effect of PLP on AADC 
Patients with AADC deficiency are thought to retain a very low level of AADC activity.  
In the current study five out of six patients had a detectable level of plasma AADC 
activity.  Similarly in previous studies the majority of AADC deficient patients have 
been shown to have a detectable level of AADC activity (Verbeek et al, 2007; 
Manegold et al, 2009).  This small amount of AADC activity may be maintaining a 
basal level of monoamines within these patients, and AADC would almost certainly be 
rate limiting for monoamine production in this situation.  In support of this in the 
current study some reductions in catecholamine production were seen, following 
addition of L-dopa, in PLP deficient cells and as well as those cells treated with 4-DP.  
The PLP deficient cells in the present study still maintained two-thirds the level of PLP 
compared to control however there was still a loss of AADC activity and protein.  
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Furthermore a nearly equivalent proportion of AADC activity and PLP were lost, 
indicating that AADC may be sensitive to PLP deficiency.  It is possible therefore that 
if patients with AADC deficiency became even mildly deficient in PLP then the already 
low level of AADC could be further reduced.  This situation could possibly lead to a 
worsening of clinical symptoms due to a reduction in residual monoamine production.  
Most patients with AADC deficiency are treated with either pyridoxine or PLP, 
although for the majority of patients this treatment does not lead to improvements in 
clinical condition (Pons et al, 2004; Lee et al, 2008a; Brun et al, 2010).  However it is 
possible that vitamin B6 supplementation rather than acting to increase AADC activity 
may operate as more of a preventative treatment against reductions in AADC that would 
result from low levels of PLP.   It should also be noted that in a recent survey of patients 
with AADC deficiency 29% of patients were not treated with either pyridoxine or PLP 
(Brun et al, 2010).  In these cases it may be important to monitor PLP status to ensure 
that these patients do not become PLP deficient. 
L-dopa is used in the treatment of several inherited metabolic conditions including 
tyrosine hydroxylase deficiency and disorders of tetrahydrobiopterin metabolism 
(Hyland, 2007; Pearl et al, 2007).  Furthermore L-dopa is also administered to patients 
with Parkinson‟s disease (Schapira et al, 2009).  This treatment is reliant on AADC 
within the CNS to convert L-dopa into dopamine. Consequently the efficacy of L-dopa 
treatment may also be dependent on the availability of central PLP, not only as a 
coenzyme for AADC but also to maintain the availability of the AADC enzyme.  If the 
availability of PLP was reduced in L-dopa treated patients then there could potentially 
be a resultant decrease in AADC and consequently this would reduce the conversion of 
administered L-dopa into dopamine.  Certainly PLP-deficient cells treated with 4-DP 
demonstrated reduced L-dopa metabolism, and PLP-deficient cells without 4-DP also 
showed reduced extracellular dopamine, compared to control, following addition of L-
dopa. Furthermore this potential effect could be particularly important in patients treated 
with L-dopa due to a Pictet-Spengler reaction of L-dopa and PLP producing a 
tetrahydroisoquinoline derivative (see figure 6.10; Evered, 1971).  Therefore L-dopa 
treatment may directly reduce PLP availability.   This reaction may also be important in 
AADC deficiency where L-dopa accumulates due to the metabolic block at AADC.  
Consequently determining PLP status could be important for the monitoring of patients 
with AADC deficiency and also in other conditions when attempting to optimise L-dopa 
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treatment.  This could be analogous to the need to monitor 5-methyltetrahydrofolate (5-
MTHF) status in AADC deficiency and L-dopa treatment, where methylation of the 
high levels of L-dopa by COMT can deplete 5-MTHF (Surtees and Hyland, 1990; 
Brautigam et al, 2000).   
 
 
Figure 6.10 L-dopa-pyridoxal 5’-phosphate Pictet Spengler adduct. 
 
In Parkinson‟s disease patients treated with L-dopa the administration of pyridoxine has 
been demonstrated to reverse the clinical effect of L-dopa (Duvoisin et al, 1969).  
However when L-dopa is co-administered with a peripheral AADC inhibitor such as 
benserazide or carbidopa, pyridoxine does not reverse the clinical effect of this 
treatment (Klawans et al, 1971).  This suggests that pyridoxine administration increases 
peripheral AADC activity, leading to increased breakdown of L-dopa peripherally.  In 
the current study increasing PLP availability to SH-SY5Y cells did not lead to 
significant changes in AADC.  However this treatment also failed to increase 
intracellular concentrations of PLP and consequently the effect of increased PLP 
availability on AADC requires further investigation. Nonetheless if pyridoxine therapy 
was considered as a treatment for any patient receiving L-dopa therapy then it would be 
essential that this patient were also treated with a peripheral AADC inhibitor to prevent 
pyridoxine reversing the clinical effect of L-dopa.  However pyridoxine treatment has 
been suggested to be beneficial for some Parkinson‟s disease patients who have a 
particular genetic variant of the COMT gene (Tan et al, 2005).  Additionally higher 
dietary intake of vitamin B6 has been suggested to decrease the risk of Parkinson‟s 
disease, although only for smokers (de Lau et al, 2006).  Furthermore a recent study has 
linked a single nucleotide polymorphism in the pyridoxal kinase gene with Parkinson‟s 
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disease, indicating that PLP availability could in some cases play a role in the aetiology 
of Parkinson‟s disease (Elstner et al, 2009).  Whether alterations in AADC availability 
are associated with these observations is unknown, however as this would directly relate 
vitamin B6 to dopaminergic neurons that degenerate in Parkinson‟s disease, this 
potential connection may be worthy of further investigation. 
Patients with PNPO deficiency present with neonatal seizures that are responsive to 
PLP treatment but not to pyridoxine (Mills et al, 2005; Hoffmann et al, 2007).  
Monoamine metabolites in the CSF of patients with PNPO deficiency have been 
reported to be variable.  With decreases in both HVA and 5-HIAA coupled with 
increases in 3-OMD reported in some cases, similar to that seen in AADC deficiency 
(Brautigam et al, 2002; Mills et al, 2005; Hoffmann et al, 2007).  In the present study 
decreases in AADC activity were found in the plasma of two patients with PNPO 
deficiency.  Consequently both of the biochemical hallmarks of AADC deficiency, CSF 
findings and plasma AADC activity, can be similarly altered in PNPO deficiency.  
Therefore there is the potential for confusion, at least at the biochemical level, when 
diagnosing these conditions.  As seizures have also been reported in AADC deficiency 
there is also the possibility of some overlap in clinical phenotype between these two 
conditions (Swoboda et al, 2003; Hsieh et al, 2005; Anselm and Darras, 2006; Ito et al, 
2008).  In consequence to ensure a full distinction can be made between these two 
conditions it could be important to determine PLP status, which should be very low in 
PNPO deficiency as well as glycine and threonine levels in CSF and urine which may 
be elevated in PNPO deficiency but not AADC deficiency (Mills et al, 2005; Hoffman 
et al, 2007).  Conversely HVA has been demonstrated to be normal or variable in some 
cases of PNPO deficiency (Hoffman et al, 2007).  It is interesting to note therefore that 
in PLP-deficient cells treated with 4-DP that HVA was unaffected despite significant 
reductions in both dopamine and DOPAC.  This potentially indicates, albeit in a greatly 
simplified system, that the loss of dopamine may need to be quite severe before 
alterations are seen in the levels of HVA.   
Drug-induced Parkinsonism and Tardive dyskinesia are common and often persistent 
side-effects of neuroleptic medication (reviewed by Haddad and Dursun, 2008).  
Several individual case reports and one small scale clinical trial have found 
improvements in these side effects following administration of pyridoxine (DeVeaugh-
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Geiss and Manion 1978; Sandyk and Pardeshi, 1990; Lerner et al, 1999; Lerner et al, 
2007).  In one case report the authors proposed that the effect of pyridoxine treatment 
was related to increases in AADC activity, which in turn enhanced dopamine and 
serotonin production (Sandyk and Pardeshi, 1990).  In the current study treatment of 
cells with PLP failed to alter intracellular PLP concentrations or AADC activity, and so 
it remains unknown if increasing intracellular PLP availability can increase AADC 
activity.  However deficiency of PLP could potentially be a risk factor for drug-induced 
movement disorders and consequently those patients that are responsive to pyridoxine 
treatment may have an underlying PLP deficiency (Sandyk and Pardeshi, 1990; 
Miodownik et al, 2008).   It is possible that this PLP deficiency would lead to a 
reduction in AADC and therefore in this circumstance increasing intracellular PLP 
availability may increase AADC levels, and this could be involved in the improvement 
of side-effects in these cases. 
6.8 Conclusions 
The data presented in this chapter would suggest that PLP deficiency such as occurs in 
PNPO deficiency can lead to a loss of active AADC.  This loss is unlikely to be related 
to a decrease in enzyme stability or to increased degradation.  As 4-DP decreased 
AADC mRNA levels it is possible that AADC expression can be influenced by PLP.  
However PLP deficiency in SH-SY5Y cells did not alter AADC expression, but still 
reduced AADC activity and protein, indicating an alternative mechanism for the loss of 
active AADC.  The effect of PLP deficiency on AADC demonstrates the potential 
importance of maintaining adequate PLP availability in patients with AADC deficiency, 
to ensure that residual AADC is not further depleted by PLP deficiency.  Likewise this 
observation may have implications for L-dopa therapy, as a loss of AADC due to 
decreased PLP availability may decrease L-dopa efficacy. Additionally determining the 
PLP status of patients when plasma AADC activity is measured may be useful for the 
biochemical distinction of AADC deficiency and PNPO deficiency.  Finally the 
potential benefit of pyridoxine treatment for patients with neuroleptic-induced 
movement disorders may relate to the relief of PLP deficiency consequently leading to 
an increase in AADC levels. 
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AADC deficiency results in a deficit of dopamine and serotonin, as well as an 
accumulation of their precursors L-dopa and 5-HTP respectively.  The resultant clinical 
phenotype affects central neurological systems and peripheral functions and in the 
majority of cases response to treatment is poor (Swoboda et al, 1999; Swoboda et al, 
2003; Pons et al, 2004; Brun et al, 2010).  The first aim of this study was to establish 
the plasma AADC activity assay as a diagnostic test within the UK.  This assay which is 
described in chapter 3 (see section 3.5.1) is now established within the Neurometabolic 
Unit (National Hospital, Queen Square, London) and has been used in the diagnosis of 
six new cases of AADC deficiency.    
Imaging results from the brains of patients with AADC deficiency are suggestive of 
neurodegeneration in some cases (Lee et al, 2009; Manegold et al, 2009; Brun et al, 
2010).  Consequently during this study the hypotheses that L-dopa and 5-HTP 
accumulation lead to alterations in antioxidant status, damage to the mitochondrial 
respiratory chain and neuronal cell death were investigated in neuronal-like and 
astrocyte-like cell culture.  L-dopa was found to be toxic to neuronal-like cells, however 
this toxicity was only observed at >250µM.  Additionally the L-dopa metabolite 3-
OMD that accumulates to a greater extent than L-dopa was not found to be toxic to 
neuronal cells at concentrations <500µM.  This implicates COMT, the enzyme 
responsible for the methylation of L-dopa, as an important step in the detoxification of 
accumulating L-dopa.  5-HTP alone was found to be both growth inhibitory and induce 
some cell lysis of neuronal-like cells, although this effect was only observed at 5-HTP 
concentrations >1000µM. 
The level of L-dopa or 5-HTP required for the observed effects are above the level 
expected in the brain of patients with AADC deficiency, and are certainly above the 
level in patient CSF.  However in this study only acute effects rather than chronic 
effects were observed.  In AADC deficient patients neurons would be continually 
exposed to L-dopa and 5-HTP.  It is possible that this persistent exposure would have a 
cumulative effect that would be detrimental to neurons over a longer time period.  Both 
L-dopa and 5-HTP are used as pharmacological treatments in a range of neurological 
conditions (Ramaekers et al, 2001; Turner et al, 2006; Hyland, 2007; Pearl et al, 2007; 
Longo et al, 2009; Schapira et al, 2009).  As treatments generally neither L-dopa nor 5-
HTP are considered to be neurotoxic (Hefti et al, 1981; Nardini et al, 1983; Perry et al, 
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1984; Quinn et al, 1986; Meltzer et al, 1997; Zeng et al, 2001; Mytilineou et al, 2003; 
Turner et al, 2006).  However there may be an important fundamental difference 
between drug administration and endogenous accumulation.  Administered 5-HTP and 
L-dopa would be taken up by appropriate neuronal systems, converted into their 
respective neurotransmitters and packaged into vesicles.  In AADC deficiency 5-HTP 
and L-dopa would be produced within neurons and due to the deficiency in conversion 
to dopamine and serotonin would then be free within the cytosol.  Increased cytosolic 
dopamine has been found to lead to neurodegeneration in rats (Caudle et al, 2007; Chen 
et al, 2008a) and in the current study L-dopa was found to be similarly toxic to 
dopamine and consequently cytosolic accumulation of L-dopa may also lead to 
neurodegeneration.  In support of this expression of AADC and VMAT2 were found to 
protect neurons against L-dopa toxicity (Doroudchi et al, 2005). 
This thesis investigated the effect of L-dopa and 5-HTP on isolated neuronal-like cells.  
It is possible that other cell types may influence the toxicity of these metabolites.  It was 
hypothesised that the kynurenine pathway, an alternative metabolic route for 5-HTP 
metabolism, led to the production of toxic metabolites in AADC deficiency.  The effect 
of 5-HTP in isolated astrocyte-like cells was investigated and was found to have a small 
effect on cell lysis only at a concentration of 1000µM and in the presence of IFN-γ, an 
activator of the kynurenine pathway.  This could indicate some toxicity of 5-HTP to 
astrocyte-like cells when the kynurenine pathway is activated, however the activity of 
the kynurenine pathway was not measured in these cells.  IFN-γ also influenced the 
effects of 5-HTP on neuronal-like cells leading to cell loss although not cell lysis. This 
could suggest that IFN-γ and 5-HTP treatment induced some toxicity, although other 
explanations are also possible (see section 4.6.2). 5-HTP and serotonin concentrations 
were not decreased by IFN-γ treatment which may suggest that the kynurenine pathway 
may have not been activated by IFN-γ in neuronal-like cells.  Other cell types within the 
brain particularly microglial cells have been implicated as being involved in kynurenine 
metabolism (Guillemin et al, 2005b).  It seems plausible therefore that metabolic 
interactions between different cell types may alter the toxicity of 5-HTP.   
It is possible that together L-dopa and 5-HTP could have a cumulative effect.  For 
example the auto-oxidation of L-dopa within the cytosol of dopaminergic neurons could 
lead to neurodegeneration.  Neurodegeneration can lead to immune activation of 
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microglial cells and astrocytes, which can include induction of IDO the rate-limiting 
enzyme in the kynurenine pathway (Heyes et al, 1993; Kreutzberg, 1996; Alberti-Giani 
and Cesura, 1998; Mrak and Griffin, 2005; Amor et al, 2010).  Hypothetically 
accumulated 5-HTP could then be converted via the kynurenine pathway into a putative 
toxic metabolite which could then inflict a secondary insult.  Similarly immune 
activation and production of the kynurenine metabolite quinolinic acid has been linked 
to the progression and severity of Huntington‟s disease (Whetsell and Schwarcz, 1989; 
Forrest et al, 2010; Sathyasaikumar et al, 2010; Schwarcz et al, 2010). In particular 
quinolinic acid has been demonstrated to induce excitotoxicity through activation of 
glutamatergic NMDA receptors leading to neurodegeneration (Stone and Perkins, 1981; 
Foster et al, 1983; Beal et al, 1986).  Further work is needed first to assess whether 5-
HTP-kynurenine metabolism can lead to the production of toxic metabolites.  In the 
current study IFN-γ was found to influence the effects of 5-HTP on cell growth, 
however it was unclear whether IDO was active in neuronal-like cells.  Secondly 
additional experiments are required to investigate whether there are interactions 
between L-dopa and 5-HTP which may be deleterious to patients with AADC 
deficiency. 
During this study it was demonstrated that dopamine and to a lesser extent serotonin 
were able to increase the availability of GSH within neuronal-like cells.  GSH plays an 
important role in the detoxification of free radicals and H2O2 (reviewed by Martin and 
Teismann, 2009; Ballatori et al, 2009), consequently both dopamine and serotonin may 
act to enhance antioxidant defence within neurons.  Therefore due to dopamine and 
serotonin deficits the neurons of patients with AADC deficiency could potentially have 
a lowered antioxidant status and may be more susceptible to oxidative stress. In addition 
GSH status has previously been demonstrated to be an important factor during apoptosis 
(Froissard et al, 1997; Hou et al, 1997; Nicole et al, 1998).  Depletion of cellular GSH 
has been shown to either initiate or potentiate apoptosis, whilst increased expression of 
γ-glutamylcysteine ligase can increase resistance to apoptosis (Froissard et al, 1997; 
Nicole et al, 1998; Armstrong et al, 2004; Botta et al, 2004; Diaz-Hernandez et al, 
2005). AADC deficiency is also likely to result in a deficiency in melatonin a product of 
serotonin produced mainly in the pineal gland (reviewed by Maronde and Stehle, 2007).  
In addition to being a neurohormone melatonin has been demonstrated to act as an 
antioxidant with greater potency than serotonin and other related indolic compounds 
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(Poeggeler et al, 2002; Hardeland et al, 1993; Tan et al, 1994).  Furthermore increased 
lipid peroxidation, GSH depletion and decreased superoxide dismutase activity 
observed in the brain of a mouse model of Alzheimer‟s disease expressing a mutant 
amyloid precursor protein (APP) could be prevented by administration of melatonin 
(Feng et al, 2006).  Therefore it is possible that the absence of melatonin in AADC 
deficient patients could also reduce brain antioxidant status. Further work will be 
required particularly direct clinical or pathological observations may be important in 
determining the role of decreases antioxidant status in AADC deficiency.  If this were to 
be involved then it is possible that pharmacological treatment with antioxidants or 
neuroprotective agents could be of benefit in AADC deficiency.  For example the 
compound AEOL 10150, a metallo-porphyrin which catalyses the reduction of O2
•-
, 
H2O2 and ONOO
•-
, is undergoing clinical trials for treatment of the neurodegenerative 
disorder amyotrophic lateral sclerosis (Traynor et al, 2006; Scatena et al, 2007; Chen et 
al, 2008b).  Additionally the MAO inhibitor selegiline is thought to elicit some 
neuroprotection that is unrelated to inhibition of MAO (Maruyama et al, 2002; Magyar 
et al, 2006; Naoi et al, 2007).  
Dopamine as well as increasing GSH within neuronal-like cells was also demonstrated 
in the current study to increase GSH release from astrocyte-like cells.  Astrocytic 
release of GSH is considered to be the first stage of GSH trafficking from astrocytes to 
neurons (see section 1.7.6 and figure 1.9; Dringen et al, 1999; Stewart et al, 2002).  
Consequently dopamine may play a dual role in increasing neuronal GSH status, firstly 
by increasing GSH synthesis within neurons and secondly by increasing the availability 
of substrates for GSH synthesis through increased trafficking from astrocytes.  It is 
possible that dopamine treatment led to activation of the Nrf2/keap1 signalling pathway, 
which in turn led to upregulation of genes that can be controlled by the ARE promoter 
sequence (see section 5.6.3; Rushmore et al, 1991; Venugopal et al, 1996; Itoh et al, 
1997; Itoh et al, 1999; Zipper and Mulcahy, 2002; Itoh et al, 2003).  It was notable that 
whilst dopamine increased GSH, L-dopa in the absence of AADC activity was unable to 
elicit such an effect.  This suggests that dopamine provides a specific signal for 
upregulation of GSH synthesis and trafficking.  Both serotonin and 5-HTP treatment 
also induced increases in GSH levels within neuronal-like cells, although this effect was 
much smaller than that observed with dopamine.  It is possible that the increase in GSH 
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following 5-HTP or serotonin treatment was related to the ability of indolic compounds 
to act as reducing agents (Herraiz and Galisteo, 2004; Munoz-Castaneda et al, 2006).   
GSH plays a particularly important role in maintaining mitochondrial redox balance and 
preventing oxidative damage to the respiratory chain (Bolanos et al, 1994; Heales et al, 
1995; Bolanos et al, 1996).  Mitochondrial respiratory chain complexes I and III 
produce O2
•-
 which must be detoxified to avoid oxidative damage to proteins within the 
mitochondrial matrix (Kudin et al, 2005).  Furthermore the respiratory chain complexes 
are known to be targets for oxidative damage (Zhang et al, 1990; Benzi et al, 1991).  In 
the current study L-dopa or 5-HTP treatment of neuronal-like cells did not lead to any 
loss of activity of the mitochondrial respiratory chain complexes.  This indicates that 
oxidative damage to the respiratory chain did not occur in response to these treatments.  
It is possible that a chronic exposure to L-dopa or 5-HTP could eventually lead to 
damage to the respiratory chain although this will require further investigation.  
Dopamine treatment led to an increase in complex I activity, whilst 5-HTP and 
serotonin treatment may have led to an increase in complex II/III activity.  These 
increase could relate to increased levels of GSH decreasing basal ROS in turn allowing 
electron transport to operate at a more efficient level or alternatively to an upregulation 
of mitochondrial complex expression (see section 5.6.4).  
Vitamin B6, usually in the form of pyridoxine but also sometimes as PLP, has been used 
as a treatment in AADC deficiency since the first two described cases (Hyland and 
Clayton, 1990; Brun et al, 2010).  This treatment has not been reported to improve 
clinical symptoms in the majority of cases (Hyland et al, 1992; Korenke et al, 1997; 
Maller et al, 1997; Swoboda et al, 1999; Pons et al, 2004).  In the current study the 
involvement of PLP availability in maintaining active AADC was investigated.  It was 
demonstrated that in PLP deficiency AADC activity was reduced in patients and in cell 
culture.  In cell culture this deficit was related to a loss of protein, although not to 
changes in stability or expression (see section 6.7.1).  This work demonstrates the level 
of active AADC is dependent on appropriate PLP availability.  Similar results have 
been demonstrated previously in rodents and PC12 cells, although the mechanism for 
this effect has not previously been investigated (Rahman et al, 1982; Siow and 
Dakshinamurti, 1985; Guilarte et al, 1987; Matsuda et al, 2004). The majority of 
patients with AADC deficiency are thought to maintain a residual level of AADC
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Figure 7.1 Summary of results. In AADC deficiency it is possible that GSH status in neurons may be impaired due to the potential positive effects of 
dopamine and serotonin on GSH status.  Pyridoxal 5‟-phosphate (PLP) may be important in maintaining the level of active AADC consequently in 
AADC deficiency maintaining PLP levels could be an important therapeutic strategy to avoid loss of residual AADC activity.  AADC: aromatic L-
amino acid decarboxylase, GSH: reduced glutathione, 5-HTP: L-5-hydroxytryptophan, L-dopa: L-3,4-dihydroxyphenylalanine.
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activity, which could be preserving a basal level of monoamines.  Both a low level of 
plasma AADC activity and CSF HVA and 5-HIAA have been detected in the majority 
of patients (see figure 6.3; Verbeek et al, 2007; Manegold et al, 2009; Brun et al, 2010). 
Reductions in PLP levels led to a concomitant decrease in active AADC and therefore 
in AADC deficiency prevention of PLP deficiency may be an important therapeutic 
aim.  Patients with AADC deficiency could be at increased risk of PLP deficiency due 
to a potential reaction between PLP and accumulated L-dopa forming a PLP-L-dopa 
Pictet-Spengler adduct (Evered, 1971).  Additionally feeding difficulties have been 
reported in some cases of AADC deficiency (Pons et al, 2004), which could potentially 
lead to a dietary deficiency of PLP.  Consequently the evidence presented in this thesis 
(see section 6.6) provides a potential justification for the continued use of vitamin B6 
treatment in AADC deficiency.  Although this treatment may not improve clinical 
symptoms in AADC deficiency, potentially it could prevent PLP deficiency and any 
associated loss of residual active AADC. 
Whilst decreasing PLP availability led to a loss of active AADC, increasing PLP 
availability in cell culture did not lead to an increase in AADC.  However PLP was not 
increased intracellularly following PLP treatment and consequently the effect of 
increased PLP availability on AADC requires further investigation.  A range of 
treatments have been demonstrated to increase AADC activity and availability in rodent 
brain (Boomsma et al, 1989; Zhu et al, 1992; Hadjiconstantinou et al, 1993; Cho et al, 
1999; Duchemin et al, 2000; Neff et al, 2006; Duchemin et al, 2010).  Direct 
phosphorylation of AADC by both cAMP and cGMP-dependent protein kinases has 
been reported (Duchemin et al, 2000; Duchemin et al, 2010).  Furthermore AADC 
appears to be regulated by a feedback mechanism such that treatment with dopamine or 
serotonin receptor antagonists or AADC inhibitors leads to an upregulation of AADC 
(Boomsma et al, 1989; Zhu et al, 1992; Hadjiconstantinou et al, 1993; Cho et al, 1999; 
Neff et al, 2006).  Increased plasma AADC activity has been reported in Parkinson‟s 
disease patients treated with L-dopa and a peripheral AADC inhibitor (Boomsma et al, 
1989).  A potential future treatment of AADC deficiency could aim to harness AADC 
regulation to maximise the residual level of AADC activity in patients and possibly 
improve monoamine production (see Allen et al, 2009).  For example the antipsychotic 
clozapine, which antagonises D2-like dopamine receptors and serotonin receptors, can 
increase striatal AADC activity 40-50% in mouse (Neff et al, 2006).  Dopamine and 
serotonin antagonists are likely to exacerbate the symptoms of AADC deficiency 
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through blockade of dopamine and serotonin receptors.  However a drug screening 
study could reveal other compounds which can similarly increase AADC activity 
without inhibiting monoamine systems. 
An alternative to pharmacological treatment could be to use gene therapy to re-
introduce the human AADC gene into the brains of patients with AADC deficiency.  
Gene transfer is achieved by using recombinant viral vectors such as adeno-associated 
viruses (AAVs).  A gene therapy approach using the human AADC gene delivered 
using an AAV has been developed for Parkinson‟s disease treatment (Carlsson et al, 
2007).  The aim of this therapy is to increase AADC expression to extend the treatment 
window of L-dopa therapy.  This approach has been reported to be successful in a 
primate model of Parkinson‟s disease and in a safety trial of five Parkinson‟s disease 
patients (Bankiewicz et al, 2006; Eberling et al, 2008). A similar system could be used 
to re-introduce the AADC gene into selected brain regions of patients with AADC 
deficiency. Indeed a gene therapy trial using the human AADC gene is currently 
underway in Taiwan where one patient with AADC deficiency has been treated 
(http://www.wretch.cc/blog/aadc/33573305). It is unclear however how a brain that has 
developed in the near absence of monoamines will react to their production later in life.   
An improved understanding of the pathogenesis of AADC deficiency, which the current 
study has begun to investigate, will hopefully lead to new treatment targets and 
improved medication for this debilitating and often intractable disorder.  
7.1 Conclusions 
Evidence presented in this thesis indicates that L-dopa and 5-HTP are capable of 
inducing some neuronal toxicity in cell culture although only at concentrations above 
that seen in AADC deficiency.  However it is possible that this toxicity could become 
more potent during prolonged exposure as would be the case in patients.  The enzyme 
COMT may protect against L-dopa toxicity by converting L-dopa to the non-toxic 
metabolite 3-OMD.  Dopamine deficiency could potentially lead to impairment of 
antioxidant signalling resulting in decreased GSH in neurons and decreased GSH 
release from astrocytes.  Serotonin deficiency may also lead to a decrease in GSH levels 
within neurons.  Vitamin B6 treatment should be considered as a preventative treatment 
against PLP deficiency in AADC deficient patients and leading to a consequent loss of 
residual AADC enzyme activity.  In AADC deficient patients not receiving vitamin B6 
supplementation monitoring of PLP status could be important.  Future treatments of 
223 
 
AADC deficiency could aim to increase AADC activity either by pharmacological 
strategies to maximise residual activity or through gene therapy. 
7.2 Further work 
The results of this thesis were obtained from neuroblastoma and astrocytoma cells and 
AADC deficiency was modelled using the chemical AADC inhibitor NSD-1015.  In 
order to confirm and extend these results other models of AADC deficiency and direct 
measurement of patient samples should be employed including: 
 A knock down animal model. 
 Direct clinical or pathological evidence of neurodegeneration and reduced 
antioxidant status.   
 Patient CSF analysis to determine GSH status and identify degenerative markers 
and indicators of oxidative stress.   
IFN-γ treatment was used in this thesis to activate IDO the rate limiting enzyme in the 
kynurenine pathway.  Whilst IFN-γ treatment was found to alter the response of 
neuroblastoma cells to 5-HTP it was not directly determined whether the kynurenine 
pathway was active.  This work could be extended by: 
 Measuring IDO activity and quinolinic acid levels in neuroblastoma and 
astrocytoma cells.   
 Examining the effect of microglial cells upon 5-HTP metabolism and toxicity 
using a co-culture system with both microglial and neuronal cells (Bolanos et al, 
1996; Stewart et al, 1998; Stewart et al, 2000; Gegg et al, 2005).  
 Determining the metabolic fate of accumulated 5-HTP by adding a stable 
isotope [
13
C-3]-5-HTP to cell culture and identifying the resultant metabolites by 
mass spectrometry (Zamboni et al, 2009; Hiller et al, 2010).   
 Investigating the levels of kynurenine metabolites in the CSF of AADC deficient 
patients. 
Dopamine treatment was found to increase GSH levels within neuroblastoma cells and 
GSH release from astrocytoma cells.  This could suggest activation of the Nrf2/keap1 
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signalling pathway.  It could be of interest to examine whether this pathway was 
activated by dopamine treatment.  This could be invstigated by: 
 Determining whether Nrf2 locates to the nucleus using confocal microscopy or 
whether the Nrf2/keap1 complex is disrupted by a co-immunoprecipitation study 
(Zipper and Mulcahy, 2002; Itoh et al, 2003).   
 Determining the activity of other enzymes, such as NQO1, that are regulated by 
Nrf2 following dopamine treatment.   
Additionally a co-culture system (Bolanos et al, 1996; Stewart et al, 1998; Stewart et al, 
2000; Gegg et al, 2005) could be employed to examine whether increased GSH release 
from astrocytomas results in increased GSH within neurons following dopamine 
treatment.  To further establish the physiological relevance of these observations the 
effect of dopamine treatment on GSH in primary rat neurons and astrocytes could also 
be investigated.  
In this thesis reduced levels of PLP were found to decrease the availability of active 
AADC in patients and in cell culture.  The mechanism for this response was found not 
to relate to expression or stability.  Alternative mechanisms could involve alterations in 
dimerisation and phosphorylation.  This work could be extended by: 
 Investigating AADC dimerisation using blue-native PAGE to determine the ratio 
of monomer to dimer (Wittig et al, 2006).   
 Determining phosphorylation status of AADC following PLP deficiency using a 
phospho-antibody raised against phosphorylated AADC (Goto and Inagaki, 
2007).   
 Further investigating whether increasing intracellular PLP concentrations can 
increase AADC activity potentially by overexpression of the PNPO gene within 
cells.   
 An siRNA knock down strategy (Cullen, 2005) against PNPO could also be 
employed to reduce intracellular PLP further to determine the effect of a greater 
level of PLP deficiency.   
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 A long-term study could be conducted to determine whether raised levels of L-
dopa can affect PLP status.   
 Monitoring PLP status in patients with AADC deficiency not treated with 
vitamin B6 could improve understanding of whether PLP deficiency is a 
potential concern in this condition. 
Further work may also need to be conducted examining the effects of 4-DP.  In this 
thesis 4-DP was used in combination with vitamin B6 deficient medium mainly to allow 
comparison to a previous study (Matsuda et al, 2004).  However to further understand 
the effects of this inhibitor it may be important to treat cells with 4-DP alone.  This 
would allow the direct effects of 4-DP upon PLP metabolism and AADC expression to 
be investigated.   
A new technology that could potentially be employed for the investigation of AADC 
deficiency is that of induced pluripotent stem (iPS) cells (Park et al, 2008a).  Here 
somatic cells such as skin fibroblasts are reprogrammed into stem cell-like cells by the 
transfection of four transcription factors (Takahashi et al, 2007; Dimos et al, 2008; Park 
et al, 2008b).  iPS cells can then be differentiated potentially into any cell type.  Using 
cells from patients this technique could be used to make patient specific neurons.  These 
neurons may perhaps be best used to perform drug screenings to investigate the 
potential of different compounds in the treatment of AADC deficiency.  For example 
the ability of a range of available pharmaceuticals could be investigated to determine 
whether a treatment could increase AADC activity in patient derived cells.   
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